US20010031768A1 - Triazole antifungal agent - Google Patents

Triazole antifungal agent Download PDF

Info

Publication number
US20010031768A1
US20010031768A1 US09/794,177 US79417701A US2001031768A1 US 20010031768 A1 US20010031768 A1 US 20010031768A1 US 79417701 A US79417701 A US 79417701A US 2001031768 A1 US2001031768 A1 US 2001031768A1
Authority
US
United States
Prior art keywords
group
phenyl
thio
triazol
butanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/794,177
Inventor
Sadao Oida
Teruo Tanaka
Yawara Tajima
Toshiyuki Konosu
Atsushi Somada
Takeo Miyaoka
Hiroshi Yasuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Priority to US09/794,177 priority Critical patent/US20010031768A1/en
Publication of US20010031768A1 publication Critical patent/US20010031768A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A01N43/647—Triazoles; Hydrogenated triazoles
    • A01N43/653—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00

Definitions

  • the present invention relates to a 1,2,4-triazole compound represented by the formula (I) which is particularly effective for mycotic disease of a human being and an animal.
  • [0004] is bonded to an alkyl, a cycloalkylalkyl group or a cycloalkyl group, has antifungal activities.
  • the present invention relates to a compound having the formula (I):
  • Ar 1 represents a phenyl group or a phenyl group having 1 to 3 substituent(s), (the substituent(s) represent(s) a halogen atom or a trifluoromethyl group);
  • Ar 2 represents a phenyl group, a 5- or 6-membered aromatic heterocyclic group (the aromatic heterocyclic group has at least one nitrogen, oxygen or sulfur atom) or a phenyl group or a 5- or 6-membered aromatic heterocyclic group having 1 to 3 substituents
  • the substituent(s) represent(s) a lower alkyl group, a lower alkoxy group, a halogen atom, a lower alkyl group substituted with a halogen atom or halogen atoms, a lower alkoxy group substituted with a halogen atom or halogen atoms, a nitro group, a cyano group, a —S(O) m R 6 group (R 6 represents a lower alkyl group which may be substituted with a halogen atom or halogen atoms and m represents 0, 1 or 2) or a —NHCOR 7 group (R 7 represents a lower alkyl group) and the aromatic heterocyclic group
  • R 0 represents a hydrogen atom or a lower alkyl group
  • R 1 represents a lower alkyl group
  • R 2 , R 3 , R 4 and R 5 may be the same or different and represent a hydrogen atom, a lower alkyl group or a lower alkyl group substituted with a halogen atom or halogen atoms and, where q and/or s represent 2, each of R 2 , R 3 , R 4 and R 5 represents independently a group which is the same or different from the other R 2 , R 3 , R 4 and R 5 respectively;
  • n 0, 1 or 2;
  • p represents 0 or 1
  • A represents a 4- to 7-membered aliphatic carbocyclic group comprising 4 to 7 carbon atoms or a 4- to 7-membered aliphatic heterocyclic group having at least one nitrogen, oxygen or sulfur atom,
  • halogen atom is, for example, a fluorine, chlorine or bromine atom, preferably a fluorine or chlorine atom.
  • the lower alkyl group is, for example, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl group, preferably a methyl, ethyl, propyl or isopropyl group.
  • the lower alkoxy group is, for example, a methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy or tert-butoxy group, preferably a methoxy, ethoxy, propoxy or isopropoxy group.
  • the 5- or 6-membered aromatic heterocyclic group of Ar 2 is, for example, a furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl or pyrazyl group, preferably a furyl, thienyl, pyrrolyl or pyridyl group.
  • the 4- to 7-membered aliphatic carbocyclic group comprising 4 to 7 carbon atoms of A is, for example, a cyclobutane, cyclopentane, cyclohexane or cyclobutane ring, preferably a cyclobutane, cyclopentane or cyclohexane ring.
  • the 4- to 7-membered aliphatic heterocyclic group having at least one nitrogen, oxygen or sulfur atom of A is, for example, an azetidine, pyrrolidine, piperidine, homopiperidine, oxetane, tetrahydrofuran, tetrahydropyran, thietane, tetrahydrothiophene, pentamethylenesulfide, 1,4,5,6-tetrahydropyrimidine, 1,3-dioxane, 1,3-dithiane, dihydroxazine, tetrahydroxazine, dihydrothiazine or tetrahydrothiazine ring, preferably an azetidine, piperidine, 1,3- dioxane, 1,4,5 ,6-tetrahydropyrimidine, tetrahydroxazine or 1,3-dithiane ring.
  • the preferable compound having the formula (I) is the compound in which:
  • Ar 1 is a dichlorophenyl, difluorophenyl, chlorophenyl, fluorophenyl, (trifluoromethyl)phenyl or fluoro(trifluoromethyl)phenyl group, preferably a 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-(trifluoromethyl)phenyl or 2-fluoro-4-(trifluoromethyl)phenyl group, particularly preferably a 2,4-dichlorophenyl, 2,4-difluorophenyl or 4-(trifluoromethyl)phenyl group;
  • Ar 2 is a fluorophenyl, chlorophenyl, difluorophenyl, dicblorophenyl, (trifluoromethyl)phenyl, (trichloromethyl)phenyl, fluoro-(trifluoromethyl)phenyl, (difluoromethoxy)phenyl, (trifluoromethoxy)phenyl, (2,2,2-trfluoroethoxy)phemyl, (1,1,2,2-tetrafluoroethoxy)phenyl, (2,2,3,3-tetrafluoropropoxy)phenyl, fluoro-(2,2,3,3-tetrafluoropropoxy)phenyl, nitrophenyl, fluoro-nitrophenyl, cyanophenyl, chloro-cyanophenyl, (methylthio)phenyl, (methylsulfinyl) phenyl, (methylsulfonyl) phenyl, (trifluoromethylthio
  • R 0 is a hydrogen atom, a methyl, ethyl or propyl group, preferably a hydrogen atom, a methyl or ethyl group, particularly preferably a hydrogen atom or a methyl group;
  • R 1 is a methyl, ethyl or propyl group, preferably a methyl or ethyl group, particularly preferably a methyl group;
  • R 2 , R 3 , R 4 and R 5 may be the same or different and are a hydrogen atom, a methyl, ethyl, propyl or trifluorometbyl group, preferably a hydrogen atom, a methyl or trifluorometbyl group, particularly preferably a hydrogen atom or a trifluoromethyl group;
  • n is 0, 1 or 2, particularly preferably 0;
  • p is 0 or 1, particularly preferably 0;
  • q is 0, 1 or 2, particularly preferably 1;
  • r is 0, 1 or 2, particularly preferably 0 or 1;
  • s is 0, 1 or 2, particularly preferably 1;
  • A is a cyclobutane, cyclopentane, cyclohexaue, azetidine, pyrrolidine, piperidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, 1,3-dioxane, 1,3-dithiane, tetrahydroxazime or tetrahydrothiazine ring, preferably a cyclobutane, cyclohexane, azetidine, piperidine, 1,3-dioxane, 1,3-dithiane, tetrahydroxazine or tetrahydrothiazine ring, particularly preferably a cyclohexane, piperidine, 1,3-dioxane or 1,3-dithiane ring.
  • the preferable compound (I) can be exemplified by the compound in which Ar 1 is a 4-chlorophenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl or 4-(trifluoromethyl)phenyl group; R 0 is a hydrogen atom or a methyl group; R 1 is a methyl group; and the moiety represented by the formula:
  • [0036] is a group as shown in Table 1.
  • Table 1 Example —S(O) n —A—(CO) p —(R 2 C ⁇ CR 3 ) q —(C ⁇ C) r —(R 4 C ⁇ CR 5 ) s —Ar 2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126
  • Preferred compounds in Table 1 include those having the substituents of 4, 6, 7, 13, 16, 18, 22, 25, 32, 36, 40, 43, 44, 47, 52, 53, 61, 63, 71, 76, 96, 107, 123, 127, 142, 174, 176, 177, 178, 181, 182, 183 and 186, and particularly preferable compounds may include
  • the triazole compound (I) of the present invention has at least two asymmetric carbon atoms, and optical isomers and diastereomers exist.
  • optical isomer both antipodes can be obtained by general optical resolution or asymmetric synthesis.
  • diastereomers can be separated by conventional separation methods such as fractional recrystallization and chromatography.
  • the compound (I) of the present invention includes one of these isomers or mixtures thereof.
  • the triazole compound (I) of the present invention can be used as an antifungal agent as such or in the form of a pharmacologically acceptable salt.
  • the pharmacologically acceptable salt of the compound (I) includes, for example, a salt of inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and nitric acid, a salt of carboxylic acids such as acetic acid, fumaric acid, maleic acid, oxalic acid, malonic acid, succinic acid, citric acid and malic acid, a salt of sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benenesulfonic acid and toluenesulfonic acid and a salt of amino acids such as glutamic acid and aspartic acid, preferably a salt of carboxylic acids.
  • a hydrate of the compound (I) and a hydrate of the salt of the compound (I) are also included in the compound of the present invention.
  • the compound (I) and a pharmacologically acceptable salt thereof of the present invention exhibit excellent antifungal activities and in the case where the compound (I) and a pharmacologically acceptable salt thereof are used as an antifungal agent, they can be administered as such or as a mixture, for example, with a suitable pharmacologically acceptable excipient or diluent orally in the form of a tablet, a capsule, a granule, a powder or a syrup or parenterally in the form of injection preparations.
  • excipients for example, sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbitol; starch derivatives such as corn starch, mashed potato starch, ⁇ -starch, dextrine and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, low bydroxypropyl-substituted cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium and internally bridged carboxymethyl cellulose sodium; gum arabic; dextran; Pullulan; silicate derivatives such as light silicic acid anhydride, synthetic aluminum silicate and magnesium meta-silicic acid aluminate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; and sulfate derivatives such as calcium sulfate), binders (for example, the above excipients; gelatin; polyvinylpyrrolidone
  • the dose varies depending on the condition and age of the patient to be treated, it is desirably administered 1 to 6 times daily depending on the condition: in the case of oral administration, the lower limit of 1 mg each time (preferably 5 mg) and the upper limit of 2000 mg (preferably 1000 mg) for an adult; and in the case of intravenous administration, the lower limit of 0.1 mg each time (preferably 0.5 mg) and the upper limit of 600 mg (preferably 500 mg) for an adult.
  • the desired compound (Ia) is prepared by reacting an epoxide compound (2) described in Japanese Unexamined Patent Publication (KOKAI) No. Hei 2-191262 (Jul. 27, 1990) with mercaptan (3) or an acetic acid ester derivative thereof under basic conditions.
  • the solvent employable in the reaction includes preferably alcohols such as methanol, ethanol and propanol, aprotic solvents such as dimethylformamide, dimethylacetamide, dimethyl sulfoxide, acetonitrile and tetrahydrofuran.
  • aprotic solvent such as dimethylformamide, dimethylacetamide, dimethyl sulfoxide, acetonitrile and tetrahydrofuran.
  • the base employable in the reaction includes sodium hydride, sodium methoxide, sodium ethoxide, lithium methoxide, potassium tert-butoxide, lithium hydroxide, sodium hydroxide and potassium hydroxide.
  • the amount to be used is 0.1 to 2 molar equivalents based on the compound (2).
  • Mercaptan (3) or the acetic acid derivative thereof (4) is used in 1 to 3 molar equivalents.
  • the reaction temperature is room temperature to 100° C. and the reaction time is 2 to 10 hours.
  • the compound (Ia) can be obtained by treating the reaction mixture by conventional procedures (an oil obtained by extraction with an organic solvent and then evaporation of the solvent is purified by column chromatography or recrystallization).
  • the acid chloride (10) used in the above reaction can be obtained by treating a carboxylic acid, obtained by alkali-decomposing the unsaturated ester (7a) or (7b) described above, with thionyl chloride.
  • the solvent employable in the reaction includes methanol, ethanol, propanol, butanol, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, acetonitrile, tetrahydrofuran, dioxane, diethyl ether, acetone, benzene, toluene, xylene, etc.
  • the base employable in the reaction includes triethylamine, diisopropylethylamine, sodium hydride, sodium methoxide, sodium ethoxide, lithium methoxide, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, etc., and the amount used is 1 to 3 molar equivalents based on the compound (11).
  • the alkylating reagent (12) is used in 1 to 3 molar equivalents.
  • the reaction temperature is ⁇ 50 to 100° C. and the reaction time is 2 to 10 hours.
  • the compound (Ia) can be obtained by treating the reaction mixture by conventional procedures (an oil obtained by extraction with an organic solvent and then evaporation of the solvent is purified by column chromatography or recrystallization).
  • the alkylating reagent R 8 -X (12) used in the above reaction can be obtained according to the process shown below.
  • the process is to prepare the desired compound (Ib) by reacting the above epoxide compound (2) with a thioacetic acid derivative (15) obtained by the reaction of the above )mown compound (5) with sodium thioacetate under the same conditions as in the reaction of (2) and (4) to obtain the compound (16), deprotecting the compound (16) according to conventional procedures such as the treatment with an acid to obtain the compound (17) and reacting the compound (17) with the above aldehyde compound (6).
  • the reaction of the compounds (17) and (6) is usually carried out under acidic conditions.
  • the acid employable here includes, for example, hydrogen chloride, sulfuric acid, nitric acid, boron trifluoride, metbiazesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid and the amount of the acid used is 1 to 2 molar equivalents based on (17).
  • the aldehyde (6) is used in 1 to 2 molar equivalents.
  • aprotic solvents such as methylene chloride, chloroform, 1,2-dichloroethane, benzene, toluene, xylene, diethyl ether and tetrahydrofuran are used.
  • the reaction is carried out in the range of 0° C. to a boiling point of the solvent and the reaction time is 2 to 10 hours. While water produced by the reaction can be removed by azeotropic distillation, molecular sieves may be used as a dehydrating agent.
  • the compound (Ib) can be obtained by neutralizing the reaction mixture with an aqueous sodium bydrogencarbonate solution and then treating it by conventional procedures (an oil obtained by extraction with an organic solvent and then evaporation of the solvent is purified by column chromatography or recrystallization).
  • the process is to prepare the desired compound (Ic) by reacting the above epoxide compound (2) with the mercaptan compound (18), obtained by treating the above thioacetic acid derivative (9) with an alkali, under the same conditions as in the reaction of (2) and (3) to obtain the compound (19), deprotecting (19) by treating it with an acid according to conventional procedures to obtain the compound (20) and reacting the compound (20) with the above acid chloride (10).
  • reaction of compounds (20) and (10) is carried out in an inert solvent such as benzene, toluene, methylene chloride, chloroform or tetrabydrofuran in the presence of an appropriate base by conventional procedures (Reference example Nos. 13, 14, 18 and 19).
  • an inert solvent such as benzene, toluene, methylene chloride, chloroform or tetrabydrofuran
  • the solvent employable here is not particularly limited so long as it does not inhibit the reaction and dissolves the starting materials to some extent and may include preferably a halogenated hydrocarbon such as methylene chloride and chloroform.
  • the oxidizing agent employable here may include, for example, peracetic acid and 3-chloroperbenzoic acid.
  • the reaction is carried out at 0 to 50° C., preferably at room temperature, and the reaction time is usually 30 minutes to 2 hours.
  • the desired compound (Id) is prepared by reacting bromoketone (21), obtained according to the procedures described in Japanese Unexamined Patent Publication (KOKAI) No. Hei 7-2802 (Jan. 6, 1995), with the above mercaptan (3) or an acetic acid derivative thereof (4) under alkaline conditions to obtain a thioether derivative (22) and reacting (22) with trimethylsulfoxonium iodide and 1,2,4-triazole in the presence of a base.
  • bromoketone (21) obtained according to the procedures described in Japanese Unexamined Patent Publication (KOKAI) No. Hei 7-2802 (Jan. 6, 1995)
  • KOKAI Japanese Unexamined Patent Publication
  • mercaptan (3) or an acetic acid derivative thereof (4) under alkaline conditions to obtain a thioether derivative (22) and reacting (22) with trimethylsulfoxonium iodide and 1,2,4-triazole in the presence of a base.
  • the solvent used in the reaction of (21) and (3) or (4) includes preferably alcohols such as methanol, ethanol and propanol, and the alkali employable here includes sodium hydroxide, potassium hydroxide, sodium methoxide and sodium ethoxide.
  • the solvent used in the reaction for converting the thioether derivative (22) to (Id) includes preferably alcohols such as methanol, ethanol, propanol, butanol and t-butanol and aprotic solvents such as dimethylformamide, dimethylacetamide, dimethyl sulfoxide, acetonitrile and tetrahydrofuran.
  • the base used in the reaction includes sodium hydride, sodium methoxide, sodium ethoxide, lithium methoxide, potassium tert-butoxide, lithium hydroxide, sodium hydroxide and potassium hydroxide, and the amount used is 2 to 5 molar equivalents based on the compound (22).
  • Trimetbylsulfoxonium iodide and 1,2,4-triazole are used in 1 to 2 molar equivalents based on the compound (22), respectively.
  • the reaction temperature is room temperature to 100° C. and the reaction time is 2 to 10 hours.
  • the aldehyde compounds used in Examples are synthesized according to the procedures described in the literature and/or the citation of the literature in the cases where the literature is indicated in parenthesis.
  • the aldehyde compounds for which the literature is not indicated are commercially available or can be obtained by the procedures for synthesizing an aldehyde which are described in the literature in the parenthesis of Examples or are described in the citation of the literature or a process according to the procedures for synthesizing an aldehyde described in Reference example of the present specification.
  • This compound was mixed with 1 equivalent of oxalic acid in a mixed solvent of ethyl acetate-hexane to obtain an oxalic acid salt crystal having a melting point of 132 to 135° C.
  • This compound was mixed with 1 equivalent of oxalic acid in a mixed solvent of ethyl acetate-hexane to obtain an oxalic acid salt crystal having a melting point of 103 to 105° C.
  • This compound was mixed with 1 equivalent of oxalic acid in a mixed solvent of ethyl acetate-hexane to obtain an oxalic acid salt crystal having a melting point of 164 to 165° C.
  • This compound was mixed with 1 equivalent of oxalic acid in a mixed solvent of ethyl acetate-hexane to obtain an oxalic acid salt crystal having a melting point of 53 to 57° C.
  • Mass spectrum m/e: 582, 563, 522, 500, 427, 359, 299, 258, 215, 187, 144, 101, 82.
  • Mass spectrum m/e: 512, 510, 452, 430, 425, 367, 357, 289, 229, 224, 188, 145, 117, 82.
  • Mass spectrum m/e: 544, 525, 513, 483, 461, 388, 365, 284, 260, 224, 219, 176, 144, 130, 82.
  • Mass spectrum m/e: 608, 589, 548, 526, 453, 433, 385, 325, 241, 224, 213, 144, 127, 82.
  • Mass spectrum m/e: 499, 439, 417, 410, 365, 344, 307, 275, 247, 216, 144, 132, 104, 82.
  • Mass spectrum m/e: 554, 535, 472, 384, 331, 271, 224, 215, 187, 127, 87.
  • the reaction mixture was poured into 20 ml of a 3% aqueous sodium hydrogencarbonate solution under ice-cooling and the mixture was stirred for 5 minutes. Then, the molecular sieves was removed by filtration and the organic layer was collected by fractions, followed by drying and evaporation of the solvent under reduced pressure. 908 mg of the thus obtained oil were subjected to column chromatography using 19 g of silica gel and eluted with a mixed solvent of hexane-ethyl acetate (1:1) to obtain 448 mg (yield: 63%) of the desired title compound as an oil.
  • Mass spectrum m/e: 587, 568, 331, 298, 256, 201, 159, 131.
  • Mass spectrum m/e: 614, 541, 494, 478, 406, 348, 256, 211.
  • Mass spectrum m/e: 599, 580, 557, 530, 500, 438, 388, 376, 346, 284, 258, 224, 183.
  • Mass spectrum m/e: 616, 600, 547, 400, 370, 342, 284, 252, 224, 183.
  • Mass spectrum m/e: 563, 544, 340, 310, 277, 224, 159, 127.
  • Mass spectrum m/e: 238 (M + ), 237, 195, 162(100%), 149, 116, 107, 73.
  • the reaction mixture was washed with an aqueous sodium hydrogencarbonate solution and the solid obtained by evaporation of the solvent was washed with a mixed solvent of ethyl acetate-hexane to obtain 328 mg (yield: 83%) having a melting point of 192 to 194° C.
  • the insolubles were removed by filtration using Celite and the filtrate was extracted with ethyl acetate and dried, followed by evaporation of the solvent to obtain an oil.
  • the oil was subjected to column chromatography using 5 g of silica gel and eluted with a mixed solvent of 30 to 40% ethyl acetate-hexane to obtain 90 mg of the title compound as an oil.
  • Mass spectrum m/e: 259, 244, 216, 202, 186, 183, 160, 144, 127, 116, 97, 84, 57.
  • Mass spectrum m/e: 217, 202, 184, 161, 144, 127, 117, 84, 82.
  • Mass spectrum m/e: 468, 408, 395, 365, 321, 284, 253, 224, 188, 166, 144, 127.
  • Mass spectrum m/e: 368, 308, 286, 284, 253, 224, 213, 183, 165, 144, 116, 113, 84.
  • reaction mixture was subjected to silica gel column chromatography and eluted with a mixed solvent of hexane-ethyl acetate (2:1 to 1:1) to obtain 2.32 g (yield: 95%) of the desired compound as a slightly yellow solid.
  • Mass spectrum m/e: 373, 330, 298, 256, 228, 215, 187, 158, 136, 116, 101.
  • Mass spectrum m/e; 441, 425, 385, 367, 341, 311, 284, 252, 224, 199, 183, 165, 141, 127, 88.
  • Mass spectrum m/e: 200 (M + ), 199, 171, 151, 145, 131 (100%)), 103, 102.
  • Mass spectrum m/e: 216 (M + ), 215, 187, 175, 162, 131(100%), 119, 101.
  • Mass spectrum m/e: 281 (M + ), 236(100%), 180, 152, 151, 123, 122, 93.
  • Mass spectrum m/e: 239 (M + ), 210, 188, 168, 138(100%), 109, 108, 78.
  • Mass spectrum m/e: 237 (M + ), 186, 166, 136(100%), 107, 106, 78.
  • Mass spectrum m/e: 289 (M + ), 260, 188, 178, 160, 145, 128, 117, 81, 69(100%).
  • This product was stirred in 15 ml of a 0.07 N sodium methoxide-methanol solution at room temperature for 2 to 3 hours. To the mixture was added 0.2 ml of acetic acid, and the resulting mixture was diluted with ethyl acetate and washed with an aqueous NaCl solution. After the mixture was dried, the solvent was distilled off to obtain 865 mg of a 4:1 mixture of the title trans form and a cis form as a solid. The solid was recrystallized from a mixed solvent of ether-hexane to obtain 220 mg of the trans form title compound having a melting point of 44 to 46° C.
  • Cis isomer exhibited a signal at ⁇ 3.67 (2 H, s) and ⁇ 9.64 (1 H, s).
  • Mass spectrum m/e: 268, 240, 127, 125, 110.
  • the mixture was diluted with toluene and washed with water and an aqueous NaCl solution. After the mixture was dried, the crude product obtained by evaporation of the solvent was subjected to column chromatography using 5 g of silica gel and eluted with a mixed solvent of methylene chloride-hexane (1:2). The eluted portion was recrystallized from hexane to obtain 86 mg (yield: 31%) of the title compound having a melting point of 142 to 144° C.
  • Mass spectrum m/e: 436, 417, 403, 311, 277, 235, 159, 125.
  • Mass spectrum m/e: 452, 436, 327, 278, 277, 159, 125.
  • the crude product obtained by evaporation of the solvent was subjected to column chromatography using 5 g of silica gel and eluted with a mixed solvent of methylene cbloride-hexane (1:1), followed by purification over Rover column [GrosseB, a mixed solvent of ethyl acetate-hexane (1:19)] to obtain 98 mg (yield: 70%) of the title compound having a melting point of 113 to 115° C.
  • Mass spectrum m/e: 354, 335, 311, 277, 235, 159.
  • Mass spectrum m/e: 200, 183, 171, 151, 131.
  • Mass spectrum m/e: 198, 197, 170, 151, 120.
  • Mass spectrum m/e: 224, 196, 195, 175, 170, 146.
  • mice one group consisting of 10 mice, which were innoculated with 4 to 9 ⁇ 10 6 Candida albicans, were administered orally 20 mg/kg of preparations after 1, 4 and 24 hours, and thereafter the survival rate until 21 days after infection was examined.
  • the results of comparison of the compound (I) of the present invention with commercially available Fluconazol are shown in Table 2. From the results, it apparent that the compound (I) exhibits an excellent antifungal activity.
  • TABLE 2 Survival rate % Compound 14 days 21 days Example 2 100 100 11 100 100 15 100 100 16 100 100 18 100 100 21 100 60 30 100 100 100 32 100 100 100 35 100 100 37 100 100 Fluconazol 70 60
  • the compound having the general formula (I) or a pharmacologically acceptable salt thereof of the present invention has an excellent antifungal activity and is useful as an antifungal agent.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A compound having the formula:
Figure US20010031768A1-20011018-C00001
[wherein Ar1 represents a phenyl which may be substituted, Ar2 represents a phenyl which may be substituted or a heterocyclic group which may be substituted, R0 represents a hydrogen atom or a lower alkyl; R1 represents a lower alkyl; R2 to R5 represent a hydrogen atom or an alkyl which may be substituted with halogen, n represents 0 to 2; p represents 0 or 1; q, r and s represent 0 to 2; A represents a 4- to 7-membered carbon ring or a 4- to 7-membered heterocyclic group].
The compound of the present invention exhibits excellent antifungal activities.

Description

  • This application is a continuation-in-part application of International application PCT/JP96/00932 filed Apr. 5, 1996, which is hereby incorporated in its entirety.[0001]
  • The present invention relates to a 1,2,4-triazole compound represented by the formula (I) which is particularly effective for mycotic disease of a human being and an animal. [0002]
    • BACKGROUND OF THE INVENTION
  • In the Japanese Unexamined Patent Publication (KOKAI) No. Sho 61-85369, it is described that an analogous compound of the compound of the present invention, in which the following moiety (which corresponds to the right hand moiety of formula (I) which starts with —A—): [0003]
  • —A—(CO)p−(R2C═CR3)q−(C≡C)r−(R4C═CR5)s−Ar2
  • is bonded to an alkyl, a cycloalkylalkyl group or a cycloalkyl group, has antifungal activities. [0004]
  • However, the present inventors made intensive studies in order to find a more excellent antifungal agent and found that the compound of the present invention is an excellent antifungal agent to accomplish the present invention. [0005]
    • SUMMARY OF THE INVENTION
  • The present invention relates to a compound having the formula (I): [0006]
    Figure US20010031768A1-20011018-C00002
  • wherein Ar[0007] 1 represents a phenyl group or a phenyl group having 1 to 3 substituent(s), (the substituent(s) represent(s) a halogen atom or a trifluoromethyl group);
  • Ar[0008] 2 represents a phenyl group, a 5- or 6-membered aromatic heterocyclic group (the aromatic heterocyclic group has at least one nitrogen, oxygen or sulfur atom) or a phenyl group or a 5- or 6-membered aromatic heterocyclic group having 1 to 3 substituents [the substituent(s) represent(s) a lower alkyl group, a lower alkoxy group, a halogen atom, a lower alkyl group substituted with a halogen atom or halogen atoms, a lower alkoxy group substituted with a halogen atom or halogen atoms, a nitro group, a cyano group, a —S(O)mR6 group (R6 represents a lower alkyl group which may be substituted with a halogen atom or halogen atoms and m represents 0, 1 or 2) or a —NHCOR7 group (R7 represents a lower alkyl group) and the aromatic heterocyclic group has at least one nitrogen, oxygen or sulfur atoms;
  • R[0009] 0 represents a hydrogen atom or a lower alkyl group;
  • R[0010] 1 represents a lower alkyl group;
  • R[0011] 2, R3, R4 and R5 may be the same or different and represent a hydrogen atom, a lower alkyl group or a lower alkyl group substituted with a halogen atom or halogen atoms and, where q and/or s represent 2, each of R2, R3, R4 and R5 represents independently a group which is the same or different from the other R2, R3, R4 and R5 respectively;
  • n represents 0, 1 or 2; [0012]
  • p represents 0 or 1; [0013]
  • q, r and s represent 0, 1 or 2; and [0014]
  • A represents a 4- to 7-membered aliphatic carbocyclic group comprising 4 to 7 carbon atoms or a 4- to 7-membered aliphatic heterocyclic group having at least one nitrogen, oxygen or sulfur atom, [0015]
  • or a pharmacologically acceptable salt thereof. [0016]
  • The above-mentioned halogen atom is, for example, a fluorine, chlorine or bromine atom, preferably a fluorine or chlorine atom. [0017]
  • The lower alkyl group is, for example, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl group, preferably a methyl, ethyl, propyl or isopropyl group. [0018]
  • The lower alkoxy group is, for example, a methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy or tert-butoxy group, preferably a methoxy, ethoxy, propoxy or isopropoxy group. [0019]
  • The 5- or 6-membered aromatic heterocyclic group of Ar[0020] 2 is, for example, a furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl or pyrazyl group, preferably a furyl, thienyl, pyrrolyl or pyridyl group.
  • The 4- to 7-membered aliphatic carbocyclic group comprising 4 to 7 carbon atoms of A is, for example, a cyclobutane, cyclopentane, cyclohexane or cyclobutane ring, preferably a cyclobutane, cyclopentane or cyclohexane ring. [0021]
  • The 4- to 7-membered aliphatic heterocyclic group having at least one nitrogen, oxygen or sulfur atom of A is, for example, an azetidine, pyrrolidine, piperidine, homopiperidine, oxetane, tetrahydrofuran, tetrahydropyran, thietane, tetrahydrothiophene, pentamethylenesulfide, 1,4,5,6-tetrahydropyrimidine, 1,3-dioxane, 1,3-dithiane, dihydroxazine, tetrahydroxazine, dihydrothiazine or tetrahydrothiazine ring, preferably an azetidine, piperidine, 1,3- dioxane, 1,4,5 ,6-tetrahydropyrimidine, tetrahydroxazine or 1,3-dithiane ring. [0022]
  • The preferable compound having the formula (I) is the compound in which: [0023]
  • Ar[0024] 1 is a dichlorophenyl, difluorophenyl, chlorophenyl, fluorophenyl, (trifluoromethyl)phenyl or fluoro(trifluoromethyl)phenyl group, preferably a 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-(trifluoromethyl)phenyl or 2-fluoro-4-(trifluoromethyl)phenyl group, particularly preferably a 2,4-dichlorophenyl, 2,4-difluorophenyl or 4-(trifluoromethyl)phenyl group;
  • Ar[0025] 2 is a fluorophenyl, chlorophenyl, difluorophenyl, dicblorophenyl, (trifluoromethyl)phenyl, (trichloromethyl)phenyl, fluoro-(trifluoromethyl)phenyl, (difluoromethoxy)phenyl, (trifluoromethoxy)phenyl, (2,2,2-trfluoroethoxy)phemyl, (1,1,2,2-tetrafluoroethoxy)phenyl, (2,2,3,3-tetrafluoropropoxy)phenyl, fluoro-(2,2,3,3-tetrafluoropropoxy)phenyl, nitrophenyl, fluoro-nitrophenyl, cyanophenyl, chloro-cyanophenyl, (methylthio)phenyl, (methylsulfinyl) phenyl, (methylsulfonyl) phenyl, (trifluoromethylthio)phenyl, (trifluoromethylsulfinyl)phenyl, (trifluoromethylsulfonyl)phenyl, chloropyridyl, (trifluoromethyl)pyridyl, (2,2,3,3-tetrafluoropropoxy)pyridyl, (trifluoromethyl) furyl, chlorothienyl or (trifluoromethyl) thienyl group, preferably a 4-fluorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl, 4-(trifluoromethyl)phenyl, 4-(trichloromethyl)phenyl, 2-fluoro-4-(trifluoromethyl)phenyl, 4-(difluoromethoxy)phenyl, 3-(trifluoromethoxy)phenyl, 4-(trifluoromethoxy)phenyl, 4-(2,2,2-trifluoroethoxy)phenyl, 4-(1,1,2,2-tetrafluoroethoxy)phenyl, 4-(2,2,3,3-tetrafluoropropoxy)phenyl, 2-fluoro-4-(2,2,3,3-tetrafluoropropoxy)phenyl, 4-nitrophenyl, 2-fluoro-4-nitrophenyl, 4-cyanophenyl, 2-chloro-4-cyanophenyl, 4-(methylthio)phenyl, 4-(methylsulfinyl)phenyl, 4-(methylsulfonyl)phenyl, 4-(trifluoromethylthio)phenyl, 4-(trifluoromethylsulfinyl)phenyl, 4-(trifluoromethylsulfonyl)phenyl, 6-chloro-3-pyridyl, 6-(trifluoromethyl)-3-pyridyl, 5-chloro-2-pyridyl, 6-(2,2,3,3-tetrafluoropropoxy)-3-pyridyl, 5-(trifluoromethyl)-2-furyl, 5-chloro-2-thienyl or 5-(trifluoromethyl)-2-thienyl group, particularly preferably a 4-chlorophenyl, 4-(trifluoromethylthio)phenyl, 4-(trifluoromethylsulfonyl)phenyl, 4-(trifluoromethyl)phenyl, 4-(trifluoromethoxy)phenyl or 4-(2,2,3,3-tetrafluoropropoxy)phenyl group;
  • R[0026] 0 is a hydrogen atom, a methyl, ethyl or propyl group, preferably a hydrogen atom, a methyl or ethyl group, particularly preferably a hydrogen atom or a methyl group;
  • R[0027] 1 is a methyl, ethyl or propyl group, preferably a methyl or ethyl group, particularly preferably a methyl group;
  • R[0028] 2, R3, R4 and R5 may be the same or different and are a hydrogen atom, a methyl, ethyl, propyl or trifluorometbyl group, preferably a hydrogen atom, a methyl or trifluorometbyl group, particularly preferably a hydrogen atom or a trifluoromethyl group;
  • n is 0, 1 or 2, particularly preferably 0; [0029]
  • p is 0 or 1, particularly preferably 0; [0030]
  • q is 0, 1 or 2, particularly preferably 1; [0031]
  • r is 0, 1 or 2, particularly preferably 0 or 1; [0032]
  • s is 0, 1 or 2, particularly preferably 1; [0033]
  • A is a cyclobutane, cyclopentane, cyclohexaue, azetidine, pyrrolidine, piperidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, 1,3-dioxane, 1,3-dithiane, tetrahydroxazime or tetrahydrothiazine ring, preferably a cyclobutane, cyclohexane, azetidine, piperidine, 1,3-dioxane, 1,3-dithiane, tetrahydroxazine or tetrahydrothiazine ring, particularly preferably a cyclohexane, piperidine, 1,3-dioxane or 1,3-dithiane ring. [0034]
  • The preferable compound (I) can be exemplified by the compound in which Ar[0035] 1 is a 4-chlorophenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl or 4-(trifluoromethyl)phenyl group; R0 is a hydrogen atom or a methyl group; R1 is a methyl group; and the moiety represented by the formula:
  • —S(O)n—A−(CO)p−(R2C═CR3)q−(C≡C)═−(R4C═CR5)s−Ar2
  • is a group as shown in Table 1. [0036]
    TABLE 1
    Example —S(O)n—A—(CO)p—(R2C═CR3)q—(C≡C)r—(R4C═CR5)s—Ar2
    1
    Figure US20010031768A1-20011018-C00003
    2
    Figure US20010031768A1-20011018-C00004
    3
    Figure US20010031768A1-20011018-C00005
    4
    Figure US20010031768A1-20011018-C00006
    5
    Figure US20010031768A1-20011018-C00007
    6
    Figure US20010031768A1-20011018-C00008
    7
    Figure US20010031768A1-20011018-C00009
    8
    Figure US20010031768A1-20011018-C00010
    9
    Figure US20010031768A1-20011018-C00011
    10
    Figure US20010031768A1-20011018-C00012
    11
    Figure US20010031768A1-20011018-C00013
    12
    Figure US20010031768A1-20011018-C00014
    13
    Figure US20010031768A1-20011018-C00015
    14
    Figure US20010031768A1-20011018-C00016
    15
    Figure US20010031768A1-20011018-C00017
    16
    Figure US20010031768A1-20011018-C00018
    17
    Figure US20010031768A1-20011018-C00019
    18
    Figure US20010031768A1-20011018-C00020
    19
    Figure US20010031768A1-20011018-C00021
    20
    Figure US20010031768A1-20011018-C00022
    21
    Figure US20010031768A1-20011018-C00023
    22
    Figure US20010031768A1-20011018-C00024
    23
    Figure US20010031768A1-20011018-C00025
    24
    Figure US20010031768A1-20011018-C00026
    25
    Figure US20010031768A1-20011018-C00027
    26
    Figure US20010031768A1-20011018-C00028
    27
    Figure US20010031768A1-20011018-C00029
    28
    Figure US20010031768A1-20011018-C00030
    29
    Figure US20010031768A1-20011018-C00031
    30
    Figure US20010031768A1-20011018-C00032
    31
    Figure US20010031768A1-20011018-C00033
    32
    Figure US20010031768A1-20011018-C00034
    33
    Figure US20010031768A1-20011018-C00035
    34
    Figure US20010031768A1-20011018-C00036
    35
    Figure US20010031768A1-20011018-C00037
    36
    Figure US20010031768A1-20011018-C00038
    37
    Figure US20010031768A1-20011018-C00039
    38
    Figure US20010031768A1-20011018-C00040
    39
    Figure US20010031768A1-20011018-C00041
    40
    Figure US20010031768A1-20011018-C00042
    41
    Figure US20010031768A1-20011018-C00043
    42
    Figure US20010031768A1-20011018-C00044
    43
    Figure US20010031768A1-20011018-C00045
    44
    Figure US20010031768A1-20011018-C00046
    45
    Figure US20010031768A1-20011018-C00047
    46
    Figure US20010031768A1-20011018-C00048
    47
    Figure US20010031768A1-20011018-C00049
    48
    Figure US20010031768A1-20011018-C00050
    49
    Figure US20010031768A1-20011018-C00051
    50
    Figure US20010031768A1-20011018-C00052
    51
    Figure US20010031768A1-20011018-C00053
    52
    Figure US20010031768A1-20011018-C00054
    53
    Figure US20010031768A1-20011018-C00055
    54
    Figure US20010031768A1-20011018-C00056
    55
    Figure US20010031768A1-20011018-C00057
    56
    Figure US20010031768A1-20011018-C00058
    57
    Figure US20010031768A1-20011018-C00059
    58
    Figure US20010031768A1-20011018-C00060
    59
    Figure US20010031768A1-20011018-C00061
    60
    Figure US20010031768A1-20011018-C00062
    61
    Figure US20010031768A1-20011018-C00063
    62
    Figure US20010031768A1-20011018-C00064
    63
    Figure US20010031768A1-20011018-C00065
    64
    Figure US20010031768A1-20011018-C00066
    65
    Figure US20010031768A1-20011018-C00067
    66
    Figure US20010031768A1-20011018-C00068
    67
    Figure US20010031768A1-20011018-C00069
    68
    Figure US20010031768A1-20011018-C00070
    69
    Figure US20010031768A1-20011018-C00071
    70
    Figure US20010031768A1-20011018-C00072
    71
    Figure US20010031768A1-20011018-C00073
    72
    Figure US20010031768A1-20011018-C00074
    73
    Figure US20010031768A1-20011018-C00075
    74
    Figure US20010031768A1-20011018-C00076
    75
    Figure US20010031768A1-20011018-C00077
    76
    Figure US20010031768A1-20011018-C00078
    77
    Figure US20010031768A1-20011018-C00079
    78
    Figure US20010031768A1-20011018-C00080
    79
    Figure US20010031768A1-20011018-C00081
    80
    Figure US20010031768A1-20011018-C00082
    81
    Figure US20010031768A1-20011018-C00083
    82
    Figure US20010031768A1-20011018-C00084
    84
    Figure US20010031768A1-20011018-C00085
    85
    Figure US20010031768A1-20011018-C00086
    86
    Figure US20010031768A1-20011018-C00087
    87
    Figure US20010031768A1-20011018-C00088
    88
    Figure US20010031768A1-20011018-C00089
    89
    Figure US20010031768A1-20011018-C00090
    90
    Figure US20010031768A1-20011018-C00091
    91
    Figure US20010031768A1-20011018-C00092
    92
    Figure US20010031768A1-20011018-C00093
    93
    Figure US20010031768A1-20011018-C00094
    94
    Figure US20010031768A1-20011018-C00095
    95
    Figure US20010031768A1-20011018-C00096
    96
    Figure US20010031768A1-20011018-C00097
    97
    Figure US20010031768A1-20011018-C00098
    98
    Figure US20010031768A1-20011018-C00099
    99
    Figure US20010031768A1-20011018-C00100
    100
    Figure US20010031768A1-20011018-C00101
    101
    Figure US20010031768A1-20011018-C00102
    102
    Figure US20010031768A1-20011018-C00103
    103
    Figure US20010031768A1-20011018-C00104
    104
    Figure US20010031768A1-20011018-C00105
    105
    Figure US20010031768A1-20011018-C00106
    106
    Figure US20010031768A1-20011018-C00107
    107
    Figure US20010031768A1-20011018-C00108
    108
    Figure US20010031768A1-20011018-C00109
    109
    Figure US20010031768A1-20011018-C00110
    110
    Figure US20010031768A1-20011018-C00111
    111
    Figure US20010031768A1-20011018-C00112
    112
    Figure US20010031768A1-20011018-C00113
    113
    Figure US20010031768A1-20011018-C00114
    114
    Figure US20010031768A1-20011018-C00115
    115
    Figure US20010031768A1-20011018-C00116
    116
    Figure US20010031768A1-20011018-C00117
    117
    Figure US20010031768A1-20011018-C00118
    118
    Figure US20010031768A1-20011018-C00119
    119
    Figure US20010031768A1-20011018-C00120
    120
    Figure US20010031768A1-20011018-C00121
    121
    Figure US20010031768A1-20011018-C00122
    122
    Figure US20010031768A1-20011018-C00123
    123
    Figure US20010031768A1-20011018-C00124
    124
    Figure US20010031768A1-20011018-C00125
    125
    Figure US20010031768A1-20011018-C00126
    126
    Figure US20010031768A1-20011018-C00127
    127
    Figure US20010031768A1-20011018-C00128
    128
    Figure US20010031768A1-20011018-C00129
    129
    Figure US20010031768A1-20011018-C00130
    130
    Figure US20010031768A1-20011018-C00131
    131
    Figure US20010031768A1-20011018-C00132
    132
    Figure US20010031768A1-20011018-C00133
    133
    Figure US20010031768A1-20011018-C00134
    134
    Figure US20010031768A1-20011018-C00135
    135
    Figure US20010031768A1-20011018-C00136
    136
    Figure US20010031768A1-20011018-C00137
    137
    Figure US20010031768A1-20011018-C00138
    138
    Figure US20010031768A1-20011018-C00139
    139
    Figure US20010031768A1-20011018-C00140
    140
    Figure US20010031768A1-20011018-C00141
    141
    Figure US20010031768A1-20011018-C00142
    142
    Figure US20010031768A1-20011018-C00143
    143
    Figure US20010031768A1-20011018-C00144
    144
    Figure US20010031768A1-20011018-C00145
    145
    Figure US20010031768A1-20011018-C00146
    146
    Figure US20010031768A1-20011018-C00147
    147
    Figure US20010031768A1-20011018-C00148
    148
    Figure US20010031768A1-20011018-C00149
    149
    Figure US20010031768A1-20011018-C00150
    150
    Figure US20010031768A1-20011018-C00151
    151
    Figure US20010031768A1-20011018-C00152
    152
    Figure US20010031768A1-20011018-C00153
    153
    Figure US20010031768A1-20011018-C00154
    154
    Figure US20010031768A1-20011018-C00155
    155
    Figure US20010031768A1-20011018-C00156
    156
    Figure US20010031768A1-20011018-C00157
    157
    Figure US20010031768A1-20011018-C00158
    158
    Figure US20010031768A1-20011018-C00159
    159
    Figure US20010031768A1-20011018-C00160
    160
    Figure US20010031768A1-20011018-C00161
    161
    Figure US20010031768A1-20011018-C00162
    162
    Figure US20010031768A1-20011018-C00163
    163
    Figure US20010031768A1-20011018-C00164
    164
    Figure US20010031768A1-20011018-C00165
    165
    Figure US20010031768A1-20011018-C00166
    166
    Figure US20010031768A1-20011018-C00167
    167
    Figure US20010031768A1-20011018-C00168
    168
    Figure US20010031768A1-20011018-C00169
    169
    Figure US20010031768A1-20011018-C00170
    170
    Figure US20010031768A1-20011018-C00171
    171
    Figure US20010031768A1-20011018-C00172
    172
    Figure US20010031768A1-20011018-C00173
    173
    Figure US20010031768A1-20011018-C00174
    174
    Figure US20010031768A1-20011018-C00175
    175
    Figure US20010031768A1-20011018-C00176
    176
    Figure US20010031768A1-20011018-C00177
    177
    Figure US20010031768A1-20011018-C00178
    178
    Figure US20010031768A1-20011018-C00179
    179
    Figure US20010031768A1-20011018-C00180
    180
    Figure US20010031768A1-20011018-C00181
    181
    Figure US20010031768A1-20011018-C00182
    182
    Figure US20010031768A1-20011018-C00183
    183
    Figure US20010031768A1-20011018-C00184
    184
    Figure US20010031768A1-20011018-C00185
    185
    Figure US20010031768A1-20011018-C00186
    186
    Figure US20010031768A1-20011018-C00187
    187
    Figure US20010031768A1-20011018-C00188
  • Preferred compounds in Table 1 include those having the substituents of 4, 6, 7, 13, 16, 18, 22, 25, 32, 36, 40, 43, 44, 47, 52, 53, 61, 63, 71, 76, 96, 107, 123, 127, 142, 174, 176, 177, 178, 181, 182, 183 and 186, and particularly preferable compounds may include [0037]
  • 2-(2,4-difluorophenyl)-3-[[2- [2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-1-(1H-1,2,4-triazol-1-yl)-2-butanol (the compound corresponding to Example 2), [0038]
  • 2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[2-[4-(trifluoromethoxy)phenyl[vinyl]-1,3-dioxan-5-yl]thio]-2-butanol (the compound corresponding to Example 11), [0039]
  • 2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol (the compound corresponding to Example 15), [0040]
  • 2-(2,4-difluorophenyl)-3-[[2-[4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol (the compound corresponding to Example 16), [0041]
  • 2-(2,4-difluorophenyl)-3-[[2-[4-[4-(chlorophenyl)-4,4,4-trifluoro-1,3-pentadien-1-yl]-1,3-dioxan-1-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol (the compound corresponding to Example 18), [0042]
  • 2-(2,4-difluorophenyl)-3-[[1-[4-(trifluoromethoxy) cinnamoyl]piperidin-4-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol (the compound corresponding to Example 21), [0043]
  • 2-(2,4-difluorophenyl)-3-[[1-[4-nitrocinnamoyl]piperidin-4-yl]thio]-1-(1H-1,2,4-triazol-1-yl)-2-butanol (the compound corresponding to Example 23), [0044]
  • 2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[1-[5-[4-(trifluoromethoxy)phenyl]-2,4-pentadienoyl]piperidin-4-yl]thio]-2-butanol (the compound corresponding to Example 24), [0045]
  • 3-methyl-1-(1 H-1,2,4-triazol-1-yl) -2-[4-(trifluoromethyl)phenyl]-3-[[2-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thiol]-2-butanol (the compound corresponding to ple 31), [0046]
  • 2-(2,4-diflucrophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[(2-[4-(trifluoromethylthio)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol (the compound corresponding to Example 32), [0047]
  • 3-[[2-[4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thiol]-1-(1H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol (the compound corresponding to Example 33), [0048]
  • 1-(1 H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol (the compound corresponding to Example 34), [0049]
  • 2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethylsulfinyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol (the compound corresponding to Example 35), [0050]
  • 2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-cyclohexyl]thiol]-2-butanol (the compound corresponding to Example 36), [0051]
  • 2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[6-[4-(trifluoromethyl)phenyl]-1,3,5-hexatrien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol (the compound corresponding to Example 37), [0052]
  • 2-(2,4-difluorophenyl)-3-methyl-1-(1H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol (the compound corresponding to Example 38) and [0053]
  • 2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-([[2-[4-[4-(trifluoromethyl)phenyl]-1-buten-3-yn-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol (the compound corresponding to Example 39). [0054]
  • The triazole compound (I) of the present invention has at least two asymmetric carbon atoms, and optical isomers and diastereomers exist. In the optical isomer, both antipodes can be obtained by general optical resolution or asymmetric synthesis. Further, the diastereomers can be separated by conventional separation methods such as fractional recrystallization and chromatography. The compound (I) of the present invention includes one of these isomers or mixtures thereof. [0055]
  • The triazole compound (I) of the present invention can be used as an antifungal agent as such or in the form of a pharmacologically acceptable salt. The pharmacologically acceptable salt of the compound (I) includes, for example, a salt of inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and nitric acid, a salt of carboxylic acids such as acetic acid, fumaric acid, maleic acid, oxalic acid, malonic acid, succinic acid, citric acid and malic acid, a salt of sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benenesulfonic acid and toluenesulfonic acid and a salt of amino acids such as glutamic acid and aspartic acid, preferably a salt of carboxylic acids. [0056]
  • Incidentally, a hydrate of the compound (I) and a hydrate of the salt of the compound (I) are also included in the compound of the present invention. [0057]
  • The compound (I) and a pharmacologically acceptable salt thereof of the present invention exhibit excellent antifungal activities and in the case where the compound (I) and a pharmacologically acceptable salt thereof are used as an antifungal agent, they can be administered as such or as a mixture, for example, with a suitable pharmacologically acceptable excipient or diluent orally in the form of a tablet, a capsule, a granule, a powder or a syrup or parenterally in the form of injection preparations. [0058]
  • These preparations are prepared by the known method using additives such as excipients (for example, sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbitol; starch derivatives such as corn starch, mashed potato starch, α-starch, dextrine and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, low bydroxypropyl-substituted cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium and internally bridged carboxymethyl cellulose sodium; gum arabic; dextran; Pullulan; silicate derivatives such as light silicic acid anhydride, synthetic aluminum silicate and magnesium meta-silicic acid aluminate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; and sulfate derivatives such as calcium sulfate), binders (for example, the above excipients; gelatin; polyvinylpyrrolidone; and Macrogol); disintegrating agents (for example, the above excipients; chemically modified starch-cellulose derivatives such as Crosscarmelose sodium, sodium carboxymethyl starch and bridged polyvinylpyrrolidone) , lubricants (for example, talc; stearic acid; and metal stearates such as calcium stearate and magnesium stearate; colloidal silica; waxes such as beeswax and spermaceti; boric acid; glycol; carboxylic acid such as fumaric acid and adipic acid; sodium carboxylate such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium laurylsulfate and magnesium laurylsulfate; silicic acids such as silicic acid anhydride and silicic acid hydrate; and starch derivatives in the above excipients), stabilizers (for example, p-hydroxybenzoates such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; phenols such as phenol and cresol; thimerosal; acetic anhydride; and sorbic acid); corrigents (for example, sweeteners, sour agents and perfumes conventionally used), suspending agents (for example, polysorbate 80 and carboxymethyl cellulose sodium), diluents and solvents for preparations (for example, water, ethanol and glycerin). While the dose varies depending on the condition and age of the patient to be treated, it is desirably administered 1 to 6 times daily depending on the condition: in the case of oral administration, the lower limit of 1 mg each time (preferably 5 mg) and the upper limit of 2000 mg (preferably 1000 mg) for an adult; and in the case of intravenous administration, the lower limit of 0.1 mg each time (preferably 0.5 mg) and the upper limit of 600 mg (preferably 500 mg) for an adult. [0059]
  • Among the compounds having the formula (I) of the present invention, the compound (Ia) in which R[0060] 0 is a hydrogen atom and n=0 can be prepared according to the process shown below:
    Figure US20010031768A1-20011018-C00189
  • (wherein Ar[0061] 1 and R1 have the same meanings as defined above and R8 represents the formula:
  • —A—(CO)p−(R2C=CR3)q−(C≡C)r−(R4C═CR5)s−Ar2
  • described above). More specifically, the desired compound (Ia) is prepared by reacting an epoxide compound (2) described in Japanese Unexamined Patent Publication (KOKAI) No. Hei 2-191262 (Jul. 27, 1990) with mercaptan (3) or an acetic acid ester derivative thereof under basic conditions. The solvent employable in the reaction includes preferably alcohols such as methanol, ethanol and propanol, aprotic solvents such as dimethylformamide, dimethylacetamide, dimethyl sulfoxide, acetonitrile and tetrahydrofuran. However, in the case where the reaction is carried out in the above aprotic solvent using an acetyl derivative (4), it is required to coexist alcohols or water. The base employable in the reaction includes sodium hydride, sodium methoxide, sodium ethoxide, lithium methoxide, potassium tert-butoxide, lithium hydroxide, sodium hydroxide and potassium hydroxide. The amount to be used is 0.1 to 2 molar equivalents based on the compound (2). Mercaptan (3) or the acetic acid derivative thereof (4) is used in 1 to 3 molar equivalents. The reaction temperature is room temperature to 100° C. and the reaction time is 2 to 10 hours. The compound (Ia) can be obtained by treating the reaction mixture by conventional procedures (an oil obtained by extraction with an organic solvent and then evaporation of the solvent is purified by column chromatography or recrystallization). [0062]
  • Incidentally, R[0063] 8SH (3) or R8SAc (4) used in the above reaction can be obtained according to the process shown below. More specifically, the componnd (3) or (4) in which A in R8 is a 1,3-dioxane ring and p=0 can be prepared using the known compound (5) [reference: O. E. van Lobuizen, P. E. Verkade, Rec. trav. chim., 78, 460 (1959)] as a starting material according to the scheme shown below (with respect to the reaction conditions and the isolation method in each step, see Reference examples 3, 4, 5, 6 and 7):
    Figure US20010031768A1-20011018-C00190
  • (wherein R[0064] 2, R3, R4, R5, Ar2, q, r and a have the same meanings as defined above). Among the unsaturated aldehydes (6) used in the above reaction, the compound (6a) in which r=0 can be generally obtained through an unsaturated ester (7a) according to the process shown below (with respect to the reaction conditions and the isolation method in each step, see Reference examples 8, 9, 10, 20, 21, 22, 23, 33 and 49):
    Figure US20010031768A1-20011018-C00191
  • (wherein R[0065] 2, R3, R4, R5, Ar2, q and s have the same meanings as defined above and DIBAL-H represents diisobutyl aluminum hydride).
  • Among the unsaturated aldebydes (6), the compound (6b) in which r=1 or 2 can be generally obtained through an unsaturated ester (7b) according to the process shown below (with respect to the reaction conditions and the isolation method in each step, see Reference examples 44, 45, 46, 47 and 48): [0066]
    Figure US20010031768A1-20011018-C00192
  • (wherein R[0067] 2, R3, R4, R5, q, r and s have the same meanings as defined above and DIBAL-H represents diisobutyl aluminum hydride).
  • Further, the compound (3b) or (4b) in which A in R[0068] 8 of R8SH (3) or R8SAc (4) is a 4- to 7-membered nitrogen-containing heterocyclic group (azetidine, pyrrolidine, piperidine, homopiperidine) and p=1 can be obtained according to the process shown below (with respect to the reaction conditions and the isolation method in each step, see Reference examples 16 and 17):
    Figure US20010031768A1-20011018-C00193
  • (wherein R[0069] 2, R3, R4, R5, q, r and s have the same meanings as defined above, t represents 3, 4, 5 or 6 and Boc represents tert-butoxycarbonyl).
  • The acid chloride (10) used in the above reaction can be obtained by treating a carboxylic acid, obtained by alkali-decomposing the unsaturated ester (7a) or (7b) described above, with thionyl chloride. [0070]
  • Among the compounds having the formula (I) of the present invention, the compound (Ia) in which R[0071] 0 is a hydrogen atom and n=0 can be also obtained according to the process shown below
    Figure US20010031768A1-20011018-C00194
  • (wherein Ar[0072] 1, R1 and R8 have the same meanings as defined above and X represents a chlorine, bromine or iodine atom, methanesulfonyloxy, benzenesulfonyloxy or toluenesulfonyloxy). More specifically, the process is to prepare the desired compound (Ia) by reacting a triazolylmercapto alcohol derivative (11) described in Japanese Unexamined Patent Publication (KOKAI) No. Hei 3-240778 (Oct. 28, 1991) with an alkylating agent (12) under basic conditions. The solvent employable in the reaction includes methanol, ethanol, propanol, butanol, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, acetonitrile, tetrahydrofuran, dioxane, diethyl ether, acetone, benzene, toluene, xylene, etc. The base employable in the reaction includes triethylamine, diisopropylethylamine, sodium hydride, sodium methoxide, sodium ethoxide, lithium methoxide, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, etc., and the amount used is 1 to 3 molar equivalents based on the compound (11). The alkylating reagent (12)is used in 1 to 3 molar equivalents. The reaction temperature is −50 to 100° C. and the reaction time is 2 to 10 hours. The compound (Ia) can be obtained by treating the reaction mixture by conventional procedures (an oil obtained by extraction with an organic solvent and then evaporation of the solvent is purified by column chromatography or recrystallization).
  • The alkylating reagent R[0073] 8-X (12) used in the above reaction can be obtained according to the process shown below. The compound (12a) in which A in R8 is a 1,3-dioxane ring and p=0 can be obtained, for example, by reacting a diol compcund (13), obtained by treating the above compound (5) with an acid in methanol, with the above unsaturated aldebyde (6) under acidic conditions (Reference example Nos. 56 and 57):
    Figure US20010031768A1-20011018-C00195
  • (wherein R[0074] 2, R3, R4, R5, Ar2, q, r and s have the same meanings as defined above). Further, the compound (12b) in which A in R8 is a 4- to 7-membered nitrogen-containing heterocyclic group (azetidine, pyrrolidine, piperidine, homopiperidine) and p=1 can be obtained, for example, by reacting a compound (14) obtained by treating the above cyclic amine derivative (8) with HCl, with the above acid chloride (10) in the presence of a base such as triethylamine:
    Figure US20010031768A1-20011018-C00196
  • (wherein R[0075] 2, R3, R4, R5, Ar2, q, r, s and t have the same meanings as defined above).
  • Among the compounds having the formula (I) of the present invention, the coatound (Ib) in which R[0076] 0 is a hydrogen atom, n=0, p=0 and A is a 1,3-dioxane ring can be also prepared according to the process shown below:
    Figure US20010031768A1-20011018-C00197
  • (wherein Ar[0077] 1, Ar2, R1, R2, R3, R4, R5, p, q and r have the same meanings as defined above) More specifically, the process is to prepare the desired compound (Ib) by reacting the above epoxide compound (2) with a thioacetic acid derivative (15) obtained by the reaction of the above )mown compound (5) with sodium thioacetate under the same conditions as in the reaction of (2) and (4) to obtain the compound (16), deprotecting the compound (16) according to conventional procedures such as the treatment with an acid to obtain the compound (17) and reacting the compound (17) with the above aldehyde compound (6). The reaction of the compounds (17) and (6) is usually carried out under acidic conditions. The acid employable here includes, for example, hydrogen chloride, sulfuric acid, nitric acid, boron trifluoride, metbiazesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid and the amount of the acid used is 1 to 2 molar equivalents based on (17). The aldehyde (6) is used in 1 to 2 molar equivalents. As the solvent, aprotic solvents such as methylene chloride, chloroform, 1,2-dichloroethane, benzene, toluene, xylene, diethyl ether and tetrahydrofuran are used. The reaction is carried out in the range of 0° C. to a boiling point of the solvent and the reaction time is 2 to 10 hours. While water produced by the reaction can be removed by azeotropic distillation, molecular sieves may be used as a dehydrating agent. The compound (Ib) can be obtained by neutralizing the reaction mixture with an aqueous sodium bydrogencarbonate solution and then treating it by conventional procedures (an oil obtained by extraction with an organic solvent and then evaporation of the solvent is purified by column chromatography or recrystallization).
  • Among the compounds of the present invention, the compound (Ic) in which R[0078] 0 is a hydrogen atom, n=0, p=1 and A is a 4- to 7-membered nitrogen-containing heterocyclic group (azetidine, pyrrolidine, piperidine, homopiperidine) can be obtained according to the process shown below:
    Figure US20010031768A1-20011018-C00198
  • (wherein Ar[0079] 1, Ar2, R1, R2, R3, R4, R5, q, r, s and t have the same meanings as defined above and Boc represents tert-butoxy carbonyl). More specifically, the process is to prepare the desired compound (Ic) by reacting the above epoxide compound (2) with the mercaptan compound (18), obtained by treating the above thioacetic acid derivative (9) with an alkali, under the same conditions as in the reaction of (2) and (3) to obtain the compound (19), deprotecting (19) by treating it with an acid according to conventional procedures to obtain the compound (20) and reacting the compound (20) with the above acid chloride (10). The reaction of compounds (20) and (10) is carried out in an inert solvent such as benzene, toluene, methylene chloride, chloroform or tetrabydrofuran in the presence of an appropriate base by conventional procedures (Reference example Nos. 13, 14, 18 and 19).
  • Among the compounds (I) of the present invention, the compound in which n=1 or n=2 can be prepared according to the process mentioned below. More specifically, the compound (I) in which n=1 can be prepared by oxidizing the compound (I) in which n=0 obtained by the above process in a solvent using 1 equivalent of an oxidizing agent, and the compound (I) in which n=2 can be prepared by oxidizing it using 2 or more equivalents of an oxidizing agent. The solvent employable here is not particularly limited so long as it does not inhibit the reaction and dissolves the starting materials to some extent and may include preferably a halogenated hydrocarbon such as methylene chloride and chloroform. The oxidizing agent employable here may include, for example, peracetic acid and 3-chloroperbenzoic acid. The reaction is carried out at 0 to 50° C., preferably at room temperature, and the reaction time is usually 30 minutes to 2 hours. The compound (I) (n=1 or 2) can be obtained by treating the reaction mixture according to conventional procedures (after the reaction mixture is washed with aqueous sodium hydrogencarbonate, the crude product obtained by evaporation of the solvent is purified by chromatography or recrystallization). [0080]
  • Among the compounds having the formula (I) of the present invention, the compound (Id) in which R[0081] 0 is lower alkyl and n=0 can be prepared according to the process shown below:
    Figure US20010031768A1-20011018-C00199
  • (wherein Ar[0082] 1, R0, R1 and R8 have the same meanings as defined above). More specifically, the desired compound (Id) is prepared by reacting bromoketone (21), obtained according to the procedures described in Japanese Unexamined Patent Publication (KOKAI) No. Hei 7-2802 (Jan. 6, 1995), with the above mercaptan (3) or an acetic acid derivative thereof (4) under alkaline conditions to obtain a thioether derivative (22) and reacting (22) with trimethylsulfoxonium iodide and 1,2,4-triazole in the presence of a base. The solvent used in the reaction of (21) and (3) or (4) includes preferably alcohols such as methanol, ethanol and propanol, and the alkali employable here includes sodium hydroxide, potassium hydroxide, sodium methoxide and sodium ethoxide. The solvent used in the reaction for converting the thioether derivative (22) to (Id) includes preferably alcohols such as methanol, ethanol, propanol, butanol and t-butanol and aprotic solvents such as dimethylformamide, dimethylacetamide, dimethyl sulfoxide, acetonitrile and tetrahydrofuran. The base used in the reaction includes sodium hydride, sodium methoxide, sodium ethoxide, lithium methoxide, potassium tert-butoxide, lithium hydroxide, sodium hydroxide and potassium hydroxide, and the amount used is 2 to 5 molar equivalents based on the compound (22). Trimetbylsulfoxonium iodide and 1,2,4-triazole are used in 1 to 2 molar equivalents based on the compound (22), respectively. The reaction temperature is room temperature to 100° C. and the reaction time is 2 to 10 hours. The compound (Id) (n=0) can be obtained by treating the reaction mixture by conventional procedures (a crude product obtained by extraction with an organic solvent and then evaporation of the solvent is purified by column chromatography or recrystallization). Among the compounds (I), the compound (Ie) in which n=0, p=0 and A is a 1,3-dioxane ring can be obtained from the compound (23) in which R8 is a group represented by the formula:
    Figure US20010031768A1-20011018-C00200
  • in the compound (Id) obtained by the above process through a triol (24) according to the process shown below: [0083]
    Figure US20010031768A1-20011018-C00201
  • (wherein R[0084] 0 represents lower alkyl and Ar1, Ar2, R1, R2, R3, R4, R5, q, r and s have the same meanings as defined above). The reaction conditions in the above respective steps are the same as those described in the reaction of (16)→(17)→(Ib).
  • The present invention will be explained below in more detail by referring to Examples, Reference examples, Test examples and Preparation examples but the scope of the present invention is not limited thereto. [0085]
  • Incidentally, the aldehyde compounds used in Examples are synthesized according to the procedures described in the literature and/or the citation of the literature in the cases where the literature is indicated in parenthesis. The aldehyde compounds for which the literature is not indicated are commercially available or can be obtained by the procedures for synthesizing an aldehyde which are described in the literature in the parenthesis of Examples or are described in the citation of the literature or a process according to the procedures for synthesizing an aldehyde described in Reference example of the present specification. [0086]
  • [Best mode for practicing the invention][0087]
    • EXAMPLE 1
  • (2R, 3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(E)-1-methyl-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-2-butanol [0088]
    Figure US20010031768A1-20011018-C00202
  • In 2 ml of dimethylformamide were dissolved 166 mg (0.48 mmol) of trans-4-(acetylthio)-2-[(E)-1-methyl-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxane as described in Reference example 7 and 110 mg (0.44 mmol) of (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1H-1,2,4-triazol-1-yl)methyl]oxirane, and 0.15 ml (0.24 mmol) of a 1.6 M sodium methoxide-metbanol solution were added thereto under nitrogen atmosphere, followed by stirring of the resulting mixture at 55° C. for 6 hours. After cooling, ethyl acetate was added to the reaction mixture to dilute it and the resulting mixture was washed with a saturated aqueous NaCl solution. An oil obtained by distilling off the solvent was subjected to column chromatography using 15 g of silica gel and was eluted by a mixed solvent of hexane-ethyl acetate (2:1) to obtain 180 mg (yield: 74%) of the desired compound as an oil. [0089]
  • NMR spectrum (60 MHz, CDCl[0090] 3) δ ppm: 1.19 (3 H, d, J=7 Hz), 1.90 (3 H, d, J=1.5 Hz), 3.34 (1 H, q, J=7 Hz), 3.0-3.9 (3 H, m), 4.1-4.6 (2 H, m), 4.80 (1 H, d, J=14 Hz), 4.94 (1 H, s), 5.02 (1 H, d, J=1 Hz), 5.05 (1 H, d, J=14 Hz), 6.4-7.0 (3 H, m), 7.1-7.6 (1 H, m), 7.40 (2 H, d, J=9 Hz), 7.62 (2 H, d, J=9 Hz), 7.80 (2 H, s).
    • EXAMPLE 2
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-1- (1 H-1,2,4-triazol-1-yl)-2-butanol [0091]
    Figure US20010031768A1-20011018-C00203
  • Reaction and treatment were carried out in the same manner as in Example 1 using (2 R,3 S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1 H-1,2,4-triazol-1-yl)methyl[oxirane and trans-5-(acetylthio)-2-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxane to obtain the desired compound having a melting point of 73 to 75° C. in a yield of 70%. [0092]
  • Specific rotation [α][0093] D 25 −73.8° (c=1.00, CHCl3)
  • NMR spectrum (270 MEz, CDCl[0094] 3) δ ppm: 1.19 (3 H, d, J=7.3 Hz), 3.34 (1 H, q, J=7.3 Hz), 3.43 (H, tt, J=11.2, 4.6 Hz), 3.65 (1 H, t, J=11.2 Hz), 3.67 (1 H, t, J=11.2 Hz), 4.33 (1 H, ddd, J=11.2, 4.6, 2.0 Hz), 4.46 (1 H, ddd, J=11.2, 4.6, 2.0 Hz), 4.82 (1 H, d, J=13.8 Hz), 5.03 (1 H, d, J=13.8 Hz), 5.04 (1 H, br s), 5.14 (1 H, d, J=4.6 Hz), 6.25 (1 H, dd, J=15.8, 4.6 Hz), 6.7-7.8 (2 H, m), 6.83 (1 H, d, J=15.8 Hz), 7.3-7.45 (1 H, m), 7.49 (2 H, d, J=8.6 Hz), 7.58 (2 H, d, J=8.6 Hz), 7.79 (2 H, s).
    • EXAMPLE 3
  • (2R,3R)-3-[[Trans-4-[(E)-2-(4-chlorophenyl)vinyl]cyclohexyl]thio]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0095]
    Figure US20010031768A1-20011018-C00204
  • Reaction and treatment were carried out in the same manner as in Example 1 using (2 R,3 S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1 H-1,2,4-triazol-1-yl)methyl]oxirane and trans-1-(acetylthio)-4-[(E)-2-(4-chlorophenyl)vinyl]cyclohexane to obtain the desired compound having a melting point of 64 to 66° C. in a yield of 31%. [0096]
  • Specific rotation [α][0097] D 25 −84.1° (c=2.69, CHCl3)
  • NMR spectrum (270 MEz, CDCl[0098] 3) δ ppm: 1.16 (3 H, d, J=7.3 Hz), 1.2-1.6 (4 H, m), 1.9-2.0 (2 H, m), 2.1-2.25 (3 H, m), 2.70 (1 H, tt, J=11.2, 4.0 Hz), 3.36 (1 H, q, J=7.3 Hz), 4.60 (1 H, s) , 4.83 (1 H, d, J=13.9 Hz), 5.10 (1 H, d, J=13.9 Hz), 6.11 (1 H, dd, J=15.8, 7.3 Hz), 6.32 (1 H, d, J=15.8 Hz), 6.74 (2 H, t-like, J=9 Hz), 7.26 (4 H, s), 7.37 (1 H, td, J=8.6, 6.5 Hz), 7.76 (1 H, s), 7.83 (1 H, s).
    • EXAMPLE 4
  • (2R, 3R)-3-[[Trans-2-[(E)-2-(4-chlorophenyl)vinyl]-1,3-dioxan-5-yl]thio]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0099]
    Figure US20010031768A1-20011018-C00205
  • In 14 ml of methylene chloride were dissolved 294 mg (0.82 mmol) of (2 R,3 R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol as described in Reference example 2 and 191 mg (1.15 mnol) of trans-4-chlorocinnamaldehyde [Bull. Chem. Soc. Japan 52 555 (1979)], and 233 mg (1.23 mmol) of p-toluenesulfonic acid monohydrate and 1.5 g of molecular sieves 4A were added thereto, followed by stirring of the resulting mixture for 1 hour and 15 minutes. An aqueous sodium hydrogencarbonate solution was added to the reaction mixture and the mixture was stirred for 10 minutes, followed by removal of the molecular sieves by filtration. The organic layers were collected and dried to distil off the solvent under reduced pressure. The thus obtained oil was subjected to column chromatography using 15 g of silica gel and eluted with a mixed solvent hexane-ethyl acetate (3:2) to obtain 280 mg (yield: 67%) of the desired title compound, trans isomer (A) as an oil. Further, the oil was eluted with a mixed solvent of hexane-ethyl acetate (1:1) to obtain 35 mg (yield: 8%) of the cis isomer (B) as an oil. [0100]
  • Specific rotation (A) [α][0101] D 25 −68° (c=1.22, CHCl3)
  • Specific rotation (B) [α][0102] D 25 −80° (c=1.30, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0103] 3) δ ppm: (A), 1.19 (3 H, d, J=7.3 Hz), 3.34 (1 H, q, J=7.3 Hz), 3.41 (1 H, tt, J=11.2, 4.6 Hz), 3.64 (1 H, t, J=11.2 Hz), 3.66 (1 H, t, J=11.2 Hz), 4.32 (1 H, ddd, J=11.2, 4.6, 2.6 Hz), 4.44 (1 H, ddd, J=11.2, 4.6, 2.6 Hz), 4.82 (1 H, d, J=13.9 Hz), 5.01 (1 H, s), 5.04 (1 H, d, J=13.9 Hz), 5.11 (1 H, d, J=4.6 Hz), 6.15 (1 H, dd, J=15.8, 4.6 Hz), 6.7-6.8 (2 H, m), 6.76 (1 H, d, J=15.8 Hz), 7.25-7.45 (5 H, m), 7.78 (2 H, s); (B), 1.21 (3 H, d, J=7.3 Hz), 3.11 (1 H, s-like), 3.50 (1 H, q, J=7.3 Hz), 4.2-4.4 (4 H, m), 4.88 (1 H, J=14.5 Hz), 4.93 (1 H, s), 5.16 (1 H, d, J=14.5 Hz), 5.23 (1 H, d, J=4.6 Hz), 6.21 (1 H, dd, J=16.5, 4.6 Hz), 6.65-6.8 (2 H, m), 6.76 (1 H, d, J=16.5 Hz), 7.25-7.45 (5 H, m), 7.77 (1 H, s), 7.80 (1 H, s).
  • In ethyl acetate was dissolved 54 mg of (A), and 19 mg of oxalic acid was added to the solution, followed by addition of hexane to the resulting mixture. The precipitated cystal was collected by filtration to obtain 65 mg of the oxalic acid salt having a melting point of 89 to 92° C. The oxalate of (B) having a melting point of 94 to 98° C. was obtained analogously. [0104]
    • EXAMPLE 5
  • (2R,3P)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(E)-2-(3-pyridyl)vinyl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0105]
    Figure US20010031768A1-20011018-C00206
  • In 5 ml of methylene chloride were dissolved 120 mg (0.33 mmol) of (2R,3R)-2-(2,4-difluoroohenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol and 60 mg (0.45 mmol) of trans-β-(3-pyridyl)acrolein [J. Med. Chem. 18 839 (1975)], 190 mg (1.00 mmol) of p-toluenesulfonic acid monohydrate and 1.2 g of molecular sieves 4A were added to the solution, followed by stirring of the resulting mixture for 1 hour and 15 minutes. An aqueous sodium hydrogencarbonate solution was added to the reaction mixture and the mixture was stirred for 10 minutes, followed by removal of the molecular sieves by filtration and extraction with chloroform. An oil obtained by evaporation of the solvent after drying was subjected to column chromatography using 15 g of silica gel and eluted with a mixed solvent of hexane-ethyl acetate (1:4 to 1:5) to obtain 82 mg (yield: 52%) of the title compound, trans isomer (A) as an oil. Further, the oil was eluted with ethyl acetate-S% methanol-ethyl acetate to obtain 28 mg (yield: 15%) of the cis isomer (B) having a melting point of 118 to 125° C. as a solid. [0106]
  • NMR spectrum (270 MHz, CDCl[0107] 3) δ ppm: (A), 1.20 (3 H, d, J=7.3 Hz), 3.34 (1 H, q, J=7.3 Hz), 3.43 (1 H, tt, J=11.2, 4.6 Hz), 3.65 (1 H, t, J=11.2 Hz), 3.68 (1 H, t, J=11.2 Hz), 4.33 (1 H, m), 4.46 (1 E, m), 4.83 (1 H, d, J=13.9 Hz), 5.04 (1 H, s), 5.04 (1 H, d, J=13.9 Hz), 5.14 (1 H, d, J=4.0 Hz), 6.25 (1 H, dd, J=16.5, 4.0 Hz), 6.7-6.8 (2 H, m), 6.81 (1 H, d, J=16.5 Hz), 7.29 (1 H, dd, J=7.9, 4.6 Hz), 7.3-7.45 (1 H, m), 7.73 (1 H, dt, J=7.9, 1 Hz),8.51 (1 H, dd, J=4.6, 1 Hz), 8.62 (1 H, d, J=1 Hz); (B), 1.22 (3 H, d, J=7.3 Hz), 3.13 (1 H, br s), 3.50 (1 H, q, J=7.3 Hz), 4.2-4.4 (4 H, m), 4.88 (1 H, d, J=13.9 Hz), 4.94 (1 H, s), 5.17 (1 H, d, J=13.9 Hz), 5.26 (1 H, d, J=4.6 Hz), 6.31 (1 H, dd, J=16.5, 4.6 Hz), 6.65-6.8 (2 H, m), 6.81 (1 H, d, J=16.5 Hz), 7.26 (1 H, dd, J=7.9, 4.6 Hz), 7.74 (1 H, td, J=7.2, 6.6 Hz), 7.74 (1 H, br d, J=7.9 Hz), 7.77 (1 H, s), 7.80 (1 H, s), 8.50 (1 H, br d, J=4.6 Hz), 8.63 (1 H, br s).
    • EXAMPLE 6
  • (2R,3R) -2- (2,4-Difluorophenyl)-3- [[trans-2-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0108]
    Figure US20010031768A1-20011018-C00207
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydoxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-1 -yl)-2-butanol and trans-4-(trifluoromethyl)cinnamaldehyde as described in Reference example 22 to obtain the desired compound as a major product (yield: 62%). Physical data and spectral data coincided with those of the comound described in Example 2. [0109]
    • EXAMPLE 7
  • (2R,3R) -2-(2,4-Difluorophenyl)-3-[[trans-2[(E)-2-(4-fluorophenyl)vinyl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0110]
    Figure US20010031768A1-20011018-C00208
  • Reaction and treatment were carried out in the same maser as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-diydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol and trans-4-fluorocinnamaldehyde [Arch. Pharm. 316 574 (1983)] to obtain the title compound, a major product as an oil in a yield of 66%. [0111]
  • NMR spectrum (60 MHz, CDCl[0112] 3) δ ppm: 1.20 (3 H, d, J=7 Hz), 3.1-3.9 (4 H, m), 4.1-4.6 (2 H, m), 4.78 (1 H, d, J=14 Hz), 4.99 (1 H, d, J=1.5 Hz), 5.06 (1 H, d, J=14 Hz), 5.09 (1 H, d, J=4 Hz), 6.07 (1 H, dd, J=16.4 Hz), 6.79 (1 H, d, J=16 Hz), 6.5-7.6 (7 H, m), 7.78 (2 H, s).
  • This compound was mixed with 1 equivalent of oxalic acid in a mixed solvent of ethyl acetate-hexane to obtain an oxalic acid salt crystal having a melting point of 132 to 135° C. [0113]
    • EXAMPLE 8
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(E)-2-[2-fluoro-(4-trifluoromethyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0114]
    Figure US20010031768A1-20011018-C00209
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and trans-2-fluoro-4-(trifluoromethyl)cinnamaldehyde to obtain the title coupond, a major product as an oil in a yield of 66%. [0115]
  • Specific rotation [α][0116] D 25 −72° (c=0.63, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0117] 3) δ ppm: 1.20 (3 H, d, J=7.0 Hz), 3.34 (1 H, q, J=7.0 Hz) , 3.43 (1 H, tt, J=11.3, 4.6 Hz), 3.65 (1 H, t, J=11.3 Hz), 3.68 (1 H, t, J=11.3 Hz), 4.34 (1 H, m), 4.46 (1 H, m), 4.83 (1 H, d, J=14.0 Hz), 5.04 (d, J=14.0 Hz), 5.04 (1 H, d, J=1.1 Hz), 5.15 (1 H, d, J=4.2 Hz), 6.36 (1 H, dd, J=16.3, 4.2 Hz), 6.7-6.8 (2 H, m), 6.97 (1 H, d, J=16.0 Hz), 7.3-7.45 (3 H, m), 7.58 (1 H, t, J=7.6 Hz), 7.79 (2 H, s).
    • EXAMPLE 9
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(E)-2-[4-(methylsulfonyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0118]
    Figure US20010031768A1-20011018-C00210
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-((1 H-1,2,4-triazol-1-yl)-2-butanol and trans-4-(methylsulfonyl)cinnamaldehyde to obtain the title compound, a major product as an oil in a yield of 58%. [0119]
  • NMR spectrum (60 MHz, CDCl[0120] 3+D2O) δ ppm: 1.20 (3 H, d, J=7 Hz), 3.00 (3 H, s), 3.33 (1 H, q, J=7 Hz), 3.5-4.0 (3 H, m), 4.2-4.8 (2 H, m), 4.80 (1 H, d, J=14 Hz), 5.08 (1 H, d, J=14 Hz), 5.15 (1 H, d, J=4 Hz), 6.30 (1 H, dd, J=17, 4 Hz), 6.90 (1 H, d, J=17 Hz), 6.55-7.0 (2 H, m), 7.2-7.6 (1 H, m), 7.58 (2 H, d, J=8 Hz), 7.80 (2 H, s), 7.94 (2 H, d, J=8 Hz).
    • EXAMPLE 10
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(E)-2-(4-nitrophenyl)vinyl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0121]
    Figure US20010031768A1-20011018-C00211
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and trans-4-nitrocinzamaldehyde to obtain the title compound, a major product as an oil in a yield of 40%. [0122]
  • Specific rotation [α][0123] D 25 −64.1° (c=2.43, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0124] 3) δ ppm: 1.19 (3 H, d, J=7.3 Hz), 3.35 (1 H, q, J=7.3 Hz), 3.44 (1 H, tt, J=11.2, 4.6 Hz), 3.66 (1 H, t, J=11.2 Hz), 3.68 (1 H, t, J=11.2 Hz), 4.34 (1 H, m), 4.46 (1 H, m), 4.83 (1 H, d, J=13.9 Hz), 5.04 (1 H, d, J=13.9 Hz), 5.04 (1 H, s), 5.16 (1 H, d, J=4.0 Hz), 6.32 (1 H, dd, J=16.5, 4.0 Hz), 6.7-6.8 (2 H, m), 6.87 (1 H, d, J=16.5 Hz), 7.36 (1 H, m), 7.53 (2 H, d, J=8.6 Hz), 7.79 (1 H, s), 7.80 (1 H, s), 8.19 (2 H, d, J=8.6 Hz).
  • This compound was mixed with 1 equivalent of oxalic acid in a mixed solvent of ethyl acetate-hexane to obtain an oxalic acid salt crystal having a melting point of 103 to 105° C. [0125]
    • EXAMPLE 11
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[trans-2-[(E)-2-[4-(trifluoromethoxy)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-2-butanol [0126]
    Figure US20010031768A1-20011018-C00212
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and trans-4-(trifluoromethoxy)cinnamaldehyde as described in Reference example 33 to obtain the title comoound, a major product as an oil in a yield of 43%. [0127]
  • Specific rotation [α][0128] D 25 −77° (c=0.52, CHCl3)
  • NMR spectrum (270 MEz, CDCl[0129] 3) δ ppm: 1.20 (3 H, d, J=7.3 Hz), 3.34 (1 H, g, J=2.3 Hz), 3.42 (1 H, tt, J=11.2, 4.6 Hz), 3.65 (1 H, t, J=11.2 Hz), 3.67 (1 H, t, J=11.2 Hz), 4.32 (1 H, ddd, J=11.2, 4.6, 2.0 Hz), 4.45 (1 H, ddd, J=11.2, 4.6, 2.0 Hz), 4.83 (1 H, d, J=14.5 Hz), 5.01 (1 H, s), 5.03 (1 H, d, J=14.5 Hz), 5.12 (1 H, d, J=4.0 Hz), 6.15 (1 H, dd, J=16.5, 4.0 Hz), 6.7-6.8 (2 H, m), 6.79 (1 H, d, J=16.5 Hz), 7.17 (2 H, d, J=8.6 Hz), 7.3-7.45 (1 H, m), 7.42 (2 H, d, J=8.6 Hz), 7.79 (2 H, s).
    • EXAMPLE 12
  • (2R,3R)-3-[[Trans-2-[(E)-2-(4-cyanophenyl)vinyl]-1,3-dioxan-5-yl]thio]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0130]
    Figure US20010031768A1-20011018-C00213
  • Reaction and treatment were carried out in the same meaer as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and trans-4-cyanocinnamaldehyde [Mol. Cryst. Liq. Cryst. 123 257 (1985)] to obtain the title compound, a major product as an oil in a yield of 66%. [0131]
  • Specific rotation [α][0132] D 25 −78° (c=0.52, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0133] 3) δ ppm: 1.20 (3 H, d, J=7.0 Hz), 3.34 (1 H, br q, J=7.0 Hz), 3.43 (1 H, tt, J=11.3, 4.8 Hz), 3.65 (1 H, t, J=11.3 Hz), 3.67 (1 H, t, J=11.3 Hz), 4.33 (1 H, m), 4.46 (1 H, m), 4.83 (1 H, d, J=14.2 Hz), 5.03 (1 H, d, J=1.2 Hz), 5.04 (1 H, d, J=14.2 Hz), 5.14 (1 H, d, J=4.1 Hz), 6.28 (1 H, dd, J=16.1, 4.1 lHz), 6.7-6.8 (2 H, m), 6.82 (1 H, d, J=16.1 Hz), 7.36 (1 H, m), 7.49 (2 H, d, J=8.3 Hz), 7.62 (2 H, d, J=8.3 Hz), 7.79 (2 H, s) .
  • This compound was mixed with 1 equivalent of oxalic acid in a mixed solvent of ethyl acetate-hexane to obtain an oxalic acid salt crystal having a melting point of 164 to 165° C. [0134]
    • EXAMPLE 13
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(E)-2-methyl-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0135]
    Figure US20010031768A1-20011018-C00214
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol and trans-β-methyl-4-(trifluoromethyl)cinnamaldehyde to obtain the desired title compound, a major product as an oil in a yield of 73%. [0136]
  • NMR spectrum (270 MHz, CDCl[0137] 3) δ ppm: 1.20 (3 H, d, J=7.1 Hz), 2.16 (3 H, s), 3.36 (1 H, q, J=7.1 Hz), 3.41 (1 H, tt, J=11.3, 4.6 Hz), 3.66 (1 H, t, J=11.3 Hz), 3.68 (1 H, t, J=11.3 Hz), 4.32 (1 H, m), 4.44 (1 H, m), 4.83 (1 H, d, J=13.9 Hz), 5.03 (1 H, s), 5.04 (1 H, d, J=13.9 Hz), 5.33 (1 H, d, J=6.0 Hz), 5.83 (1 H, br d, J=6.0 Hz), 6.7-6.8 (2 H, m), 7.3-7.45 (1 H, m), 7.51 (2 H, d, J=8.3 Hz), 7.59 (2 H, d, J=8.3 Hz), 7.79 (2 H, s).
    • EXAMPLE 14
  • (2R,3R)-3-[[Trans-2-[(E)-2-(5-chloro-2-thienyl)vinyl]-1,3-dioxan-5-yl]thio]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0138]
    Figure US20010031768A1-20011018-C00215
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluoroplheyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and trans-β-(5-chloro-2-thienyl)acrolein [Chem. Abst. 51 1284h (1941)] to obtain the title compound as an oil in a yield of 50%. [0139]
  • Specific rotation [α][0140] D 25 −75.7° (c=0.56, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0141] 3) δ ppm: 1.19 (3 H, d, J=7.3 Hz), 3.33 (1 H, q, J=7.3 Hz), 3.40 (1 H, tt, J=11.2, 4.6 Hz), 3.62 (1 H, t, J=11.2 Hz), 3.64 (1 H, t, J=11.2 Hz), 4.36 (1 H, m), 4.42 (1 H, m), 4.82 (1 H, d, J=13.8 Hz), 5.02 (1 H, br s), 5.03 (1 H, d, J=13.8 Hz), 5.06 (1 H, d, J=4.6 Hz), 5.88 (1 H, dd, J=15.8, 4.6 Hz), 6.7-6.85 (3 H, m), 6.78 (2 H, s) , 7.36 (1 H, m) , 7.87 (2 H, s).
  • This compound was mixed with 1 equivalent of oxalic acid in a mixed solvent of ethyl acetate-hexane to obtain an oxalic acid salt crystal having a melting point of 53 to 57° C. [0142]
    • EXAMPLE 15
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl) -3-[[trans-2-[(1 E,3 E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol [0143]
    Figure US20010031768A1-20011018-C00216
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and (2 E,4 E)-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienal as described in Reference example 25 to obtain the title compound, a major product as an oil in a yield of 67%. [0144]
  • Specific rotation [α][0145] D 25 −69.8° (c=100, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0146] 3) δ ppm: 1.19 (3 H, d, J=7.3 Hz), 3.33 (1 H, q, J=7.3 Hz), 3.40 (1 H, tt, J=11.2, 4.6 Hz), 3.62 (1 H, t, J=11.2 Hz), 3.64 (1 H, t, J=11.2 Hz), 4.30 (1 H, m), 4.42 (1 H, m), 4.82 (1 H, d, J=13.9 Hz), 5.01 (1 H, s), 5.03 (1 H, d, J=13.9 Hz), 5.06 (1 H, d, J=4.6 Hz), 5.84 (1 H, dd, J=15.2, 4.6 Hz), 6.60 (1 H, dd, J=15.2, 10.6 Hz), 6.73 (1 H, d, J=15.8 Hz), 6.7-6.8 (2 H, m), 6.85 (1 H, dd, J=15.8, 10.6 Hz), 7.3-7.45 (1 H, m), 7.49 (2 H, d, J=8.6 Hz), 7.56 (2 H, d, J=8.6 Hz), 7.78 (2 H, s).
    • EXAMPLE 16
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(1 E,3 E)-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0147]
    Figure US20010031768A1-20011018-C00217
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and (2 E,4 E)-5-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-2,4-pentadienal as described in Reference example 32 to obtain the title compound having a melting point of 75 to 85° C. (crystallization from a mixed solvent of hexane-ether), a major product as a powder in a yield of 60%. [0148]
  • Specific rotation [α][0149] D 25 −69° (c=0.56, CHCl3)
  • NMR spectrum (270 MEz, CDCl[0150] 3) δ ppm: 1.18 (3 H, d, J=7.0 Hz), 3.33 (1 H, q, J=7.0 Hz), 3.39 (1 H, tt, J=11.3, 4.8 Hz), 3.62 (1 H, t, J=11.3 Hz), 3.64 (1 H, t, J=11.3 Hz), 4.30 (1 H, m), 4.35 (2 H, br t, J=11.8 Hz), 4.41 (1 H, m), 4.82 (1 H, d, J=14.1 Hz), 4.99 (1 H, d, J=1.6 Hz), 5.03 (1 H, d, J=14.1 Hz), 5.04 (1 H, d, J=4.6 Hz), 5.75 (1 H, dd, J=15.7, 4.6 Hz), 6.06 (1 H, tt, J=53.0, 5.1 Hz), 6.56 (1 H, dd, J=15.7, 10.2 Hz), 6.57 (1 H, d, J=15.0 Hz), 6.68 (1 H, dd, J=15.0, 10.2 Hz), 6.7-6.8 (2 H, m), 6.88 (2H, d, J=8.7Hz), 7.3-7.4 (1 H, m), 7.37 (2 H, d, J=8.7 Hz), 7.79 (2 H, s).
    • EXAMPLE 17
  • (2R,3R)-3-[[Trans-2-[(1 E,3 E) -4-(6-chloro-3-pyridyl)-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0151]
    Figure US20010031768A1-20011018-C00218
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1- (1 H-1,2,4-triazol-5-yl)-2-butanol and (2 E,4 E)-5-(6-chloro-3-pyridyl)-2,4-pentadienal as described in Reference example 38 to obtain the title compound having a melting point of 88 to 90° C., a major product as a crystalline solid in a yield of 69%. [0152]
  • Specific rotation [α][0153] D 25 −74° (c=0.59, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0154] 3) δ ppm: 1.19 (3 H, d, J=7.1 Hz), 3.33 (1 H, q, J=7.1 Hz), 3.40 (1 H, tt, J=11.3, 4.7 Hz), 3.62 (1 H, t, J=11.3 Hz) , 3.64 (1 H, t, J=11.3 Hz), 4.30 (1 H, m), 4.42 (1 H, m), 4.82 (1 H, d, J=14.3 Hz) , 5.00 (1 H, s) , 5.03 (1 H, d, J=14.3 Hz), 5.05 (1 H, d, J=4.2 Hz), 5.84 (1 H, dd, J=15.1, 4.2 Hz), 6.56 (1 H, d, J=15.5 Hz), 6.58 (1 H, dd, J=15.1, 10.5 Hz), 6.7-6.8 (2 H, m), 6.80 (1 H, dd, J=15.5, 10.5 Hz), 7.28 (1 H, d, J=8.3 Hz), 7.3-7.4 (1 H, m), 7.70 (1 H, dd, J=8.3, 2.5 Hz), 7.79 (2 H, s), 8.37 (1 H, d, J=2.5 Hz).
    • EXAMPLE 18
  • (2R,3R) -2-(2,4-Difluorophenyl)-3-[[trans-2-[(1 E,3 Z)-4-(4-chlorophenyl)-5,5,5-trifluoro-1,3-pentadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0155]
    Figure US20010031768A1-20011018-C00219
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H, 1,2,4-triazol-5-yl)-2-butanol and (2 E,4 Z)-5-(4-chlorophenyl)-6,6,6-trifluoro-2,4-hexadienal as described in Reference example 52 to obtain the title compound, a major product as an oil in a yield of 31%. [0156]
  • Specific rotation [α][0157] D 25 −59.4° (c=0.90, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0158] 3) δ ppm: 1.19 (3 H, d, J=7.3 Hz) , 3.33 (1 H, br q, J=7.3 Hz), 3.40 (1 H, tt, J=11.2, 4.6 Hz), 3.61 (1 H, t, J=11.2 Hz), 3.64 (1 H, t, J=11.2 Hz) , 4.31 (1 H, m) , 4.43 (1 H, m), 4.82 (1 H, d, J=13.9 Hz), 5.02 (1 H, s), 5.03 (1 H, d, J=13.9 Hz), 5.09 (1 H, d, J=4.6 Hz), 5.96 (1 H, dd, J=15.2, 4.6 Hz), 6.50 (1 H, d, J=11.9 Hz), 6.7-6.8 (2 H, m), 6.9-7.1 (1 H, m), 7.25-7.4 (5 H, m), 7.79 (2 H, s).
    • EXAMPLE 19
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(1E,3E)-2-methyl-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0159]
    Figure US20010031768A1-20011018-C00220
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2, 4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and (2E,4E)-3-methyl-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienal as described in Reference example 10 to obtain the title compound, a major product as an oil in a yield of 70%. [0160]
  • Specific rotation [α][0161] D 25 −68° (c=0.50, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0162] 3) δ ppm: 1.27 (3 H, d, J=7.1 Hz), 1.99 (3 H, s), 3.34 (1 H, q, J=7.1 Hz), 3.39 (1 H, tt, J=11.3, 4.8 Hz), 3.64 (1 H, t, J=11.3 Hz), 3.66 (1 H, t, J=11.3 Hz), 4.30 (1 H, m), 4.41 (1 H, m), 4.83 (1 H, d, J=14.1 Hz), 5.01 (1 H, s), 5.04 (1 H, d, J=14.1 Hz), 5.32 (1 H, d, J=6.2 Hz), 5.66 (1 H, d, J=6.2 Hz), 6.66 (1 H, d, J=16.1 Hz), 6.7-6.8 (2 H, m), 6.86 (1 H, d, J=16.1 Hz), 7.3-7.4 (1 H, m), 7.51 (2 H, d, J=8.4 Hz), 7.57 (2 H, d, J=8.4 Hz), 7.78 (2 H, s).
    • EXAMPLE 20
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(1E,3E)-3-methyl-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0163]
    Figure US20010031768A1-20011018-C00221
  • Reaction and treatment were carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and (2E,4E)-4-methyl-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienal to obtain the title compound, a major product as an oil in a yield of 69%. [0164]
  • Specific rotation [α][0165] D 25 −63.4° (c=1.07, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0166] 3) δ ppm: 1.19 (3 H, d, J=7.0 Hz), 2.00 (3 H, s), 3.33 (1 H, q, J=7.0 Hz), 3.41 (1 H, tt, J=11.2, 4.6 Hz), 3.64 (1 H, t, J=11.2 Hz), 3.66 (1 H, t, J=11.2 Hz), 4.31 (1 H, m), 4.43 (1 H, m), 4.83 (1 H, d, J=14.2 Hz), 5.01 (1 H, s), 5.04 (1 H, d, J=14.2 Hz), 5.09 (1 H, d, J=4.6 Hz), 5.81 (1 H, dd, J=16.0, 4.6 Hz), 6.60 (1 H, s), 6.63 (1 H, d, J=16.0 Hz), 6.7-6.8 (2 H, m), 7.3-7.4 (1 H, m), 7.38 (2 H, d, J=8.2 Hz), 7.59 (2 H, d, J=8.2 Hz), 7.79 (2 H, s).
    • EXAMPLE 21
  • (2R,3R)-2-(2,4-Difluorophenyl) -3-[[1-[(E)-4-(trifluoromethoxy)cinaamoyl]piperidin-4-yl]thio]-1-(1 H-1,2,4-triazol-1 -yl)-2-butanol [0167]
    Figure US20010031768A1-20011018-C00222
  • [Process A][0168]
  • To a mixture o f I150 mg (0.340 mmol) of (2R,3R)-(2, 4-difluorophenyl)-3-(1 H-1,2,4-triazol-1-yl)-3-[(piperidin-4-yl)thio]-2-butanol dihydrochloride as described in Reference example 14 and 3 ml of dichloromethane were added 142 μl (1.02 mmol) of triethylamine at 0° C. under nitrogen atmosphere and, after 5 minutes, 128 mg (0.510 mmol) of (E)-4-(trifluoromethoxy)cinnamoyl chloride. The mixture was stirred at the same temperature for 30 minutes and the solvent was distilled off, and then ethyl acetate was added to the thus obtained residue, followed by washing of the mixture with an aqueous NaCl solution. The solvent was distilled off and the residue was subjected to silica gel column chromatography, followed by elution with ethyl acetate to obtain 160 mg (yield: 81%) of the title compound as a colorless foam. [0169]
  • NMR spectrum (270 MHz, CDCl[0170] 3) δ ppm: 1.19 (3 H, d, J=7.0 Hz) , 1.6-1.8 (2 H, m), 2.0-2.1 (2 H, m), 3.0-3.2 (2 H, m), 3.35 (1 H, q, J=7.0 Hz), 3.2-3.4 (1 H, m), 4.0-4.1 (1 H, m), 4.2-4.3 (1 H, m), 4.83 (1 H, s), 4.83 (1 H, d, J=14.0 Hz), 5.09 (1 H, d, J=14.0 Hz), 6.7-6.8 (2 H, m), 6.87 (1 H, d, J=15.5 Hz), 7.22 (2 H, d, J=8.5 Hz), 7.3-7.4 (1 H, m), 7.55 (2 H, d, J=8.5 Hz), 7.65 (1 H, d, J=15.5 Hz) , 7.78 (1 H, s), 7.82 (1 H, s).
  • IR spectrum υ[0171] max KBrcm−1: 3421, 1695, 1686, 1617, 1591.
  • Mass spectrum m/e: 582, 563, 522, 500, 427, 359, 299, 258, 215, 187, 144, 101, 82. [0172]
  • [Process B][0173]
  • In 4 ml of dimethylformamide were dissolved 327 mg (0.875 mmol) of 4-(acetylthio)-1-[(E)-4-(trifluoromethoxy)cinnamoyl]piperidine as described in Reference example 16 and 200 mg (0.796 mmol) of (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1 H-1,2,4-triazol-1 -yl)methyl]oxirane, and 129 μl (0.613 mmol) of a 28% sodium methoxide-methanol solution were added to the mixture under nitrogen atmosphere, followed by stirring of the resulting mixture at 50° C. for 3 hours. After cooling, ethyl acetate was added to the reaction mixture to dilute it and washed with water and then a saturated aqueous NaCl solution. [0174]
  • The oil obtained by evaporation of the solvent was subjected to silica gel column chromatography and eluted with ethyl acetate to obtain 275 mg (yield: 59%) as a colorless foam. The present compound was identified as the compound obtained according to the [Process A] by means of each spectrum of NMR, IR and MS. [0175]
    • EXAMPLE 22
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[1-((E)-4-methylcinnamoyl)piperidin-4-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0176]
    Figure US20010031768A1-20011018-C00223
  • A colorless foam obtained from (E)-4-methylcinnamoyl chloride (Can. J. Chem. 45 1001 (1967)] according to [Process A] of Example 21. [0177]
  • NMR spectrum (270 MHz, CDCl[0178] 3) δ ppm: 1.19 (3 H, d, J=7.0 Hz), 1.6-1.8 (2 H, m), 2.0-2.2 (2 H, m), 2.37 (3 H, s), 3.0-3.2 (2 H, m), 3.2-3.4 (1 H, m), 3.35 (1 H, q, J=7.0 Hz), 4.0-4.2 (1 H, m), 4.4-4.6 (1 H, m), 4.83 (1 H, d, J=13.9 Hz), 4.84 (1 H, s), 5.09 (1 H, d, J=13.9 Hz), 6.7-6.8 (2 H, m), 6.85 (1 H, d, J=15.5 Hz), 7.18 (2 H, d, J=8.3 Hz), 7.3-7.4 (1 H, m), 7.43 (2 H, d, J=8.3 Hz), 7.65 (1 H, d, J=15.5 Hz), 7.77 (1 H, s), 7.82 (1 H, s).
  • IR spectrum υ[0179] max KBrcm−1: 3333, 1645, 1599.
  • Mass spectrum m/e: 512, 510, 452, 430, 425, 367, 357, 289, 229, 224, 188, 145, 117, 82. [0180]
    • EXAMPLE 23
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[1-((E)-4-nitrocinnamoyl)piperidin-4-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0181]
    Figure US20010031768A1-20011018-C00224
  • A slightly yellow foam obtained from (E)-4-nitrocizmamoyl chloride according to [Process A] of Example 21. [0182]
  • NMR spectrum (270 MHz, CDCl[0183] 3) δ ppm: 1.26 (3 H, d, J=6.6 Hz), 1.6-1.9 (2 H, m), 2.1-2.3 (2 H, m), 3.1-3.3 (2 H, m), 3.3-3.5 (1 H, m), 3.42 (1 H, q, J=6.6 Hz), 4.0-4.2 (1 H, m), 4.4-4.6 (1 H, m), 4.89 (1 H, d, J=13.9 Hz), 4.92 (1 H, s), 5.15 (1 H, d, J=13.9 Hz), 6.7-6.9 (2 H, m), 7.10 (1 H, d, J=15.5 Hz), 7.4-7.5 (1 H, m), 7.73 (2 H, d, J=8.9 Hz), 7.75 (1 H, d, J=15.5 Hz), 7.86 (2 H, d, J=8.9 Hz), 8.29 (1 H, s), 8.32 (1 H, s).
  • IR spectrum υ[0184] max KBrcm−1: 3361, 1649, 1612, 1518, 1345.
  • Mass spectrum m/e: 544, 525, 513, 483, 461, 388, 365, 284, 260, 224, 219, 176, 144, 130, 82. [0185]
    • EXAMPLE 24
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[1-[(2E,4E)-5-[4-(trifluoromethoxy)phenyl]-2,4-pentadienoyl]piperidin-4-yl]thio]-2-butanol [0186]
    Figure US20010031768A1-20011018-C00225
  • A colorless foam obtained from (2E,4E)-5-[4-(trifluorometoxy)phenyl[-2,4-pentadienoyl chloride according to [Process A] of Example 21. [0187]
  • NMR spectrum (270 MHz, CDCl[0188] 3) δ ppm: 1.19 (3 H, d, J=6.6 Hz), 1.5-1.8 (2 H, m), 2.0-2.2 (2 H, m), 3.0-3.3 (3 H, m), 3.34 (1 H, q, J=6.6 Hz), 3.9-4.1 (1 H, m), 4.3-4.5 (1 H, m), 4.83 (1 H, d, J=13.9 Hz), 4.82 (1 H, s), 5.08 (1 H, d, J=13.9 Hz), 6.50 (1 H, d, J=14.5 Hz), 6.7-6.8 (2 H, m), 6.8-6.9 (2 H, m), 7.20 (2 H, d, J=8.9 Hz), 7.3-7.5 (2 H, m), 7.47 (2 H, d, J=8.9 Hz), 7.78 (1 H, s), 7.82 (1 H, s).
  • IR spectrum υ[0189] max KBrcm−1: 3395, 1639, 1616, 1596.
  • Mass spectrum m/e: 608, 589, 548, 526, 453, 433, 385, 325, 241, 224, 213, 144, 127, 82. [0190]
    • EXAMPLE 25
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[1-[(E)-3-(pyridin-4-yl)-acryloyl]piperidin-4-yl]thio]-2-butanol [0191]
    Figure US20010031768A1-20011018-C00226
  • A colorless foam obtained from 4-acetylthio-1-[(E)-3-(pyridin-4-yl)-acryloyl]piperidine according to [Process B] of Example 21. [0192]
  • NMR spectrum (270 MHz, CDCl[0193] 3) δ ppm: 1.20 (3 H, d, J=6.6 Hz), 1.6-1.8 (2 H, m), 2.0-2.2 (2 H, m), 3.0-3.2 (2 H, m), 3.35 (1 H, q, J=6.6 Hz), 3.2-3.4 (1 H, m), 3.9-4.1 (1 H, m), 4.3-4.5 (1 H, m), 4.83 (1 H, d, J=14.5 Hz), 4.86 (1 H, s), 5.09 (1 H, d, J=14.5 Hz), 6.7-6.8 (2 H, m), 7.06 (1 H, d, J=15.2 Hz), 7.3-7.4 (1 H, m), 7.37 (2 H, d, J=5.9 Hz), 7.57 (1 H, d, J=15.2 Hz), 7.78 (1 H, s), 7.81 (1 H, s), 8.64 (2 H, d, J=5.9 Hz).
  • IR spectrum υ[0194] max KBrcm−1: 3420, 1651, 1615, 1598.
  • Mass spectrum m/e: 499, 439, 417, 410, 365, 344, 307, 275, 247, 216, 144, 132, 104, 82. [0195]
    • EXAMPLE 26
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[1-(E)-4-(trifluoromethoxy)cinnamoyl]azetidin-3-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0196]
    Figure US20010031768A1-20011018-C00227
  • A slightly yellow foam obtained from (2R,3R)-2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[(azetidin-3-yl]thio]-2-butanol dihydrochloride according to [Process A] of Example 21. [0197]
  • NMR spectrum (270 MEz, CDCl[0198] 3) δ ppm: 1.17 (3 H, d, J=7.1 Hz), 3.32 (1 H, q, J=7.1 Hz), 4.0-4.3 (3 H, m), 4.5-4.6 (1 H, m), 4.6-4.7 (1 H, m), 4.86 (1 H, d, J=14.2 Hz), 5.05 (1 H, d, J=14.2 Hz), 5.09 (1 H, s), 6.43 (1 H, d, J=15.7 Hz), 6.7-6.8 (2 H, m), 7.22 (2 H, d, J=8.2 Hz), 7.3-7.4 (1 H, m), 7.56 (2 H, d, J=8.2 Hz), 7.65 (1 H, d, J=15.7 Hz), 7.79 (1 H, s), 7.81 (1 H, s).
  • IR spectrum υ[0199] max KBrcm−1: 3376, 1656.
  • Mass spectrum m/e: 554, 535, 472, 384, 331, 271, 224, 215, 187, 127, 87. [0200]
    • EXAMPLE 27
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(1E,3E)-4-(2,4-difluorophenyl)-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0201]
    Figure US20010031768A1-20011018-C00228
  • Reaction was carried out in the same ma=ner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and (2E,4E)-5-(2,4-difluorophenyl)-2,4-pentadienal to obtain the title compound, a major product as an oil in a yield of 61%. [0202]
  • Specific rotation [α][0203] D 25 −79.1° (c=1.04, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0204] 3) δ ppm: 1.18 (3 H, d, J=7.0 Hz), 3.33 (1 H, q, J=7.0 Hz), 3.39 (1 H, tt, J=11.3, 4.6 Hz), 3.62 (1 H, t, J=11.3 Hz), 3.64 (1 H, t, J=11.3 Hz), 4.30 (1 H, m), 4.41 (1 H, m), 4.82 (1 H, d, J=14.0 Hz), 5.00 (1 H, s), 5.03 (1 H, d, J=14.0 Hz), 5.05 (1 H, d, J=4.6 Hz), 5.79 (1 H, dd, J=15.2, 4.6 Hz), 6.58 (1 H, dd, J=15.2, 9.5 Hz), 6.65-6.9 (6 H, m), 7.3-7.5 (2 H, m), 7.79 (2 H, s).
    • EXAMPLE 28
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(1E,3E)-4-[6-(2,2,3,3-tetrafluoropropoxy)-3-pyridyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol [0205]
    Figure US20010031768A1-20011018-C00229
  • In 11 ml of methylene chloride were dissolved 404 mg (1.12 mmol) of (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol and 501 mg (1.73 mmol) of (2E,4E)-5-[6-(2,2,3,3-tetrafluoropropoxy)-3-pyridyl]-2,4-pentadienal as described in Reference example 37, and 320 mg (1.68 mmol) of p-toluenesulfonic acid monohydrate and 4 g of molecular sieves 4A were added to the solution, followed by stirring of the resulting mixture at room temperature for 1 hour. The reaction mixture was poured into 20 ml of a 3% aqueous sodium hydrogencarbonate solution under ice-cooling and the mixture was stirred for 5 minutes. Then, the molecular sieves was removed by filtration and the organic layer was collected by fractions, followed by drying and evaporation of the solvent under reduced pressure. 908 mg of the thus obtained oil were subjected to column chromatography using 19 g of silica gel and eluted with a mixed solvent of hexane-ethyl acetate (1:1) to obtain 448 mg (yield: 63%) of the desired title compound as an oil. [0206]
  • Specific rotation [α][0207] D 25 −58.6° (c=0.52, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0208] 3) δ ppm: 1.19 (3 H, J=7.0 Hz), 3.33 (1 H, q, J=7.0 Hz), 3.39 (1 H, tt, J=11.2, 4.8 Hz), 3.62 (1 H, t, J=11.2 Hz), 3.64 (1 H, t, J=11.2 Hz), 4.30 (1 H, ddd, J=11.2, 4.7, 2.1 Hz), 4.42 (1 H, ddd, J=11.2, 4.7, 2.1 Hz), 4.74 (2 H, brt, J=12.8 Hz), 4.82 (1 H, d, J=13.9 Hz), 5.01 (1 H, s), 5.03 (1 H, d, J=13.9 Hz), 5.05 (1 H, d, J=4.5 Hz), 5.78 (1 H, d, J=15.5, 4.5 Hz), 6.01 (1 H, tt, J=53.1, 4.6 Hz), 6.51-6.62 (2 H, m), 6.6-6.78 (3 H, m), 6.81 (1 H, d, J=8.6 Hz), 7.35 (1 H, m), 7.74 (1 H, dd, J=8.6, 2.3 Hz), 7.79 (2 H, s), 8.11 (1 H, d, J=2.3 Hz).
    • EXAMPLE 29
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-[(1E,3E)-1-methyl-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0209]
    Figure US20010031768A1-20011018-C00230
  • Reaction was carried cut in the same manner as in Examnple 4 using (2R, 3R)-2-(2,4-diphenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and (2E,4E)-2-methyl-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienal to obtain the title compound, a major product as an oil in a yield of 31%. [0210]
  • NMR spectrum (270 MHz, CDCl[0211] 3) δ ppm: 1.19 (3 H, d, J=7.3 Hz) , 1.94 (3 H, s) , 3.34 (1 H, q, J=7.3 Hz) , 3.39 (1 H, tt, J=11.2, 4.6 Hz), 3.36 (1 H, t, J=11.2 Hz) , 3.65 (1 H, t, J=11.2 Hz), 4.33 (1 H, m) , 4.44 (1 H, m), 4.83 (1 H, d, J=13.9 Hz), 4.89 (1 H, s), 5.02 (1 H, s), 5.04 (1 H, d, J=13.9 Hz), 6.41 (1 H, d, J=11.2 Hz), 6.62 (1 H, d, J=15.8 Hz), 6.7-6.8 (2 H, m), 7.09 (1 H, dd, J=15.8, 11.2 Hz), 7.36 (1 H, m), 7.50 (2 H, d, J=8.6 Hz), 7.56 (2 H, d, J=8.6 Hz), 7.79 (1 H, s), 7.80 (1 H, s).
    • EXAMPLE 30
  • (RS)-3-Methyl-1-(1 H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-3-[[trans-2-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-2-butanol [0212]
    Figure US20010031768A1-20011018-C00231
  • Reaction was carried out in the same manner as in Example 4 using (RS)-3-[(1,3-dihydroxy-2-propyl)thio]-3-methyl-2-[4-(trifluoromethyl)phenyl]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol as described in Reference example 55 and trans-4-(trifluoromethyl)cinnamaldehyde as described in Reference example 22 to obtain the title compound as a colorless foam. [0213]
  • NMR spectrum (270 MHz, CDCl[0214] 3) δ ppm: 1.36 (3 H, s) , 1.37 (3 H, s), 3.5-3.7 (3 H, m), 4.2-4.3 (1 H, m), 4.4-4.5 (1 H, m), 5.02 (2 H, s), 5.11 (1 H, d, J=4.1 Hz), 5.44 (1 H, s), 6.25 (1 H, dd, J=16.2, 4.1 Hz), 6.84 (1 H, d, J=16.2 Hz), 7.4-7.6 (8 H, m) , 7.70 (1 H, s), 7.93 (1 H, s).
  • IR spectrum υ[0215] max (KBr) cm−1: 3404, 1618, 1508, 1328.
  • Mass spectrum m/e: 587, 568, 331, 298, 256, 201, 159, 131. [0216]
    • EXAMPLE 31
  • (RS)-3-Methyl-1-(1 H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-3-[[trans-2-[(1E,3E)-4-[(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol [0217]
    Figure US20010031768A1-20011018-C00232
  • Reaction was carried out in the same manner as in Example 4 using (RS)-3-[(1,3-dihydroxy-2-propyl)thio]-3-methyl-2-[4-(trifluoromethyl)phenyl]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol as described in Reference example 55 and (2E,4E)-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienal as described in Reference example 25 to obtain the title compound, a major product as a colorless foam. [0218]
  • NMR spectrum (270 MHz, CDCl[0219] 3) δ ppm: 1.36 (3 H, s) , 1.37 (3 H, s), 3.4-3.7 (3 H, m), 4.2-4.3 (1 H, m), 4.4-4.5 (1 H, m), 5.01 (2 H, s), 5.02 (1 H, d, J=4.3 Hz), 5.39 (1 H, s), 5.83 (1 H, dd, J=15.2, 4.3 Hz), 6.59 (1 H, dd, J=15.2, 10.7 Hz), 6.63 (1 H, d, J=15.8 Hz), 6.85 (1 H, dd, J=15.8, 10.7 Hz), 7.4-7.6 (8 H, m), 7.73 (1 H, s), 7.93 (1 H, s).
  • IR spectrum υ[0220] max (KBr) cm−1: 3398, 1679, 1619, 1328, 1126.
  • Mass spectrum m/e: 614, 541, 494, 478, 406, 348, 256, 211. [0221]
    • EXAMPLE 32
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[trans-2-[(1E, 3E) -4-[4-(trifluoromethylthio)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol [0222]
    Figure US20010031768A1-20011018-C00233
  • Reaction was carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and (2E,4E)-5-[4-(trifluoromethylthio)phenyl]-2,4-pentadienal to obtain the title compound, a major product as a colorless foam. [0223]
  • NMR spectrum (270 MHz, CDCl[0224] 3) δ ppm: 1.19 (3 H, d, J=7.1 Hz), 3.3-3.5 (2 H, m), 3.62 (1 H, t, J=11.4 Hz), 3.64 (1 H, t, J=11.4 Hz), 4.31 (1 H, ddd, J=11.4, 4.7, 2.1 Hz), 4.42 (1 H, ddd, J=11.4, 4.7, 2.1 Hz), 4.83 (1 H, d, J=14.1 Hz), 5.01 (1 H, s), 5.03 (1 H, d, J=14.1 Hz), 5.06 (1 H, d, J=4.5 Hz), 5.83 (1 H, dd, J=15.7, 4.5 Hz), 6.60 (1 H, dd, J=15.7, 10.33 Hz), 6.62 (1 H, d, J=15.7 Hz), 6.7-6.8 (2 H, m), 6.84 (1 H, dd, J=15.7, 10.3 Hz), 7.3-7.4 (1 H, m), 7.44 (2 H, d, J=8.3 Hz), 7.60 (2 H, d, J=8.3 Hz), 7.79 (2 H, s).
  • IR spectrum υ[0225] max (KBr) cm−1: 3389, 1621, 1680, 1621, 1501, 1117.
  • Mass spectrum m/e: 599, 580, 557, 530, 500, 438, 388, 376, 346, 284, 258, 224, 183. [0226]
    • EXAMPLE 33
  • (2R*, 3R*)-3-[(Trans-2-[(1E,3E)-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-[(4-(trifluoromethyl)phenyl]-2-butanol [0227]
    Figure US20010031768A1-20011018-C00234
  • Reaction was carried out in the same manner as in Example 1 using (2R*,3R*)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol and (2E,4E)-5-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-2,4-pentadienal as described in Reference example 32 to obtain the title compound, a major product as an oil. [0228]
  • NMR spectrum (270 MHz, CDCl[0229] 3) δ ppm: 1.22 (3 H, d, J=6.6 Hz), 3.16 (1 H, q, J=6.6 Hz), 3.34 (1 H, tt, J=11.2, 4.6 Hz), 3.58 (1 H, t, J=11.2 Hz), 3.61 (1 H, t, J=11.2 Hz), 4.27 (1 H, m), 4.35 (2 H, br t, J=11.9 Hz), 4.39 (1 H, m), 4.57 (1 H, d, J=13.9 Hz), 4.77 (1 H, s), 5.02 (1 H, d, J=4.6 Hz), 5.03 (1 H, d, J=13.9 Hz), 5.72 (1 H, dd, J=15.8, 4.6 Hz), 6.05 (1 H, tt, J=52.8, 5.3Hz), 6.5-6.75 (3 H, m), 6.88 (2 H, d, J=8.6 Hz), 7.36 (2 H, d, J=8.6 Hz), 7.39 (2 H, d, J=8.6 Hz), 7.54 (2 H, d, J=8.6 Hz), 7.71 (1 H, s), 7.83 (1 H, s).
    • EXAMPLE 34
  • (2R*,3R*)-1-(1 H-1,2,4-Triazol-1-yl)-2-[4- (trifluoromethyl)phenyl]-3-[[trans-2-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol [0230]
    Figure US20010031768A1-20011018-C00235
  • Reaction was carried out in the same manner as in Example 1 using (2R*,3R*)-3-methyl-2-[(1 H-1,2,4-triazol-1-yl)methyl]oxirane and trans-5-(acetylthio)-2-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxane to obtain the title compound as an oil in a yield of 71%. [0231]
  • NMR spectrum (270 MHz, CDCl[0232] 3) δ ppm: 1.22 (3 H, d, J=7.0 Hz), 3.17 (1 H, q, J=7.0 Hz), 3.36 (1 H, tt, J=11.3, 4.7 Hz), 3.59 (1 H, t, J=11.3 Hz), 3.62 (1 H, t, J=11.3 Hz), 4.27 (1, ddd, J=11.3, 4.7, 2.2 Hz), 4.39 (1 H, ddd, J=11.3, 4.7, 2.2 Hz), 4.57 (1 H, d, J=14.0 Hz), 4.80 (1 H, s), 5.03 (1 H, d, J=14.0 Hz), 5.05 (1 H, d, J=4.5 Hz), 5.83 (1 H, dd, J=15.3, 4.5 Hz), 6.59 (1 H, dd, J=15.3, 10.7 Hz), 6.64 (1 H, d, J=15.3 Hz), 6.85 (1 H, dd, J=15.3, 10.7 Hz), 7.39 (2 H, d, J=8.4 Hz), 7.49 (2 H, d, J=8.3 Hz), 7.54 (2 H, d, J=8.3 Hz), 7.57 (2 H, d, J=8.4 Hz), 7.71 (1 H, s), 7.83 (1 H, s).
    • EXAMPLE 35
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[trans-2-[(1E,3E)-4-[4-(trifluoromethylsulfinyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol [0233]
    Figure US20010031768A1-20011018-C00236
  • Reaction was carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-5-yl)-2-butanol and (2E,4E)-5-[4-(trifluoromethylsulfinyl)phenyl]-2,4-pentadienal to obtain the title compound, a major product as a colorless foam. [0234]
  • NMR spectrum (270 MHz, CDCl[0235] 3) δ ppm: 1.19 (3 H, d, J=7.0 Hz), 3.3-3.5 (2 H, m), 3.62 (1 H, t, J=11.3 Hz), 3.64 (1 H, t, J=11.3 Hz), 4.30 (1 H, ddd, J=11.3, 4.8, 2.3 Hz), 4.42 (1 H, ddd, J=11.3, 4.8, 2.3 Hz), 4.83 (1 H, d, J=14.1 Hz), 5.01 (1 H, s), 5.03 (1 H, d, J=14.1 Hz), 5.06 (1 H, d, J=4.5 Hz), 5.83 (1 H, dd, J=15.9, 4.5 Hz), 6.60 (1 H, dd, J=15.9, 10.6 Hz), 6.62 (1 H, d, J=15.9 Hz), 6.7-6.8 (2 H, m), 6.84 (1 H, dd, J=15.9, 10.6 Hz), 7.3-7.4 (1 H, m), 7.44 (2 H, d, J=8.3 Hz), 7.60 (2 H, d, J=8.3 Hz), 7.79 (2 H, s).
  • Mass spectrum m/e: 616, 600, 547, 400, 370, 342, 284, 252, 224, 183. [0236]
    • EXAMPLE 36
  • 2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[trans-4-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]cyclohexyl]thio]-2-butanol [0237]
    Figure US20010031768A1-20011018-C00237
  • Reaction was carried out in the same manner as in Example 1 using (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1 H-1,2,4-triazol-1-yl)methyl]oxirane and trans-1-(acetylthio)-4-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]cyclohexane as described in Reference example 43 to obtain the title compound having a melting point of 74 to 76° C. in a yield of 59%. [0238]
  • Specific rotation [α][0239] D 25 −83° (c=0.90, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0240] 3) δ ppm: 1.1-1.6 (4 H, m), 1.17 (3 H, d, J=7 Hz), 1.8-2.0 (2 H, m), 2.0-2.2 (2 H, m), 2.69 (1 H, tt, J=12.3 Hz), 3.35 (1 H, q, J=7 Hz), 4.64 (1 H, s, OH), 4.83 (1 H, d, J=15 Hz), 5.10 (1 H, d, J=15 Hz), 5.83 (1 H, dd, J=15, 7 Hz), 6.22 (1 H, dd, J=15, 10 Hz), 6.48 (1 H, d, J=15 Hz), 6.74 (1 H, t, J=8 Hz), 6.81 (1 H, dd, J=15, 10 Hz), 7.1-7.5 (2 H, m), 7.45 (2 H, d, J=8 Hz), 7.54 (2 H, d, J=8 Hz), 7.76 (1 H, s), 7.84 (1 H, s).
  • IR spectrum υ[0241] max (CHCl3) cm−1: 1615, 1500, 1325, 1125, 1068.
  • Mass spectrum m/e: 563, 544, 340, 310, 277, 224, 159, 127. [0242]
    • EXAMPLE 37
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[trans-2-[(1E,3E,5E)-6-[4-(trifluoromethyl)phenyl]-1,3,5-hexatrien-1-yl]-1,3-dioxam-5-yl]thio]-2-butanol [0243]
    Figure US20010031768A1-20011018-C00238
  • Reaction was carried out in the same manner as in Example 4 using (2R, 3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol and (2E,4E,6E)-7-[4-(trifluoromethyl)phenyl]-2,4,6-heptatrienal as described in Reference example 28 to obtain the title compound, a major product as an oil in a yield of 65%. [0244]
  • NMR spectrum (2.70 MHz, CDCl[0245] 3) δ ppm: 1.18 (3 H, d, J=6.6 Hz), 3.33 (1 H, q, J=6.6 Hz) , 3.38 (1 H, tt, J=11.2, 4.6 Hz), 3.61 (1 H, t, J=11.2 Hz) , 3.63 (1 H, t, J=11.2 Hz), 4.29 (1 H, m), 4.40 (1 H, m), 4.83 (1 H, d, J=14.5 Hz), 5.00 (1 H, s), 5.02 (1 H, d, J=14.5 Hz), 5.03 (1 H, d, J=4.6 Hz), 5.74 (1 H, dd, J=15.2, 4.6 Hz), 6.35-6.55 (3 H, m), 6.59 (1 H, d, J=15.2 Hz), 6.7-6.8 (2 H, m), 6.89 (1 H, dd, J=15.2, 9.9 Hz), 7.35 (1 H, m), 7.48 (2 H, d, J=8.6 Hz), 7.56 (2 H, d, J=8.6 Hz), 7.78 (1 H, s), 7.79 (1 H, s).
    • EXAMPLE 38
  • (RS)-2-(2,4-Difluorophenyl)-3-methyl-1-(1 H-1,2,4-triazol-1-yl)-3-[]trans-2-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol [0246]
    Figure US20010031768A1-20011018-C00239
  • Reaction was carried out in the same manner as in Example 4 using (RS)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-3-methyl-1-(1 H-1,2,4-triazol-1-yl)-2-butanol and (2E,4E)-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienal as described in Reference example 25 to obtain the title compound, a major product as a colorless foam. [0247]
  • NMR spectrum (270 MHz, CDCl[0248] 3) δ ppm: 1.36 (6 H, s), 3.5-3.6 (2 H, m), 3.6-3.8 (2 H, m), 4.2-4.4 (1 H, m), 4.4-4.6 (1 H, m), 4.93 (1 H, d, J=14.1 Hz), 5.03 (1 H, d, J=4.3 Hz), 5.23 (1 H, d, J=14.1 Hz), 5.56 (1 H, s), 5.84 (1 H, dd, J=15.4, 4.3 Hz), 6.5-6.7 (3 H, m), 6.7-6.9 (2 H, m), 7.50 (2 H, d, J=8.4 Hz), 7.57 (2 H, d, J=8.4 Hz), 7.6-7.7 (1 H, m), 7.74 (1 H, s), 8.05 (1 H, s).
    • EXAMPLE 39
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[trans-2-[(E)-4-[4-(trifluoromethyl)phenyl]-1-buten-3-yn-1-yl]1,3-dioxan-5-yl]thio]-2-butanol [0249]
    Figure US20010031768A1-20011018-C00240
  • Reaction was carried out in the same manner as in Example 4 using (2R,3R)-2-(2,4-difluorophenyl)-3-[(1,3-dihydroxy-2-propyl)thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol and (E)-5-[4-(trifluoromethyl)phenyl]-2-penten-4-ynal as described in Reference example 48 to obtain the title compound, a major product as an oil in a yield of 70%. [0250]
  • Specific rotation [α][0251] D 25 −65.1° (c=0.97, CHCl3)
  • NMR spectrum (270 MHz, CDCl[0252] 3) δ ppm: 1.19 (3 H, d, J=7.0 Hz), 3.33 (1 H, q, J=7.0 Hz), 3.39 (1 H, tt, J=11.4, 4.9 Hz), 3.60 (1 H, t, J=11.4 Hz), 3.62 (1 H, t, J=11.4 Hz), 4.30 (1 H, m), 4.42 (1 H, m), 5.0-5.1 (2 H, m), 5.04 (1 H, d, J=3.2 Hz), 6.12 (1 H, d, J=16.0 Hz), 6.18 (1 H, dd, J=16.0, 3.2 Hz), 6.7-6.8 (2 H, m), 7.36 (1 H, m), 7.54 (2 H, d, J=8.5 Hz), 7.58 (2 H, d, J=8.5 Hz), 7.79 (2 H, s).
    • EXAMPLE 40
  • (2R, 3R)-2-(2,4-Difluorophenyl)-3-[[trans-2-phenyl-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0253]
    Figure US20010031768A1-20011018-C00241
  • In 20 ml of dimethylformamide were dissolved 1.65 g (6.57 mmol) of (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-(1 H-1, 2,4-triazol-1-yl)methyl]oxirane and 2.00 g (8.40 mmol) of trans-4-(acetylthio)-2-phenyl-1,3-dioxane as described in Reference example 1, and 2.5 ml (4.00 mmol) of a 1.6 M sodium methoxide-methbaol solution were added to the solution under a nitrogen atmosphere, followed by heating of the resulting mixture with stirring at 65°[0254] 0 C. for 2 hours. After cooling, ethyl acetate was added to the reaction mixture and the resulting mixture was washed with a saturated aqueous NaCl solution and dried, followed by evaporation of the solvent under reduced pressure. The thus obtained crude product was subjected to column chromatography using 60 g of silica gel and eluted with a mixed solvent of benzene-ethyl acetate (5:1) to obtain 2.53 g (yield: 91%) of the title compound as a solid. The solid was recrystallized from ethyl acetate-hexane to obtain a pure product having a melting point of 58 to 60° C.
  • Specific rotation [α][0255] D 25 −88° (c=1.07, CHCl3)
  • IR spectrum υ[0256] max (CHCl3)cm−1: 3400, 1615, 1500, 1139.
  • NMR spectrum (270 MHz, CDCl[0257] 3) δ ppm: 1.21 (3 H, d, J=7.3 Hz), 3.36 (1 H, q, J=7.3 Hz), 3.48 (1 H, tt, J=11.2, 4.6 Hz), 3.75 (1 H, t, J=11.2 Hz), 3.77 (1 H, t, J=11.2 Hz), 4.40 (1 H, ddd, J=11.2, 4.6, 2.6 Hz), 4.51 (1 H, ddd, J=11.2, 4.6, 2.6 Hz), 4.84 (1 H, d, J=13.9 Hz), 5.02 (1 H, s), 5.05 (1 H, d, J=13.9 Hz), 5.49 (1 H, s), 7.7-7.8 (2 H, m), 7.3-7.45 (4 H, m), 7.45-7.53 (2 H, m), 7.79 (2 H, s).
  • Reference Example 1 [0258]
  • Trans-4-(acetylthio)-2-phenyl-1,3-dioxane [0259]
    Figure US20010031768A1-20011018-C00242
  • In 200 ml of dimethylformamide were dissolved 29.0 g (86.8 mmol) of cis-2-phenyl-4-(p-toluenesulfonyloxy)-1,3-dioxane and 17.0 g (149 mmol) of sodium thioacetate, and the solution was heated at 115 to 120° C. under a nitrogen atmosphere for 1 hour. After cooling, benzene was added to the reaction mixture and the mixture was washed with water, followed by evaporation of the solvent. The thus obtained brown residue was subjected to column chromatography using silica gel and the fractions eluted with a mixed solvent of benzene-hexane (2:1) were collected, followed by recrystallization from a mixed solvent of benzene-hexane to obtain 8.99 g (yield: 43%) of the title compound having a melting point of 95 to 96° C. [0260]
  • NMR spectrum (270 MHz, CDCl[0261] 3) δ ppm: 2.37 (3 H, s), 3.79 (2 H, t, J=11.2 Hz), 4.03 (1 H, tt, J=11.2, 4.6 Hz), 4.31 (2 H, dd, J=11.2, 4.6 Hz), 5.47 (1 H, s), 7.35-7.5 (5 H, m).
  • IR spectrum υ[0262] max (CHCl3) cm−1: 1690, 1383, 1146, 1084.
  • Mass spectrum m/e: 238 (M[0263] +), 237, 195, 162(100%), 149, 116, 107, 73.
  • Reference Example 2 [0264]
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-[(1,3-dihydroxy-2-propyl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0265]
    Figure US20010031768A1-20011018-C00243
  • In 3. 5 ml of methanol were dissolved 253 mg of (2R, 3R)-2-(2,4-difluorophenyl)-3-[[trans-2-phenyl-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol as described in Example 40, and 0.35 ml of a 4 N HCl-dioxane solution were added to the solution, followed by stirring of the resulting mixture at room temperature for 30 minutes. To the reaction mixture were added 250 mg of a NaHCO[0266] 3 powder, and the mixture was stirred for 10 mimites, followed by filtration of the reaction mixture and concentration of the filtrate under reduced pressure. The thus obtained oil was subjected to column chromatography using 5 g of silica gel and eluted with 10% methanol-ethyl acetate to obtain 179 mg (yield: 88%) of the title compound as a viscous oil.
  • Specific rotation [α][0267] D 25 −61° (c=1.05,CHCl3)
  • IR spectrum υ[0268] max(CHCl3)cm−1: 3400, 1618, 1500.
  • NMR spectrum (60 MHz, CDCl[0269] 3+D2O) δ ppm: 1.20 (3 H, d, J=6.5 Hz), 3.0-4.0 (6 H, m), 4.80 (1 H, d, J=14 Hz), 5.16 (1 H, d, J=14 Hz), 6.6-7.0 (2 H, m), 7.43 (1 H, td, J=9, 8 Hz), 7.74 (1 H, s), 7.86 (1 H, s).
  • Reference Example 3 [0270]
  • Trans-5-[(4-chlorobenzyl)thio]-2-phenyl-1,3-dioxane [0271]
    Figure US20010031768A1-20011018-C00244
  • After 240 mg (5.50 mmol) of 55% sodium hydride were washed with hexane, it was suspended in 15 ml of dimethylformamide and 903 mg (5.70 mmol) of 4-chlorobenzylmercaptane were added to the resulting suspension with stirring under nitrogen atmosphere. After 15 minutes, 1.66 g (4.96 mmol) of cis-5-(p-toluenesulfonyloxy)-2-phenyl-1,3-dioxane were added to the mixture and the resulting mixture was stirred at 75° C. for 1 hour. After cooling, benzene was added to the reaction mixture and the mixture was washed with water and then an aqueous NaCl solution. After the solvent was distilled off, the thus obtained crystalline residue was recrystallized from a mixed solvent of benzene-hexane to obtain 670 mg (yield: 42%) of the title compound having a melting point of 95 to 99° C. as a flaky crystalline solid. [0272]
  • NMR spectrum (60 MHz, CDCl[0273] 3) δ ppm: 3.02 (1 H, tt, J=11, 5 Hz), 3 (2 H, t, J=11 Hz), 3.72 (2 H, s), 4.21 (2 H, dd, J=11, 5 Hz), 5.39 (1 H, 7.30 (5 H, s), 7.38 (4 H, s).
  • Reference Example 4 [0274]
  • 2-[(4-Chlorobenzyl)thio]-1,3-propanediol t,[0275] 0851
  • In 10 ml of methanol were dissolved 750 mg of trans-5 chlorobenzyl)thio]-2-phenyl-1,3-dioxane, and 1 ml of a 4 N hydrogen chloride-dioxane solution was added to the solution, followed by stirring of the resulting mixture at room temperature for 1 hour. After 750 mg of sodium hydrogencarbonate (powder) were added to the reaction mixture and the resulting mixture was stirred for 15 minutes, the solid was removed by filtration and the solvent was distilled off. Ethyl acetate was added to the residue and the insolubles were removed by filtration. The crystal obtained by evaporation of the solvent was recrystallized from a mixed solvent of benzene-hexane to obtain 468 mg (yield: 86%) of the title compound having a melting point of 70 to 75° C. [0276]
  • Reference Example 5 [0277]
  • Trans-5-(4-chlorobenzyl)thio]-2-[(E)-1-methyl-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxane [0278]
    Figure US20010031768A1-20011018-C00245
  • In 12 ml of benzene were dissolved 341 mg (1.46 mmol) of 2-[(4-chlorobenzyl)thio]1,3-propanediol and 375 mg (1.75 mmol) of (E)-4-(trifluoromethyl)-α-methylcinamaldehyde, and 3 mg of p-toluenesulfonic acid were added to the solution, followed by heating of the resulting mixture with reflux under nitrogen atmosphere for 2 hours. After cooling, the reaction mixture was washed with an aqueous sodium hydrogencarbonate solution. The residue obtained by evaporation of the solvent was subjected to column chromatography using 15 g of silica gel. The fractions eluted with a mixed solvent of hexane-ethyl acetate (9:1) were collected and the thus obtained solid was washed with hexane to obtain 370 mg (yield: 59%) of the title compound having a melting point of 93 to 95° C. [0279]
  • NMR spectrum (270 MHz, CDCl[0280] 3) δ ppm: 1.87 (3 H, s), 2.99 (1 H, tt, J=11.2, 4.6 Hz), 3.58 (2 H, dd, J=11.9, 11.2 Hz), 3.73 (2 H, s), 4.15 (2 H, dd, J=11.9, 4.6 Hz), 4.87 (1 H, s), 6.68 (1 H, br s), 7.25-7.3 (4 H, m), 7.36 (2 H, d, J=7.9 Hz), 7.57 (2 H, d, J=7.9 Hz).
  • Reference Example 6 [0281]
  • Trans-5-[(4-chlorobenzyl)sulfinyl]-2-[(E)-1-methyl-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxane [0282]
    Figure US20010031768A1-20011018-C00246
  • In 10 ml of methylene chloride were dissolved 382 mg (0.89 mmol) of trans-5-[(4-chlorobenzyl)thio]-2-[(E)-1-methyl-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxane, and 188 mg (0.92 mmol) of m-chloroperbenzoic acid (purity: 85%) were added to the solution, followed by stirring of the resulting mixture for 15 minutes. The reaction mixture was washed with an aqueous sodium hydrogencarbonate solution and the solid obtained by evaporation of the solvent was washed with a mixed solvent of ethyl acetate-hexane to obtain 328 mg (yield: 83%) having a melting point of 192 to 194° C. [0283]
  • NMR spectrum (60 MHz, CDCl[0284] 3) δ ppm: 1.88 (3 H, d, J=1.5 Hz), 2.8-3.3 (1 H, m), 3.8-4.5 (4 H, m), 4.01 (2 H, s), 4.95 (1 H, s), 6.73 (1 H, br s), 7.15-7.75 (8 H, m).
  • Reference Example 7 [0285]
  • Trans-4-(acetylthio)-2-[(E)-1-methyl-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxane [0286]
    Figure US20010031768A1-20011018-C00247
  • In 8 ml of a mixed solvent of tetrahydrofuran-acetonitrile (1:1) were dissolved 309 mg (0.696 mmol) of trans-5-[(4-chlorobenzyl)sulfinyl]-2-[(E)-1-methyl-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxane, and 500 mg (4.67 mmol) of 2,6-lutidine were added to the solution. To the resulting mixture were added dropwise 500 mg (2.4 mmol) of trifluoroacetic anhydride with stirring at 0° C. for about 5 minutes. After 10 minutes, about 5 ml of an aqueous sodium hydrogencarbonate solution were added to the reaction mixture and the mixture was stirred at 5 minutes, followed by extraction with ethyl acetate. An oily residue (about 350 mg) obtained by evaporation of the solvent was dissolved in 5 ml of methylene chloride and 210 mg of triethylamine were added to the solution at 0° C., followed by addition of 109 mg of acetyl chloride to the resulting mixture. After 5 minutes, the reaction mixture was washed with water and the solvent was distilled off. The residue was subjected to column chromatography using 10 g of silica gel and eluted with a mixed solvent of hexane-benzene (1:1 to 1:2) to obtain 186 mg (yield: 77%) of the title compound as a crystalline solid. The crystalline solid was recrystallized from a mixed solvent of benzene-hexane to obtain a plate-like crystalline solid having a melting point of 128 to 129° C. [0287]
  • NMR spectrum (270 MHz, CDCl[0288] 3) δ ppm: 1.92 (3 H, s), 2.36 (3 H, s), 3.70 (2 H, t, J=11.2 Hz), 3.96 (1 H, tt, J=11.2, 4.6 Hz), 4.25 (2 H, dd, J=11.2, 4.6 Hz), 4.94 (1 H, s), 6.70(1 H, br s), 7.39 (2 H, d, J=8.2 Hz), 7.59 (2 H, d, J=8.2 Hz).
  • Reference Example 8 [0289]
  • Ethyl (2E,4E)-3-methyl-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienoate [0290]
    Figure US20010031768A1-20011018-C00248
  • After 45 mg (1.03 mmol) of 55% sodium hydride were washed with hexane, it was suspended in 3 ml of 1,2-dimethoxyethane and 273 mg (1.03 mmol) of triethyl 3-methyl-4-phosphonocrotonate were added to the resulting mixture with stirring at 0° C. under nitrogen atmosphere. After 15 minutes, 100 mg (0.57 mmol) of 4-(trifluoromethyl)benzaldehyde were added to the mixture and the resulting mixture was stirred for 10 minutes. After ice-water was added to the reaction mixture, the mixture was extracted with ethyl acetate. The crude product obtained by evaporation of the solvent was subjected to column chromatography using 5 g of silica gel and eluted with a mixed solvent of ethyl acetate-hexane (4:96) to obtain 159 mg (yield: 97%) of a 5:1 mixture of the title compound, a (2E,4E) isomer and a (2Z,4E) isomer as an oil. [0291]
  • NMR spectrum (270 MHz, CDCl[0292] 3) δ ppm: (2E, 4E)-isomer, 1.31 (3 H, t, J=6.6 Hz), 2.41 (3 H, s), 4.20 (2 H, q, J=6.6 Hz), 5.95 (1 H, s), 6.86 (1 H, d, J=16.5 Hz), 6.95 (1 H, d, J=16.5 Hz), 7.5-7.65 (4 H, m): (2E, 4E)-isomer (main signal), 2.14 (3 H, s), 5.82 (1 H, s), 6.92 (1 H, d, J=16.5 Hz), 8.49 (1 H, d, J=16.5 Hz).
  • Reference Example 9 [0293]
  • (2E,4E)-3-Methyl-5-[4-(trifluoromethyl)phenyl]-2,4-pentadien-1-ol [0294]
    Figure US20010031768A1-20011018-C00249
  • After a solution in which 150 mg (0.53 mmol) of ethyl (4E)-3-methyl-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienoate ((2E)/(2Z)=5/1) as described in Reference example 8 were dissolved in 2 ml of toluene was stirred at 0° C., 0.7 ml (1.06 mmol) of a 1.5 M diisobutyl aluminum hydride-toluene solution were added to the solution. After 20 minutes, ice-water was added to the reaction mixture and the mixture was stirred for 10 minutes. The insolubles were removed by filtration using Celite and the filtrate was extracted with ethyl acetate and dried, followed by evaporation of the solvent to obtain an oil. The oil was subjected to column chromatography using 5 g of silica gel and eluted with a mixed solvent of 30 to 40% ethyl acetate-hexane to obtain 90 mg of the title compound as an oil. [0295]
  • NMR spectrum (270 MHz, CDCl[0296] 3) δ ppm: 1.34 (1 H, br s), 1.93 (3 H, s), 4.37 (2 H, d, J=6.5 hz), 5.87 (1 H, t, J=6.5 Hz), 6.58 (1 H, d, J=16.1 Hz), 6.88 (1 H, d, J=16.1 Hz), 7.50 (2 H, d, J=8.5 Hz), 7.57 (2 H, d, J=8.5 Hz).
  • Reference Example 10 [0297]
  • (2E, 4E)-3-Methyl-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienal [0298]
    Figure US20010031768A1-20011018-C00250
  • In 10 ml of methylene chloride were dissolved 460 mg (1.90 mmol) of (2E,4E)-3-methyl-5-[4-(trifluoromethyl)phenyl]-2,4-pentadien-1-ol, and 5 g of active manganese dioxide were added to the mixture, followed by stirring of the resulting mixture at room temperature for 30 minutes. The solid was removed by filtration, and after the filtrate was concentrated, it was purified over silica gel chromatography (eluting solvent: 4% ethyl acetate-heane) to obtain 460 mg of the title compound as an oil. [0299]
  • NMR spectrum (270 MHz, CDCl[0300] 3) δ ppm: 2.41 (3 H, s), 6.13 (1 H, d, J=8.0 Hz), 6.96 (1 H, d, J=16.1 Hz), 7.09 (1 H, d, J=16.1 Hz), 7.55-7.7 (4 H, m), 10.19 (1 H, d, J=8.0 Hz).
  • Reference Example 11 [0301]
  • 4-(Acetylthio)-1- (tert-butoxycarbonyl)piperidine [0302]
    Figure US20010031768A1-20011018-C00251
  • In 40 ml of dimethylformamide were dissolved 4.12 g (14.7 mmol) of 1-(tert-butoxycarbonyl)-4-(methanesulfonyloxy)piperidine, and 2.53 g (2.21 mmol) of potassium thioacetate were added to the solution, followed by stirring of the resulting mixture at 105° C. for 4 hours under nitrogen atmosphere. After cooling, the reaction mixture was diluted with ethyl acetate and washed with water and then a saturated aqueous NaCl solution, followed by evaporation of the solvent. The thus obtained residue was subjected to silica gel column chromatography and the fractions eluted with a mixed solvent of hexane-ethyl acetate (5:1) were collected to obtain 5.19 g (yield: 81%) of the title compound as an oil. [0303]
  • NMR spectrum (270 MHz, CDCl[0304] 3) δ ppm: 1.46 (9 H, s), 1.5-1.6 (2 H, m), 1.9-2.0 (2 H, m), 2.33 (3 H, s), 3.0-3.1 (2 H, m), 3.5-3.7 (1 H, m), 3.8-3.9 (2 H, m).
  • Mass spectrum m/e: 259, 244, 216, 202, 186, 183, 160, 144, 127, 116, 97, 84, 57. [0305]
  • Reference Example 12 [0306]
  • 1-(tert-Butoxycarbonyl)-4-mercaptopiperidine [0307]
    Figure US20010031768A1-20011018-C00252
  • In dry metan-ol were dissolved 520 mg (2 mmol) of 4-(acetylthio) -1-(tert-butoxycarbonyl)piperidine, and 420 μl (2 mmol) of a 28% sodium methoxide-methanol solution were added to the mixture under ice-cooling and under a nitrogen atmosphere, followed by stirring of the resulting mixture for 40 minutes. Then, 173 μl of acetic acid were added to the mixture and the solvent was distilled off at room temperature, followed by diluting of the residue with ethyl acetate. The mixture was washed successively with an aqueous sodium bydrogencarbonate solution and an aqueous NaCl solution in the order and the solvent was distilled off to obtain 430 mg of reddish orange oil. This product was used for a subsequent reaction without purification. [0308]
  • NMR spectrum (270 MHz, CDCl[0309] 3) δ ppm: 1.46 (9 H, s), 1.5-1.6 (2 H, m), 1.9-2.0 (2 H, m), 2.8-3.0 (3 H, m), 3.9-4.1 (2 H, m).
  • Mass spectrum m/e: 217, 202, 184, 161, 144, 127, 117, 84, 82. [0310]
  • Reference Example 13 [0311]
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-(1 H-1,2,4-triazol-1-yl)-3-[(1-(tert-butoxycarbonyl)piperidin-4-yl]thio]-2-butanol [0312]
    Figure US20010031768A1-20011018-C00253
  • In 6 ml of dimethylformamide was dissolved 1-(tert-butoxycarbonyl)-4-mercaptopiperidine (corresponding to 2 mmol) as described in Reference example 12, and 86 mg (1.97 mmol) of 55% sodium hydride were added to the solution at 0° C. under a nitrogen atmosphere, followed by stirring of the resulting mixture at the same temperature for 20 minutes. Then, 503 mg (2.00 mmol) of (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1 H-1,2,4-triazol-1-yl)methyl]oxirane were added to the reaction mixture and the mixture was stirred at 60° C. for 3 hours.. After cooling, ethyl acetate was added to the reaction mixture to dilute it and washed successively with water and a saturated aqueous NaCl solution. An oil obtained by evaporation of the solvent was subjected to silica gel column chromatography and eluted with ethyl acetate to obtain 557 mg (yield: 53%) of the desired compound as an oil. [0313]
  • NMR spectrum (270 MHz, CDCl[0314] 3) δ ppm: 1.17 (3 H, d, J=6.6 Hz), 1.47 (9 H, s), 1.4-1.6 (2 H, m), 1.9-2.1 (2 H, m), 2.9-3.1 (3 H, m), 3.34 (1 H, q, J=6.6 Hz), 3.9-4.1 (2 H, m), 4.77 (1 H, s), 4.82 (1 H, d, J=14.2 Hz), 5.09 (1 H, d, J=14.2 Hz), 6.7-6.8 (2 H, m), 7.3-7.4 (1 H, m), 7.77 (1 H, s), 7.82 (1 H, s).
  • IR spectrum υ[0315] max KBrcm−1: 3401, 1691.
  • Mass spectrum m/e: 468, 408, 395, 365, 321, 284, 253, 224, 188, 166, 144, 127. [0316]
  • Reference Example 14 [0317]
  • (2R,3R)-2-(2,4-Difluorophenyl)-3-(1 H-1,2,4-triazol-1-yl)-3-[(piperidin-4-yl) thio]-2 -butanol dihydrochloride [0318]
    Figure US20010031768A1-20011018-C00254
  • In 20 ml of ethyl acetate were dissolved 557 mg (1.05 mmol) of (2R,3R)-2-(2,4-difluorophenyl)-3-(1 H-1,2,4-triazol-1-yl)-3-[[1-(tert-butoxycarbonyl)piperidin-4-yl]thio]-2-butanol, and 2.63 ml (10.5 mmol) of a 4 N hydrogen chloride-ethyl acetate solution were added to the solution, followed by stirring of the resulting mixture at 40° C. for 8 hours. After cooling, the precipitated solid was collected by filtration and washed with hexane to obtain 460 mg (yield: 100%) of the desired compound as a colorless powder. [0319]
  • NMR spectrum (270 MHz, DMSO-d6+CDCl[0320] 3) δ ppm: 1.23 (3 H, d, J=6.6 Hz), 1.8-2.0 (2 H, m), 2.3-2.5 (2 H, m), 3.1-3.4 (3 H, m), 3.74 (1 H, q, J=6.6 Hz), 4.79 (1 H, d, J=14.2 Hz), 5.05 (1 H, d, J=14.2 Hz), 5.3-5.6 (1 H, br s), 6.8-6.9 (1 H, m), 7.0-7.1 (1 H, m), 7.2-7.3 (1 H, m), 7.79 (1 H, s), 8.28 (1 H, s).
  • IR spectrum υ[0321] max KBrcm−1: 3366, 3094, 2725, 2483.
  • Mass spectrum m/e: 368, 308, 286, 284, 253, 224, 213, 183, 165, 144, 116, 113, 84. [0322]
  • Reference Example 15 [0323]
  • 4-(Acetylthio)piperidine hydrochloride [0324]
    Figure US20010031768A1-20011018-C00255
  • In 45 ml of ethyl acetate were dissolved 1.25 g (4.82 mmol) of 4-(acetylthio)-1-(tert-butoxycarbonyl)piperidine as described in Reference example 11, and 12.0 ml (48.2 mmol) of a 4 N hydrogen chloride-ethyl acetate solution were added to the solution, followed by stirring of the resulting mixture at 50° C. for 4 hours. After cooling, the precipitated solid was collected by filtration and washed with hexane to obtain 885 mg (yield: 94%) of the desired compound as a slightly yellow powder. [0325]
  • NMR spectrum (270 MHz, CD[0326] 3OD) δ ppm: 1.8-2.0 (2 H, m), 2.1-2.3 (2 H, m), 2.35 (3 H, s), 3.1-3.3 (2 H, m), 3.3-3.5 (2 H, m), 3.6-3.8 (1 H, m).
  • Reference Example 16 [0327]
  • 4-(Acetylthio)-1-[(E)-4-(trifluoromethoxy)cinnamoyl]-piperidine [0328]
    Figure US20010031768A1-20011018-C00256
  • In 17 ml of dichlorometbane were suspended 1.28 g (6.53 mmol) of 4-(acetylthio)piperidine hydrochloride, and 2.27 ml (16.3 mmol) of triethylamine were added dropwise to the suspension with stirring under ice-cooling. Then, a solution in which 1.80 g (7.18 mmol) of (E)-4-(trifluoromethoxy)cinnamoyl chloride were dissolved in 6 ml of dichloromethane was added dropwise to the reaction mixture, followed by stirring of the mixture at the same temperature for 1 hour. The reaction mixture was subjected to silica gel column chromatography and eluted with a mixed solvent of hexane-ethyl acetate (2:1 to 1:1) to obtain 2.32 g (yield: 95%) of the desired compound as a slightly yellow solid. [0329]
  • NMR spectrum (270 MHz, CDCl[0330] 3) δ ppm: 1.5-1.7 (2 H, m), 1.9-2.1 (2 H, m), 2.34 (3 H, s), 3.1-3.3 (1 H, m), 3.3-3.5 (1 H, m), 3.7-3.8 (1 H, m), 3.9-4.0 (1 H, m), 4.2-4.4 (1 H, m), 6.85 (1 H, d, J=15.5 Hz), 7.21 (2 H, d, J=8.6 Hz), 7.54 (2 H, d, J=8.6 Hz), 7.63 (1 H, d, J=15.5 Hz).
  • Mass spectrum m/e: 373, 330, 298, 256, 228, 215, 187, 158, 136, 116, 101. [0331]
  • Reference Example 17 [0332]
  • 3 -(Acetylthio)-1-(tert-butoxycarbonyl) azetidine [0333]
    Figure US20010031768A1-20011018-C00257
  • An orange oil obtained from 1-(tert-butoxycarbonyl)-3-(methanesulfonyloxy)azetidine according to the procedure of Reference example 11. [0334]
  • NMR spectrum (270 MHz, CDCl[0335] 3) δ ppm: 1.44 (9 H, s), 2.33 (3 H, s), 3.81 (2 H, dd, J=9.0, 5.5 Hz), 4.1-4.2 (1 H, m), 4.37 (2 H, t, J=9.0 Hz).
  • Reference Example 18 [0336]
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[1-(tert-butoxycarbonyl)azetidin-3-yl]thio]-2-butanol [0337]
    Figure US20010031768A1-20011018-C00258
  • A pale yellow foam obtained from 3-(acetylthio)-1-(tert-butoxycarbonyl)azetidine according to the procedure of Reference examples 12 and 13. [0338]
  • NMR spectrum (270 MHz, CDCl[0339] 3) δ ppm: 1.13 (3 H, d, J=7.1 Hz), 1.45 (9 H, s), 3.27 (1 H, q, J=7.1 Hz), 3.7-3.9 (2 H, m), 3.9-4.0 (1 H, m), 4.2-4.4 (2 H, m), 4.84 (1 H, d, J=14.1 Hz), 4.98 (1 H, s), 5.04 (1 H, d, J=14.1 Hz), 6.7-6.9 (2 H, m), 7.3-7.4 (1 H, m), 7.78 (1 H, s), 7.80 (1 H, s) .
  • IR spectrum υ[0340] max KBrcm−1: 3405, 1701.
  • Mass spectrum m/e; 441, 425, 385, 367, 341, 311, 284, 252, 224, 199, 183, 165, 141, 127, 88. [0341]
  • Reference Example 19 [0342]
  • (2R,3R)-2-(2,4-Difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[(azetidin-3-yl)thio]-2-butanol dihydrochloride [0343]
    Figure US20010031768A1-20011018-C00259
  • A slightly yellow powder obtainied from (2R, 3R)-2 -(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[1-(tert-butoxycarbonyl)azetidin-3-yl]thio]-2-butanol according to the procedure of Reference example 14. [0344]
  • NMR spectrum (270 MHz, CDCl[0345] 3) δ ppm: 1.16 (3 H, d, J=6.6 Hz), 3.5 (1 H, q, J=6.6 Hz) , 3.9-4.3 (3 H, m) , 4.3-4.6 (2 H, m) , 4.98 (1 H, d, J=14.2 Hz), 5.43 (1 H, d, J=14.2 Hz), 6.6-6.9 (2 H, m), 7.2-7.4 (1 H, m), 8.40 (1 H, s), 8.95 (1 H, s), 9.0-9.6 (1 H, br).
  • Reference Example 20 [0346]
  • Ethyl trans-4-(trifluoromethyl)cinnamate [0347]
    Figure US20010031768A1-20011018-C00260
  • After 903 mg (20.7 mmol) of 55% sodium hydride were washed with hexane, it was suspended in 60 ml of 1,2-dimethoxyethane, and 4.63 g (20.7 mmol) of triethyl phosphonoacetate were added dropwise thereto while the suspension was stirred at 0° C. under nitrogen atmosphere. After 15 minutes, 2.00 g (11.5 mmol) of 4-(trifluoromethyl)benzaldehyde were added to the resulting mixture at the same temperature, followed by stirring of the mixture for 15 minutes. Ethyl acetate was added to the reaction mixture and the resulting mixture was washed with water. After drying, an oily residue obtained by evaporation of the solvent was subjected to column chromatography using silica gel and eluted with 4% ethyl acetate-hexane to obtain the title compound having a melting point of 31 to 32.5° C. in a yield of 98%. [0348]
  • NMR spectrum (270 MHz, CDCl[0349] 3) δ ppm: 1.35 (3 H, t, J=7.3 Hz), 4.48 (2 H, q, J=7.3 Hz), 6.51 (1 H, d, J=16.2 Hz), 7.66 (4 H, s), 7.69 (1 H, d, J=16.2 Hz).
  • Reference Example 21 [0350]
  • Trans-4-(trifluoromethyl)cinnamyl alcohol [0351]
    Figure US20010031768A1-20011018-C00261
  • In 15 ml of toluene were dissolved 3.00 g (12.3 mmol) of ethyl trans-4-(trifluoromethyl)cinnamate, and 16.4 ml (24.6 mmol) of a 1.5 M diisobutyl aluminum hydride-toluene solution were added to the solution with stirring at 0° C. After 20 minutes, ice-water was added to the reaction mixture and the mixture was stirred for 10 minutes, followed by removal of the insolubles by filtration using Celite. The filtrate was extracted with ethyl acetate and, after drying, the solvent was distilled off to obtain a crystalline residue. The residue was recrystallized from a mixed solvent of benzene-hexane to obtain 2.36 g (yield: 96%) of the title compound having a melting point of 53 to 55° C. [0352]
  • NMR spectrum (270 MHz, CDCl[0353] 3) δ ppm: 1.55 (1 H, t, J=5.9 Hz), 4.37 (2 H, br t), 6.46 (1 H, dt, J=16.2, 5.3 Hz), 6.67 (1 H, d, J=16.2 Hz), 7.46 (2 H, d, J=8.3 Hz), 7.57 (2 H, d, J=8.3 Hz).
  • Reference Example 22 [0354]
  • Trans-4-(trifluoromethyl)cinnamaldehyde [0355]
    Figure US20010031768A1-20011018-C00262
  • In 30 ml of methylene chloride were dissolved 2.15 g of trans-4-(trifluoromethyl)cinnamyl alcohol, and 14 g of active manganese dioxide were added to the solution at 0° C., followed by stirring of the resulting mixture for 15 minutes and then stirring at room temperature for 2 hours. The solid was removed by filtration and the filtrate was concentrated to obtain a crystalline residue. The residue was recrystallized from a mixed solvent of benzene-hexane to obtain the title compound having a melting point of 60 to 61° C. in a yield of 90%. [0356]
  • NMR spectrum (270 MHz, CDCl[0357] 3) δ ppm: 6.78 (1 H, dd, J=16.2, 7.3 Hz), 7.53 (1 H, d, J=16.2 Hz), 7.69 (4 H, s), 9.76 (1 H, d, J=7.3 Hz).
  • IR spectrum υ[0358] max (KBr) cm−1: 1680, 1630, 1321, 1173, 1123, 1066.
  • Mass spectrum m/e: 200 (M[0359] +), 199, 171, 151, 145, 131 (100%)), 103, 102.
  • Reference Example 23 [0360]
  • Ethyl (2E,4E)-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienoate [0361]
    Figure US20010031768A1-20011018-C00263
  • After 4.51 g (103 mmol) of 55% sodium hydride were washed with hexane, it was suspended in 70 ml of 1,2-dimethoxyethane, and 25.9 g (103 mmol) of triethyl phosphonocrotonate were added dropwise thereto while the suspension was stirred at 0° C. under nitrogen atmosphere. After 15 minutes, 10.0 g (57.4 mmol) of 4-(trifluoromethyl)benzaldehyde was added to the resulting mixture at the same temperature and the mixture was stirred for 10 minutes. The reaction mixture was poured in ice-water, followed by extraction with ethyl acetate. The oily residue obtained by evaporation of the solvent was subjected to column chromatography using silica gel and eluted with 6% ethyl acetate-hexane to obtain 11.2 g (yield: 72%) of the title compound as an oil. [0362]
  • NMR spectrum (270 MHz, CDCl[0363] 3) δ ppm: 1.32 (3 H, t, J=7.3 Hz), 4.24 (2 H, q, J=7.3 Hz), 6.05 (1 H, d, J=15.2 Hz), 6.85-7.0 (2 H, m), 7.44 (1 H, ddd, J=15.2, 7.9, 2.6 Hz), 7.55 (2 H, d, J=8.6 Hz), 7.61 (2 H, d, J=8.6 Hz).
  • Reference Example 24 [0364]
  • (2E,4E)-5-[4-(Trifluoromethyl)phenyl]-2,4-pentadien-1-ol [0365]
    Figure US20010031768A1-20011018-C00264
  • Ethyl (2E,4E)-5-[4-(trifluorometbyl)phenyl]-2,4-pentadienoate was treated with diisobutyl aluminum hydride in the same manner as in Reference example 21 to obtain the title compound in quantitative yield. [0366]
  • NMR spectrum (270 MHz, CDCl[0367] 3) δ ppm: 1.47 (1 H, t, J=5.9 Hz), 4.28 (2 H, t, J=5.9 Hz), 6.04 (1 H, dt, J=15.2, 5.9 Hz), 6.45 (1 H, dd, J=15.2, 10.6 Hz), 6.57 (1 H, d, J=15.8 Hz), 6.87 (1 H, dd, J=15.8, 10.6 Hz), 7.47 (2 H, d, J=8.6 Hz), 7.56 (2 H, d, J=8.6 Hz).
  • Reference Example 25 [0368]
  • (2E,4E)-5-[4-(Trifluoromethyl)phenyl]-2,4-pentadienal [0369]
    Figure US20010031768A1-20011018-C00265
  • (2E,4E)-5-[4-(Trifluoromethyl)phenyl]-2,4-pentadien-1-ol was treated with active manganese dioxide in the same manner as in Reference example 22 to obtain the title comnound in a yield of 92%. [0370]
  • NMR spectrum (270 MHz, CDCl[0371] 3) δ ppm: 6.33 (1 H, dd, J=15.2, 7.3 Hz), 7.0-7.35 (3 H, m), 7.60 (2 H, d, J=8.6 Hz), 7.64 (2 H, d, J=8.6 Hz), 9.65 (1 H, d, J=7.3 Hz).
  • Reference Example 26 [0372]
  • Ethyl (2E,4E,6E)-7-[4-(trifluoromethyl)phenyl]-2,4,6-heptatrienoate [0373]
    Figure US20010031768A1-20011018-C00266
  • (2E,4E)-5-[4-(Trifluoromethyl)phenyl]-2,4-pentadienal was reacted with triethyl phosphoncacetate in the same manner as in Reference example 20 to obtain the title compound in a yield of 95%. [0374]
  • NMR spectrum (270 MHz, CDCl[0375] 3) δ ppm: 1.31 (3 H, t, J=7.3 Hz), 4.23 (2 H, q, J=7.3 Hz), 5.96 (1 H, d, J=15.2 Hz), 6.49 (1 H, dd, J=15.2, 11.2 Hz), 6.72 (1 H, dd, J=15.2, 10.6 Hz), 6.73 (1 H, d, J=15.8 Hz), 6.94 (1 H, dd, J=5.8, 10.6 Hz), 7.37 (1 H, dd, J=15.2, 11.2 Hz), 7.51 (2 H, d, J=8.6 Hz), 7.58 (2 H, d, J=8.6 Hz).
  • Reference Example 27 [0376]
  • (2E,4E,6E)-7-[4-(Trifluorometbyl)phenyl]-2,4,6-heptatrien-1-ol [0377]
    Figure US20010031768A1-20011018-C00267
  • Ethyl (2E,4E,6E)-7-[4-(trifluoromethyl)phenyl]-2,4,6-heptatrienoate was treated with diisobutyl aluminum hydride in the same manner as in Reference example 21 to obtain the title compound in a yield of 90%. [0378]
  • NMR spectrum (270 MHz, CDCl[0379] 3) δ ppm: 1.41 (1 H, t, J=5.3 Hz), 4.25 (2 H, t, J=5.3 Hz), 5.95 (1 H, dt, J=15.0, 5.3 Hz), 6.3-6.5 (3 H, m), 6.57 (1 H, d, J=15.2 Hz), 6.90 (1 H, m), 7.47 (2 H, d, J=8.6 Hz), 7.55 (2 H, d, J=8.6 Hz)
  • Reference Example 28 [0380]
  • (2E,4E,6E)-7-[4-(Trifluoromethyl)phenyl]-2,4,6-heptatrienal [0381]
    Figure US20010031768A1-20011018-C00268
  • (2E,4E,6E)-7-[4-(Trifluoromethyl)phenyl]-2,4,6-heptatrien-1-ol was treated with active manganese dioxide in the same manner as in Reference example 22 to obtain the title compound in a yield of 88%. [0382]
  • NMR spectrum (270 MHz, CDCl[0383] 3) δ ppm: 6.23 (1 H, dd, J=15.2, 7.9 Hz), 6.62 (1 H, dd, J=14.5, 11.2 Hz), 6.82 (1 H, d, J=15.8 Hz), 6.84 (1 H, dd, J=14.5, 9.9 Hz), 6.98 (1 H, dd, J=15.8, 9.9 Hz), 7.19 (1 H, dd, J=15.2, 11.2 Hz), 7.54 (2 H, d, J=8.6 Hz), 7.61 (2 H, d, J=8.6 Hz), 9.62 (1 H, d, J=7.9 Hz).
  • Reference Example 29 [0384]
  • 4-(2,2,3,3-Tetrafluoropropoxy)benzaldehyde [0385]
    Figure US20010031768A1-20011018-C00269
  • After 1.90 g (43.5 mmol) of 55% sodium hydride were washed with hexane, it was suspended in 25 ml of N,N-dimethylacetamide and 5.3 g (43 mmol) of 4-hydroxybenzaldehyde were gradually added to the suspension at 0° C. under nitrogen atmosphere. When generation of hydrogen gas stopped, 11.14 g (39 mmol) of 2,2,3,3-tetrafluoropropyl p-toluenesulfonate were added to the reaction mixture, followed by heating of the resulting mixture at 120° C. with stirring for 2 hours and 15 minutes. After the reaction mixture was cooled, a mixed solvent of benzene-hexane (1:1) was added thereto and the resulting mixture was washed with water. After drying, the solvent was distilled off to obtain 8.85 g (yield: 96%) of the title compound as an oil. [0386]
  • NMR spectrum (270 MHz, CDCl[0387] 3) δ ppm: 4.45 (2 H, br t, J=11.9 Hz), 6.06 (1 H, tt, J=53.3, 4.6 Hz), 7.06 (2 H, d, J=8.7 Hz), 7.88 (2 H, d, J=8.7 Hz), 9.93 (1 H, s).
  • Reference Example 30 [0388]
  • Ethyl (2E,4E)-5-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-2,4-pentadienoate [0389]
    Figure US20010031768A1-20011018-C00270
  • 4-(2,2,3,3-Tetrafluoropropoxy)benzaldehyde and triethyl phosphonocrotonate were reacted in the same manner as in Reference example 23 to obtain the title compound having a melting point of 65 to 66° C. in a yield of 74%. [0390]
  • NMR spectrum (270 MHz, CDCl[0391] 3) δ ppm: 1.31 (3 H, t, J=7.3 Hz), 4.23 (2 H, q, J=7.3 Hz), 4.37 (2 H, br t, J=11.9 Hz), 5.95 (1 H, d, J=15.2 Hz), 6.06 (1 H, tt, J=53.5, 4.6 Hz), 6.77 (1 H, dd, J=15.2, 9.9 Hz), 6.86 (1 H, d, J=15.2 Hz), 6.91 (2 H, d, J=8.6 Hz), 7.42 (1 H, dd, J=15.2, 9.9 Hz), 7.44 (2 H, d, J=8.6 Hz).
  • Reference Example 31 [0392]
  • (2E,4E)-5-[4-(2,2,3,3-Tetrafluoropropoxy)phenyl]-2,4-pentadien-1-ol [0393]
    Figure US20010031768A1-20011018-C00271
  • Ethyl (2E,4E)-5-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-2,4-pentadienoate was treated with diisobutyl aluminum hydride in the same manner as in Reference example 21 to obtain the title compound having a melting point of 95 to 97° C. in a yield of 95%. [0394]
  • NMR spectrum (270 MHz, CDCl[0395] 3) δ ppm: 1.39 (1 H, t, J=5 Hz), 4.25 (2 H, t, J=5.9 Hz), 4.34 (2 H, br t, J=11.9 Hz), 5.94 (1 H, dt, J=15.1, 5.9 Hz), 6.06 (1 H, tt, J=53.2, 4.8 Hz), 6.40 (1 H, dd, J=15.1, 10.3 Hz), 6.50 (1 H, d, J=15.5 Hz), 6.69 (1 H, dd, J=15.5, 10.3 Hz), 6.88 (2 H, d, J=8.7 Hz), 7.36 (2 H, d, J=8.7 Hz).
  • Reference Example 32 [0396]
  • (2E,4E)-5-[4-(2,2,3,3-Tetrafluoropropoxy)phenyl]-2,4-pentadienal [0397]
    Figure US20010031768A1-20011018-C00272
  • Ethyl (2E,4E)-5-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-2,4-pentadien-1-ol was treated with active manganese dioxide in the same manner as in Reference example 22 to obtain the title compound having a melting point of 53 to 55° C. in a yield of 96%. [0398]
  • NMR spectrum (270 MHz, CDCl[0399] 3) δ ppm: 4.38 (2 H, br t, J=11.9 Hz), 6.06 (1 H, tt, J=52.8, 4.6 Hz), 6.25 (1 H, dd, J=15.2, 7.9 Hz), 6.90 (1 H, dd, J=15.8, 9.2 Hz), 6.94 (2 H, d, J=8.6 Hz), 6.97 (1 H, d, J=15.8 Hz), 7.25 (1 H, dd, J=15.2, 9.2 Hz), 7.48 (2 H, d, J=8.6 Hz), 9.61 (1 H, d, J=7.9 Hz).
  • Reference Example 33 [0400]
  • Trans-4-(trifluoromethoxy)cinnamaldehyde [0401]
    Figure US20010031768A1-20011018-C00273
  • 570 mg (3.0 mmol) of 4-(trifluoromethoxy)benzaldehyde and 913 mg (3.0 mmol) of (triphenylphosphoranylidene)acetaldehyde were heated under reflux in 7.5 ml of toluene under nitrogen atmosphere for 1 hour and 45 minutes. The toluene was distilled off under reduced pressure and the thus obtained residue was purified over column chromatography using 20 g of silica gel. The fractions eluted with a mixed solvent of acetic acid-hexane (1:10) were collected to obtain 387 mg (yield: 60%) of the title compound as an oil. [0402]
  • NMR spectrum (270 MHz, CDCl[0403] 3) δ ppm: 6.70 (1 H, dd, J=15.8, 7.3 Hz), 7.29 (2 H, d, J=8.6 Hz), 7.47 (1 H, d, J=15.8 Hz), 7.61 (2 H, d, J=8.6 Hz), 9.72 (1 H, d, J=7.3 Hz).
  • IR spectrum υ[0404] max (CHCl3) cm−1: 1680, 1508, 1259.
  • Mass spectrum m/e: 216 (M[0405] +), 215, 187, 175, 162, 131(100%), 119, 101.
  • Reference Example 34 [0406]
  • Ethyl 6-(2,2,3,3-tetrafluoropropoxy)nicotinate [0407]
    Figure US20010031768A1-20011018-C00274
  • After 840 mg (19.3 mmol) of 55% sodium hydride were washed with hexane, it was suspended in 40 ml of dimethylformamide, and 3.00 g (22.7 mmol) of 2,2,3,3-tetrafluoropropanol were gradually added to the suspension at 0° C. under a nitrogen atmosphere. When generation of hydrogen gas stopped, a solution in which 3.40 g (18.3 mmol) of ethyl 6-chloronicotinate was dissolved in 15 ml of dimethylformamide was added dropwise to the resulting mixture at the same temperature for about 30 minutes. After the dropwise addition, the mixture was stirred for 30 minutes and the reaction mixture was poured into ice-water, followed by extraction with benzene. After the extract was dried, the solvent was distilled off and the thus obtained oil was purified over column chromatography [eluted with a mixed solvent of benzene-hexane (1:1] using silica gel to obtain 4.42 g (yield: 86%) of the title compound as an oil. [0408]
  • NMR spectrum (270 MHz, CDCl[0409] 3) δ ppm: 1.40 (3 H, t, J=7.2 Hz), 4.39 (2 H, q, J=7.2 Hz), 4.81 (2 H, br t, J=12.6 Hz), 6.00 (1 H, tt, J=53.0, 4.6 Hz), 6.87 (1 H, d, J=8.6 Hz), 8.24 (1 H, dd, J=8.6, 2.5 Hz), 8.83 (1 H, d, J=2.5 Hz).
  • IR spectrum υ[0410] max (CHCl3) cm−1: 1717, 1604, 1280, 1119.
  • Mass spectrum m/e: 281 (M[0411] +), 236(100%), 180, 152, 151, 123, 122, 93.
  • Reference Example 35 [0412]
  • 2-(2,2,3,3-Tetrafluoropropoxy)-5-(hydroxymethyl)pyridine [0413]
    Figure US20010031768A1-20011018-C00275
  • Ethyl 6-(2,2,3,3-tetrafluoropropoxy)nicotinate was reduced with diisobutyl aluminum hydride in the same manner as in Reference example 21 to obtain the title compound as an oil in a yield of 100%. [0414]
  • NMR spectrum (270 MHz, CDCl[0415] 3) δ ppm: 1.69 (1 H, t, J=5.8 Hz), 4.66 (2 H, d, J=75.8 Hz), 4.74 (2 H, br t, J=12.8 Hz), 6.01 (1 H, tt, J=53.1, 4.6 Hz), 6.84 (1 H, d, J=8.5 Hz), 7.69 (1 H, dd, J=8.5, 2.5 Hz), 8.12 (1 H, d, J=2.5 Hz).
  • Mass spectrum m/e: 239 (M[0416] +), 210, 188, 168, 138(100%), 109, 108, 78.
  • Reference Example 36 [0417]
  • 6-(2,2,3,3-Tetrafluoropropoxy)nicotinaldehyde [0418]
    Figure US20010031768A1-20011018-C00276
  • 2-(2,2,3,3-Tetrafluorapropoxy)-5-(hydroxymethyl)pyridine was treated with active maganese dioxide in the same manner as in Reference example 22 to obtain the title compound as an oil in a yield of 96%. [0419]
  • NMR spectrum (270 MHz, CDCl[0420] 3) δ ppm: 4.86 (2 H, br t, J=12.8 Hz), 6.01 (1 H, tt, J=53.3, 4.4 Hz), 6.97 (1 H, d, J=8.6 Hz), 8.15 (1 H, dd, J=8.6, 2.3 Hz), 8.65 (1 H, d, J=2.3 Hz).
  • Mass spectrum m/e: 237 (M[0421] +), 186, 166, 136(100%), 107, 106, 78.
  • Reference Example 37 [0422]
  • (2E,4E)-5-[6-(2,2,3,3-Tetrafluoropropoxy)-3-pyridyl]-2,4-pentadienal [0423]
    Figure US20010031768A1-20011018-C00277
  • Following Reference examples 23, 24 and 25, the title compound having a melting point of 88 to 89° C. was obtained from 6-(2,2,3,3-tetrafluoropropoxy)nicotinaldehyde in 3 steps. [0424]
  • NMR spectrum (270 MHz, CDCl[0425] 3) δ ppm: 4.78 (2 H, br t, J=12.6 Hz), 6.01 (1 H, tt, J=53.3, 4.5 Hz), 6.28 (1 H, dd, J=15.2, 7.9 Hz), 6.87 (1 H, d, J=8.7 Hz), 6.85-7.0 (2 H, m), 7.25 (1 H, ddd, J=15.2, 7.8, 2.5 Hz), 7.85 (1 H, dd, J=8.7, 2.5 Hz), 8.23 (1 H, d, J=2.5 Hz), 9.63 (1 H, d, J=7.9 Hz).
  • IR spectrum υ[0426] max (CHCl3) cm−1: 1677, 1626, 1591, 1488, 1290, 1120.
  • Mass spectrum m/e: 289 (M[0427] +), 260, 188, 178, 160, 145, 128, 117, 81, 69(100%).
  • Reference Example 38 [0428]
  • (2E,4E)-5-(6-Chloro-3-pyridyl) -2,4-pentadienal [0429]
    Figure US20010031768A1-20011018-C00278
  • Following Reference examples 23, 24 and 25, the title compound was obtained as an oil from 6-chloronicotinaldehyde in 3 steps. [0430]
  • NMR spectrum (270 MHz, CDCl[0431] 3) δ ppm: 6.32 (1 H, dd, J=15.2, 7.8 Hz), 6.96 (1 H, d, J=15.4 Hz), 7.05 (1 H, dd, J=15.4, 9.8 Hz), 7.26 (1 H, dd, J=15.2, 9.8 Hz), 7.36 (1 H, d, J=8.3 Hz), 7.80 (1 H, dd, J=8.3, 2.5 Hz), 8.48 (1 H, d, J=2.5 Hz), 9.66 (1 H, d, J=7.8 Hz).
  • Reference Example 39 [0432]
  • [4-(4-Chlorobenzyl)thio]cyclohexylidene]methyl methyl ether [0433]
    Figure US20010031768A1-20011018-C00279
  • After 146 mg (3.34 mmol) of 55% sodium hydride were washed with hexane, it was suspended in 18 ml of dimethyl sulfoxide, followed by stirring of the resulting suspension at 55° C. for 2 hours. The mixture was cooled to room temperature and 1.26 g (3.34 mmol) of methoxymethyltriphenylphosphonium chloride were added to the mixture. Futher, a solution in which 426 mg (1.67 mmol) of 4-[(4-chlorobenzyl)thio]cyclohexanone were dissolved in 5 ml of dimethyl sulfoxide was added to the resulting mixture. Water was added to the mixture and the resulting mixture was extracted with toluene. After the extract was dried, the crude product obtained by evaporation of the solvent was subjected to column chromatography using 20 g of silica gel and eluted with a mixed solvent of methylene chloride-hexane (1:4) to obtain 370 mg (yield: 78%) of the title compound as an oil. [0434]
  • NMR spectrum (270 MHz, CDCl[0435] 3) δ ppm: 1.2-1.5 (2 H, m), 1.7-2.0 (3 H, m), 2.0-2.2 (1 H, m), 2.5-2.8 (2 H, m), 3.53 (3 H, s), 3.71 (2 H, s), 5.77 (1 H, s), 7.27 (4 H, s).
  • IR spectrum υ[0436] max (CHCl3) cm−1: 2935, 1689, 1491, 1443, 1123.
  • Mass spectrum m/e: 282, 157, 124, 109. [0437]
  • Reference Example 40 [0438]
  • Trans-4-[(4-chlorobenzyl)thio]cyclohexanecarboxaldehyde [0439]
    Figure US20010031768A1-20011018-C00280
  • In 20 ml of acetone were dissolved 955 mg (3.4 mmol) of [4-[(4-chlorobenryl)thio]cyclohexylidene]methyl methyl ether, and 5 ml of water were added to the solution, followed by addition of 1 ml of 5 N hydrochloric acid. The mixture was stirred at 55° C. for 20 minutes. The mixture was concentrated under reduced pressure and the residue was extracted with ethyl acetate. After the extract was dried, the crude product obtained by evaporation of the solvent was subjected to column chromatography using 15 g of silica gel and eluted with a mixed solvent of methylene chloride-hexane (1:3) to obtain 865 mg (yield: 95%) of a 1:1 mixture of a trans isomer, the title compound, and a cis isomer as an oil. [0440]
  • This product was stirred in 15 ml of a 0.07 N sodium methoxide-methanol solution at room temperature for 2 to 3 hours. To the mixture was added 0.2 ml of acetic acid, and the resulting mixture was diluted with ethyl acetate and washed with an aqueous NaCl solution. After the mixture was dried, the solvent was distilled off to obtain 865 mg of a 4:1 mixture of the title trans form and a cis form as a solid. The solid was recrystallized from a mixed solvent of ether-hexane to obtain 220 mg of the trans form title compound having a melting point of 44 to 46° C. [0441]
  • NMR spectrum (270 MHz, CDCl[0442] 3) δ ppm: 1.2-1.5 (4 H, m), 1.9-2.15 (2 H, m), 2.15-2.35 (1 H, m), 2.35-2.55 (1 H, m), 3.73 (2 H, s), 7.27 (5 H, s), 9.61 (1 H, s).
  • Cis isomer exhibited a signal at δ3.67 (2 H, s) and δ9.64 (1 H, s). [0443]
  • IR spectrum υ[0444] max (CHCl3) cm−1: 2927, 1732, 1493, 1448, 1092.
  • Mass spectrum m/e: 268, 240, 127, 125, 110. [0445]
  • Reference Example 41 [0446]
  • 4-Chlorobenzyl trans-4-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]1,3-butadienyl]cyclohexyl sulfide [0447]
    Figure US20010031768A1-20011018-C00281
  • After 50 mg (1.14 mmol) of 55% sodium hydride were washed with hexaze, it was suspended in 7 ml of dimethyl sulfoxide, followed by stirring of the suspension at 55° C. for 2.5 hours. The mixture was cooled to room temperature and 607 mg (1.26 mmol) of [(E)-4-(trifluoromethyl)cinnamyl]triphenylphosphonium chloride were added thereto. Further, 170 mg (0.63 mmol) of trans-4-[(4-chlorobenzyl)thio]cyclohexanecarboxaldehyde were added to the resulting mixture, followed by stirring of the mixture at room temperature for 15 minutes. The mixture was diluted with toluene and washed with water and an aqueous NaCl solution. After the mixture was dried, the crude product obtained by evaporation of the solvent was subjected to column chromatography using 5 g of silica gel and eluted with a mixed solvent of methylene chloride-hexane (1:2). The eluted portion was recrystallized from hexane to obtain 86 mg (yield: 31%) of the title compound having a melting point of 142 to 144° C. [0448]
  • NMR spectrum (270 MHz, CDCl[0449] 3) δ ppm: 1.1-1.3 (2 H, m), 1.3-1.5 (2 H, m), 1.7-2.0 (2 H, m), 2.0-2.2 (2 H, m), 2.64 (1 H, tt, J=12.4 Hz), 3.74 (2 H, s), 5.81 (1 H, dd, J=15, 7 Hz), 6.20 (1 H, dd, J=15, 10 Hz), 6.47 (1 H, d, J=16 Hz), 6.81 (1 H, dd, J=16, 10 Hz), 7.29 (4 H, s), 7.46 (2 H, d, J=8 Hz), 7.55 (2 H, d, J=8 Hz).
  • IR spectrum υ[0450] max (KBr) cm−1: 1641, 1612, 1490, 1326, 1167, 1127, 1069.
  • Mass spectrum m/e: 436, 417, 403, 311, 277, 235, 159, 125. [0451]
  • Reference Example 42 [0452]
  • 4-Chlorobenzyl trans-4-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadienyl]cyclohexyl sulfoxide [0453]
    Figure US20010031768A1-20011018-C00282
  • In 20 ml of methylene chloride were dissolved 211 mg (0.48 mmol) of 4-chlorobenzyl trans-4-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadienyl]cyclohexyl sulfide, and 104 mg (0.48 mmol) of m-chloroperbenzoic acid (purity: 80%) were added to the solution at 0° C., followed by stirring of the resulting mixture for 5 minutes. An aqueous sodium sulfite solution and ethyl acetate were added to the reaction mixture and the organic layer was washed with an aqueous sodium hydrogencarbonate solution and an aqueous NaCl solution. After the mixture was dried, the crude product obtained by evaporation of the solvent was recrystallized from a mixed solvent of ethyl acetate-hexane to obtain 168 mg (yield: 77%) of the title compound having a melting point of 212 to 214° C. [0454]
  • NMR spectrum (270 MHz, CDCl[0455] 3) δ ppm: 1.1-1.3 (2 H, m), 1.5-1.8 (2 H, m), 1.9-2.3 (5 H, m), 2.42 (1 H, tt, J=12, 4 Hz), 3.87 (1 H, d, J=13 Hz), 3.97 (1 H, d, J=13 Hz), 5.80 (1 H, dd, J=15, 7 Hz), 6.22 (1 H, dd, J=15, 10 Hz), 6.48 (1 H, d, J=16 Hz), 6.80 (1 H, dd, J=16, 10 Hz), 7.25 (2 H, d, J=8 Hz), 7.36 (2 H, d, J=8 Hz), 7.45 (2 H, d, J=8 Hz), 7.55 (2 H, d, J=8 Hz).
  • IR spectrum υ[0456] max (KBr) cm−1: 1612, 1492, 1325, 1168, 1128, 1069.
  • Mass spectrum m/e: 452, 436, 327, 278, 277, 159, 125. [0457]
  • Reference Example 43 [0458]
  • Trans-1-(acetylthio)-4-(1 E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]cyclohexane [0459]
    Figure US20010031768A1-20011018-C00283
  • In 11 ml of a mixed solvent of tetrahydrofuran-acetonitrile (8:3) were dissolved 178 mg (0.39 mmol) of 4-chlorobenzyl trans-4-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadienyl]cyclohexyl sulfoxide, and 168 mg (1.57 mmol) of 2,6-lutidine were added to the solution. To the mixture were added 165 mg (0.79 mmol) of trifluoroacetic anhydride with stirring at 0° C. After 3 minutes, an aqueous sodium hydrogencarbonate solution was added to the mixture, followed by extraction with ethyl acetate. The oily residue obtained by evaporation of the solvent was dissolved in 10 ml of methylene chloride, and 119 mg (1.17 mmol) of triethylamine were added to the mixture at 0° C., followed by addition of 62 mg (0.79 mmol) of acetyl chloride to the resulting mixture. After 1 hour, the reaction mixture was diluted with ethyl acetate and washed with an aqueous sodium hydrogencarbonate solution and an aqueous NaCl solution. After the mixture was dried, the crude product obtained by evaporation of the solvent was subjected to column chromatography using 5 g of silica gel and eluted with a mixed solvent of methylene cbloride-hexane (1:1), followed by purification over Rover column [GrosseB, a mixed solvent of ethyl acetate-hexane (1:19)] to obtain 98 mg (yield: 70%) of the title compound having a melting point of 113 to 115° C. [0460]
  • NMR spectrum (270 MHz, CDCl[0461] 3) δ ppm: 1.2-1.5 (4 H, m), 1.7-1.9 (2 H, m), 2.0-2.2 (3 H, m), 2.31 (3 H, s), 3.37 (1 H, tt, J=12, 4 Hz), 5.82 (1 H, dd, J=15, 7 Hz), 6.20 (1 H, dd, J=15, 10 Hz), 6.47 (1 H, d, J=16 Hz), 6.81 (1 H, dd, J=16, 10 Hz), 7.45 (2 H, d, J=8 Hz), 7.54 (2 H, d, J=8 Hz).
  • IR spectrum υ[0462] max (KBr) cm−1: 1688, 1613, 1326, 1157, 1117, 1068.
  • Mass spectrum m/e: 354, 335, 311, 277, 235, 159. [0463]
  • Reference Example 44 [0464]
  • 3-[4-(Trifluoromethyl)phenyl]-2-propyn-1-ol [0465]
    Figure US20010031768A1-20011018-C00284
  • In 50 ml of diethylamine were dissolved 5.0 g (22 mmol) of 4-bromo-α,α,α-trifluorotoluene and 1.25 g (22 mmol) of propargyl alcohol, and 80 mg (0.11 mmol) of bis(triphenylphosphine)palladium (II) chloride and 40 mg (0.22 mmol) of copper (I) iodide were added to the solution, followed by stirring of the resulting mixture at 50° C. for 35 minutes. To the mixture were added 40 mg (0.06 mmol) of bis(triphenylphosphine)palladium (II) chloride, and the resulting mixture was stirred for a further 35 mintes. After the mixture was cooled to room temperature, it was diluted with benzene and filtered, and then the filtrate was washed with water. After the mixture was dried, the crude product obtained by evaporation of the solvent was subjected to colurnm chromatography using 50 g of silica gel and eluted with a mixed solvent of ethyl acetate-hexane (3:17) to obtain 2.21 g (yield: 50%) of the title compound as an oil. [0466]
  • NMR spectrum (270 MHz, CDCl[0467] 3) δ ppm: 1.8 (1 H, br, OH), 4.52 (2 H, s), 7.54 (2 H, d, J=9 Hz), 7.57 (2 H, d, J=9 Hz).
  • IR spectrum υ[0468] max (CHCl3) cm−1: 3610, 1618, 1324, 1172, 1133, 1069, 1019, 844.
  • Mass spectrum m/e: 200, 183, 171, 151, 131. [0469]
  • Reference Example 45 [0470]
  • 3-[4-(Trifluoromethyl)phenyl]-2-propynal [0471]
    Figure US20010031768A1-20011018-C00285
  • In 20 ml of methylene chloride were dissolved 2.21 g (11.0 mmol) of 3-[4-(trifluoromethyl)phenyl]-2-propyn-1-ol, and 7.43 g (17.5 mmol) of Dess-Martin reagent were added to the solution under ice-cooling for 1.7 hours. Benzene was added to the resulting mixture and the insolubles were removed by filtration, followed by concentration of the filtrate to obtain 1.83 g (yield: 84%) of the title compound as an oil. [0472]
  • NMR spectrum (270 MHz, CDCl[0473] 3) δ ppm: 7.68 (2 H, d, J=9 Hz), 7.71 (2 H, d, J=9 Hz), 9.45 (1 H, s).
  • IR spectrum υ[0474] max (CHCl3) cm−1: 2197, 1664, 1324, 1175, 1138.
  • Mass spectrum m/e: 198, 197, 170, 151, 120. [0475]
  • Reference Example 46 [0476]
  • Ethyl (E)-5-[(4-trifluoromethyl)phenyl]-2-penten-4-ynoate [0477]
    Figure US20010031768A1-20011018-C00286
  • After 181 mg (4.54 mmol) of 55% sodium hydride were washed with hexane, it was suspended in 10 ml of 1,2-dimethoxyethane, and 1.02 g (4.54 mmol) of triethyl 4-phosphonoacetate were added to the suspension with stirring at 0° C under nitrogen atmosphere. After 20 minutes, 500 mg (2.52 mmol) of 3-[4-(trifluoromethyl)phenyl]-2-propynal were added to the mixture, followed by stirring of the resulting mixture for 20 minutes. The reaction mixture was diluted with ethyl acetate, ice was added to the mixture and then the organic layer was washed with water. The crude product obtained by distilling off the solvent was subjected to column chromatography using 15 g of silica gel and eluted with benzene to obtain 488 mg (yield: 72%) of the title compound as an oil. [0478]
  • NMR spectrum (270 MHz, CDCl[0479] 3) δ ppm: 1.32 (3 H, t, J=7 Hz), 4.25 (2 H, q, J=7 Hz), 6.35 (1 H, d, J=16 Hz), 6.97 (1 H, d, J=16 Hz), 7.5-7.7 (4 H, m).
  • IR spectrum υ[0480] max (CHCl3) cm−1: 1712, 1622, 1316, 1174, 1134.
  • Mass spectrm m/e: 268, 240, 223, 195, 183, 175. [0481]
  • Reference Example 47 [0482]
  • (E)-5-[4-(Trifluoromethyl)phenyl]-2-penten-4-yn-1-ol [0483]
    Figure US20010031768A1-20011018-C00287
  • In 4 ml of toluene were dissolved 480 mg (1.79 mmol) of ethyl (E)-5-[4-(trifluoromethyl)phenyl]-2-penten-4-ynoate, and 2.38 ml (3.58 mmol) of a 1.5 M diisobutyl aluminum hydride-toluene solution were added to the solution with stirring at 0° C. After 10 minutes, ice was added to the mixture and the insolubles were removed by filtration using Celite. After the organic layer was dried, the crude product obtained by evaporation of the solvent was subjected to column chromatography using 15 g of silica gel and eluted with a mixed solvent of ethyl acetate-hexane (3:17) to obtain 353 mg (yield: 87%) of the title compound as an oil. [0484]
  • NMR spectrum (270 MHz, CDCl[0485] 3) δ ppm: 1.60 (1 H, br, OH), 4.31 (2 H, br), 5.99 (1 H, d, J=16 Hz), 6.40 (1 H, dt, J=16, 5 Hz), 7.54 (2 H, d, J=9 Hz), 7.57 (2 H, d, J=9 Hz).
  • Reference Example 48 [0486]
  • (E)-5-(4-(Trifluoromethyl)phenyl]-2-penten-4-ynal [0487]
    Figure US20010031768A1-20011018-C00288
  • In 4 ml of methylene chloride were dissolved 350 mg (1.56 mmol) of (E)-5-[4-(trifluoromethyl)phenyl]-2-penten-4-yn-1-ol, and 3.5 g of active manganese dioxide were added to the solution, followed by stirring of the resulting mixture at room temperature for 30 minutes. The solid was removed by filtration and the filtrate was concentrated. Then, the filtrate was subjected to column chromatography using 10 g of silica gel and eluted with a mixed solvent of ethyl acetate-hexane (1:24) to obtain 245 mg (yield: 70%) of the title compound as an oil. [0488]
  • NMR spectrum (270 MHz, CDCl[0489] 3) δ ppm: 6.58 (1 H, dd, J=16, 8 Hz), 6.82 (1 H, d, J=16 Hz), 7.63 (4 H, s), 9.65 (1 H, d, J=8 Hz).
  • IR spectrum υmax (CHCl[0490] 3) cm−1: 1670, 1325, 1132, 1119, 1107, 1072, 845.
  • Mass spectrum m/e: 224, 196, 195, 175, 170, 146. [0491]
  • Reference Example 49 [0492]
  • Methyl (Z)-4-chloro-β-(trifluoromethyl)cinnamate [0493]
    Figure US20010031768A1-20011018-C00289
  • In 10 ml of tetrahydrofuran were dissolved 150 mg (0.47 mmol) of bis(2,2,2-trifluoroethyl) (methoxycarbonylmethyl)phosphonate, and 0.94 ml (0.47 mmol) of a 0.5 M potassium hexamethyldisilazide-toluene solution were added dropwise to the mixture with stirring at −78° C. under nitrogen atmosphere. Then, 622 mg (2.36 mmol) of 18-crown-6 were added to the mixture and the resulting mixture was stirred for 20 minutes, followed by addition of a solution in which 98 mg (0.47 mmol) of 4′-chloro-2,2,2-trifluoroacetophenone were dissolved in 1 ml of tetrahydrofuran. The temperature of the reaction mixture was slowly elevated to room temperature and a saturated aqueous ammonium chloride solution was added to the mixture, followed by extraction with ethyl acetate. The crude product obtained by evaporation of the solvent was purified over column chromatography (eluted with 4% ethyl acetate-hexane) using silica gel to obtain 89 mg (yield: 70%, containing about {fraction (1/10)} of (E)-isomer) of the title compound as an oil. [0494]
  • NMR spectrum (270 MHz, CDCl[0495] 3) δ ppm: 3.85 (3 H, S), 6.34 (1 H, s), 7.34 (2 H, d, J=8.6 Hz), 7.39 (2 H, d, J=8.6 Hz).
  • Reference 50 [0496]
  • (Z)-4-Chloro-β-(trifluoromethyl)cinnamaldehyde [0497]
    Figure US20010031768A1-20011018-C00290
  • Following Reference examples 21 and 22, the title compound was obtained as an oil in a yield of 81% from methyl (Z) -4-chloro-β-(trifluoromethyl)cinnamate in 2 steps. [0498]
  • NMR spectrum (270 MHz, CDCl[0499] 3) δ ppm: 6.36 (1 H, d, J=7.3 Hz), 7.38 (2 H, d, J=8.6 Hz), 7.44 (2 H, d, J=8.6 Hz), 10.21 (1 H, dq, J=7.3, 2.0 Hz).
  • Reference Example 51 [0500]
  • Methyl (2E,4Z)-5-(4-chlorophenyl)-6,6,6-trifluoro-2,4-hexadienoate [0501]
    Figure US20010031768A1-20011018-C00291
  • (Z)-4-Chloro-β-(trifluoromethyl)cianamaldehyde and trimethyl phosphonocrotonate were reacted in the same manner as in Reference example 23 to obtain the title compound as an oil in a yield of about 90% (separation and purification by column chromatography). [0502]
  • NMR spectrum (270 MHz, CDCl[0503] 3) δ ppm: 3.81 (3 H, s), 6.15 (1 H, d, J=5.2 Hz), 6.59 (1 H, d, J=11.9 Hz), 7.31 (2 H, d, J=8.6 Hz), 7.38 (1 H, d, J=8.6 Hz), 7.78 (1 H, ddq, J=15.2, 11.9, 2.0 Hz).
  • Reference Example 52 [0504]
  • (2E,4Z)-5-(4-Chlorophenyl)-6,6,6-trifluoro-2,4-hexadinal [0505]
    Figure US20010031768A1-20011018-C00292
  • Following Reference examples 21 and 22, the title compound was obtained as an oil in a yield of 71% from methyl (2E,4Z)-5-(4-chlorophenyl)-6,6,6-trifluoro-2,4-hexadienoate in 2 steps. [0506]
  • NMR spectrum (270 MHz, CDCl[0507] 3) δ ppm: 6.37 (1 H, dd, J=15.2, 7.3 Hz), 6.72 (1 H, d, J=11.9 Hz), 7.33 (2 H, d, J=8.6 Hz), 7.40 (2 H, d, J=8.6 Hz), 7.64 (1 H, ddq, J=15.2, 11.9, 2 Hz), 9.74 (1 H, d, J=7.3 Hz).
  • Reference Example 53 [0508]
  • 2-Methyl-2-(trans-2-phenyl-1,3-dioxan-5-yl)thio]-4′-(trifluoromethyl)propiophenone [0509]
    Figure US20010031768A1-20011018-C00293
  • In 3.8 ml of dimethylformamide were dissolved 619 mg (2.10 mmol) of 2-bromo-2-methyl-4′-(trifluoromethyl)propiophenone and 500 mg (2.1 mmol) of trans-4-acetylthio-2-phenyl-1,3-dioxane, and 0.44 ml (2.10 mmol) of a 28% sodium methoxide-methanol solution were added to the solution with stirring at room temperature under nitrogen atmosphere. After 30 minutes, water was added to the reaction mixture and the resulting mixture was extracted with ethyl acetate. The solvent was evaporated to obtain 860 mg (yield: −100%) of the title compound as a solid. [0510]
  • NMR spectrum (270 MHz, CDCl[0511] 3) δ ppm: 1.61 (6 H, s), 4.42 (1 H, tt, J=11.6, 5.0 Hz), 3.64 (2 H, t, J=11.6 Hz), 4.12 (2 H, dd, J=11.6, 5.0 Hz), 5.38 (1 H, s), 7.3-7.5 (5 H, m), 7.68 (2 H, d, J=8.2 Hz), 8.19 (2 H, d, J=8.2 Hz).
  • Reference Example 54 [0512]
  • (RS)-3-Methyl-3-[(trans-2-phenyl-1,3-dioxan-5-yl)thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0513]
    Figure US20010031768A1-20011018-C00294
  • 680 mg (1.66 mmol) of 2-methyl-2-[(trans-2-phenyl-1,3-dioxan-5-yl)thio]-4′-(trifluoromethyl)propiophenone, 547 mg (2.49 mmol) of trimethylsulfoxonium iodide, 381 mg (6.79 mmol) of potassium hydroxide and 264 mg (3.82 mmol) of 1,2,4-triazole were heated with stirring in 5.7 ml of t-butanol at 80° C. for 6 hours. After cooling, the reaction mixture was distributed between chloroform and water and the chloroform layer was separated and dried, followed by evaporation of the solvent. The thus obtained oil was subjected to column chromatography using silica gel and eluted with a mixed solvent of ethyl acetate-hexane (1:1) to obtain 605 mg (yield: 74%) of the title compound as a foam. [0514]
  • NMR spectrum (270 Hz, CDCl[0515] 3) δ ppm: 1.38 (3 H, s), 1.39 (3 H, s), 3.55-3.8 (3 H, m), 4.33 (1 H, m), 4.54 (1 H, m), 5.02 (2 H, S), 5.37 (1 H, s), 5.44 (1 H, s), 7.3-7.6 (5 H, m), 7.73 (1 H, s), 7.94 (1 H, s).
  • Reference Example 55 [0516]
  • (RS)-3-[(1,3-Dihydroxy-2-propyl)thio]-3-methyl-2-[4-(trifluoromethyl)phenyl]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol [0517]
    Figure US20010031768A1-20011018-C00295
  • (RS)-3-Methyl-3-[(trans-2-phenyl-1,3-dioxan-5-yl)thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol was treated with HCl in methanol in the same manner as in Reference example 2 to obtain the title compound as a foam. [0518]
  • NMR spectrum (270 MHz, CDCl[0519] 3) δ ppm: 1.30 (3 H, s), 1.42 (3 H, s), 3.35 (1 H, m), 3.55-3.8 (3 H, m), 3.96 (1 H, dd, J=10.9, 5.4 Hz), 4.83 (3 H, s), 5.26 (1 H, d, J=14.6 Hz) , 5.34 (1 H, d, J=14.6 Hz), 7.53 (2 H, d, J=8.3 Hz), 7.70 (1 H, s), 7.75 (2 H, d, J=8.3 Hz), 8.26 (1 H, s).
  • Reference Example 56 [0520]
  • 2-(p-Toluenesulfonyloxy)-1,3-propanediol [0521]
    Figure US20010031768A1-20011018-C00296
  • In 50 ml of methanol were dissolved 5.00 g of cis-2-phenyl-4-(p-toluenesulfonyloxy)-1,3-dioxane, and 5 ml of a 4 N HCl-dioxane solution were added to the solution, followed by stirring of the resulting mixture at room temperature for 2 hours. To the reaction mixture were added 3.5 g of NaHCO[0522] 3 powder, and the mixture was stirred for 10 minutes. Then, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The thus obtained oil was subjected to column chromatography using silica gel and eluted with ethyl acetate to obtain 3.70 g (yield: 100%) of the title compound as an oil.
  • NMR spectrum (60 MHz, CDCl[0523] 3) δ ppm: 2.40 (3 H, s), 3.30 (2 H, s), 3.73 (4 H, d, J=4.5 Hz), 4.55 (1 H, quintet, J=4.5 Hz), 7.33 (2 H, d, J=8 Hz), 7.84 (2 H, d, J=8 Hz).
  • Reference Example 57 [0524]
  • Cis-4-(p-toluenesulfonyloxy)-2-[(1E,3E)-4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxane [0525]
    Figure US20010031768A1-20011018-C00297
  • In 4.5 ml of methylene chloride were dissolved 200 mg (0.81 mmol) of 2-(p-toluenesulfonyloxy)-1,3-propanediol and 206 mg (0.91 mmol) of (2E,4E)-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienal, and 15 mg of p-toluenesulfonic acid and 0.8 g of molecular sieves 4A were added to the solution, followed by stirring of the resulting mixture at 0° C. for 1 hour. An aqueous sodium hydrogencarbonate solution was added to the reaction mixture and the mixture was stirred for 10 minutes. Then, the molecular sieves were removed by filtration and the filtrate was extracted with methylene chloride. The oil obtained by evaporation of the solvent was separated by preparative thin layer chromatography of silica gel (developing solvent: 20% ethyl acetate-hexane) to obtain 107 mg (yield: 29%) of a trans isomer having less polarity and 153 mg (yield: 42%) of a cis isomer having higher polarity as an oil, respectively. [0526]
  • NMR spectrum (270 MHz, CDCl[0527] 3) of cis isomer δ ppm: 2.45 (3 H, s), 3.99 (2 H, br d, J=13.2 Hz), 4.19 (2 H, br d, J=13.2 Hz), 4.45 (1 H, br s), 5.09 (1 H, d, J=4.6 Hz), 5.82 (1 H, dd, J=15.2, 4.6 Hz), 6.57 (1 H, dd, J=15.2, 10.5 Hz), 6.63 (1 H, d, J=15.2 Hz), 6.82 (1 H, dd, J=15.2, 10.5 Hz), 7.36 (2 H, d, J=8.6 Hz), 7.48 (2 H, d, J=8.6 Hz), 7.56 (2 H, d, J=8.6 Hz), 7.85 (2 H, d, J=8.6 Hz).
  • Test Example 1 [0528]
  • To mice (one group consisting of 10 mice), which were innoculated with 4 to 9×10[0529] 6 Candida albicans, were administered orally 20 mg/kg of preparations after 1, 4 and 24 hours, and thereafter the survival rate until 21 days after infection was examined. The results of comparison of the compound (I) of the present invention with commercially available Fluconazol are shown in Table 2. From the results, it apparent that the compound (I) exhibits an excellent antifungal activity.
    TABLE 2
    Survival rate %
    Compound 14 days 21 days
    Example 2 100 100
    11 100 100
    15 100 100
    16 100 100
    18 100 100
    21 100 60
    30 100 100
    32 100 100
    35 100 100
    37 100 100
    Fluconazol 70 60
  • Preparation Example 1 [0530]
    Capsule
    Compound of Examples 1 to 39 or 40 50 mg
    Lactose 128 mg
    Corn starch 70 mg
    Magnesium stearate 2 mg
    250 mg
  • The thus formulated powder was mixed and passed through a sieve of 60 mesh, and then the powder was encapsulated in No. 3 gelatin capsule of 250 mg to prepare a capsule. [0531]
  • Preparation Example 2 [0532]
    Tablet
    Compound of Examples 1 to 39 or 40 50 mg
    Lactose 126 mg
    Corn starch 23 mg
    Magnesium stearate 1 mg
    200 mg
  • The thus formulated powder was mixed and wet-granulated using a corn starch sizing agent and dried, and then a 200 mg-tablet was made by means of a tablet making machine. If necessary, sugar coating can be applied to the tablet. [0533]
  • The compound having the general formula (I) or a pharmacologically acceptable salt thereof of the present invention has an excellent antifungal activity and is useful as an antifungal agent. [0534]

Claims (26)

1. A compound having the formula:
Figure US20010031768A1-20011018-C00298
wherein Ar1 represents a phenyl group or a phenyl group having 1 to 3 substituent(s) (said substituent(s) represent(s) a halogen atom or a trifluoromethyl group);
Ar2 represents phenyl, a 5- or 6-membered aromatic heterocyclic group (said aromatic heterocyclic group has at least one nitrogen, oxygen or sulfur atom) or a phenyl group or a 5- to 6-membered aromatic heterocyclic group having 1 to 3 substituent(s) (said substituent(s) represent(s) a lower alkyl group, a lower alkoxy group, a halogen atom, a lower alkyl group substituted with a halogen atom or halogen atoms, a lower alkoxy group substituted with a halogen atom or halogen atoms, a nitro group, a cyano group, a —S(O)mR6 group (R6 represents a lower alkyl group which may be substituted with a halogen atom or halogen atoms and m represents 0, 1 or 2) or a —NHCOR7 group (R7 represents a lower alkyl group) and said aromatic heterocyclic group has at least one nitrogen, oxygen or sulfur atom);
RO represents a hydrogen atom or a lower alkyl group;
R1 represents a lower alkyl group;
R2, R3, R4 and R5 may be the same or different and represent a hydrogen atom, a lower alkyl group or a lower alkyl group substituted with a halogen atom or halogen atoms and, where q and/or s represent 2, each of R2, R3, R4 and R5 represents independently a group which is the same or different from the other R2, R3, R4 and R5 respectively;
n represents 0, 1 or 2;
p represents 0 or 1;
q, r and s represent 0, 1 or 2; and
A represents a 4- to 7-membered aliphatic carbocyclic group comprising 4 to 7 carbon atoms or a 4- to 7-membered aliphatic heterocyclic group having at least one nitrogen, oxygen or sulfur atom,
or a pharmacologically acceptable salt thereof.
2. A triazole compound or a pharmacologically acceptable salt thereof according to
claim 1
, wherein Ar1 is a phenyl group having 1 to 3 substituent(s) (said substituent(s) represent(s) a halogen atom or a trifluoromethyl group).
3. A triazole compound or a pharmacologically acceptable salt thereof according to
claim 1
, wherein Ar1 is a phenyl group having 1 or 2 substituent(s) (said substituent(s) represent(s) a fluorine atom, a chlorine atom or a trifluoromethyl group).
4. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
3
, wherein Ar2 represents a phenyl group, a 5- or 6-membered aromatic heterocyclic group (said aromatic heterocyclic group has at least one nitrogen, oxygen or sulfur atom) or a phenyl group or a 5- or 6-membered aromatic heterocyclic group having 1 to 3 substituent(s) (said substituent(s) represent(s) a lower alkyl group, a halogen atom, a lower alkyl group substituted with a halogen atom or halogen atoms, a lower alkoxy group substituted with a halogen atom or halogen atoms, a nitro group, a cyano group or a —S(O)mR6 group (R6 represents a lower alkyl group which may be substituted with a halogen atom or halogen atoms and m represents 0, 1 or 2) and said aromatic heterocyclic group has at least one nitrogen, oxygen or sulfur atom).
5. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
3
, wherein Ar2 represents a phenyl group, a 5- or 6-membered aromatic heterocyclic group (said aromatic heterocycdic group has one nitrogen, oxygen or sulfur atom) or a phenyl group or a 5- to 6-membered aromatic heterocyclic group having 1 to 3 substituent(s) (said substituent(s) represents() a lower alkyl group, a halogen atom, a lower alkyl group substituted with a halogen atom or halogen atoms, a lower alkoxy group substituted with a halogen atom or halogen atoms, a nitro group, a cyano group or a —S(O)mR6 group (R6 represents a lower alkyl group which may be substituted with a halogen atom or halogen atoms and m represents 0, 1 or 2) and said aromatic heterocyclic group has one nitrogen, oxygen or sulfur atom).
6. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
3
, wherein Ar2 represents a phenyl group, a 5- or 6-membered aromatic heterocyclic group (said aromatic heterocyclic group has one nitrogen or sulfur atom) or a phenyl group or a 5- or 6-membered aromatic heterocyclic group having 1 or 2 substituent(s) (said substituent(s) represent(s) a lower alkyl group, a halogen atom, a lower alkyl group substituted with a halogen atom or halogen atoms, a lower alkoxy group substituted with a halogen atom or halogen atoms, a nitro group, a cyano group or a —S(O)mR6 group (R6 represents a lower alkyl group which may be substituted with a halogen atom or halogen atoms and m represents 0, 1 or 2) and said aromatic heterocyclic group has one nitrogen or sulfur atom).
7. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
3
, wherein Ar2 represents a phenyl group or a pyridyl group or a phenyl group, a pyridyl group or a thienyl group having 1 or 2 substituent(s) (said substituent(s) represent(s) a lower alkyl group, a halogen atom, a lower alkyl group substituted with a halogen atom or halogen atoms, a lower alkoxy group substituted with a halogen atom or halogen atoms, a nitro group, a cyano group or a —S(O)mR6 group (R6 represents a lower alkyl group which may be substituted with a halogen atom or halogen atoms and m represents 0, 1 or 2).
8. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
7
, wherein R0 is a hydrogen atom, a methyl group, an ethyl group or a propyl group.
9. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
7
, wherein R0 is a hydrogen atom, a methyl group or an ethyl group.
10. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
7
, wherein R0 is a hydrgen atom or a methyl group.
11. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
10
, wherein R1 is a methyl group, an ethyl group or a propyl group.
12. A triazole compund or a pharmacologically acceptable salt thereof according to
claims 1
 to
10
, wherein R1 is a methyl group or an ethyl group.
13. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
10
, wherein R1 is a methyl group.
14. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
13
, wherein R2, R3, R4 and R5 may be the same or different and are a hydrogen atom, a lower alkyl group or a lower alkyl group substituted with a fluorine or chlorine atom or atoms.
15. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
13
, wherein R2, R3, R4 and R5 may be the same or different and are a hydrogen atom, a methyl group, an ethyl group or a propyl group or a methyl group, an ethyl group or a propyl group substituted with a fluorine or chlorine atom or atoms.
16. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
13
, wherein R2, R3, R4 and R5 may be the same or different and are a hydrogen atom, a methyl group or an ethyl group or a methyl group or an ethyl group substituted with a fluorine or chlorine atom or atoms.
17. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
13
, wherein R2, R3, R4 and R5 may be the same or different and are a hydrogen atom or a methyl group or a methyl group substituted with a fluorine or chlorine atom or atoms.
18. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 2
 to
17
, wherein n is 0, 1 or 2.
19. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
17
, wherein n is 0.
20. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 2
 to
19
, wherein p is 0 or 1.
21. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 2
 to
20
, wherein q, r and s are 0, 1 or 2.
22. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
21
, wherein A is a 5- or 6-membered aliphatic carbocyclic group comprising 5 or 6 carbon atoms or a 4- to 6-membered aliphatic heterocyclic group having at least one nitrogen, oxygen or sulfur atom.
23. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
21
, wherein A is a 5- or 6-membered aliphatic carbocyclic group comprising 5 or 6 carbon atoms or a 4- to 6-membered aliphatic heterocyclic group having 1 or 2 nitrogen, oxygen or sulfur atom(s).
24. A triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
21
, wherein A is cyclohexane, piperidine, 1,3-dioxane or 1,3-dithiane ring.
25. 2-(2,4-Difluorophenyl)-3-[[2-[2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol,
2-(2, 4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[2-[4-(trifluoromethoxy)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-2-butanol, 2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
2-(2,4-difluorophenyl)-3-([[2-[4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol,
2-(2,4-difluorophenyl)-3-[[2-[4-[4-(chlorophenyl)-4,4,4-trifluoro-1,3-pentadien-1-yl]-1,3-dioxan-1-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol,
2-(2,4-difluorophenyl)-3-[[1-[4-(trifluoromethoxy)cinnamoyl]piperidin-4-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol,
2-(2,4-difluorophenyl)-3- [[1-[4-nitrocinnamoyl]piperidin-4-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-butanol,
2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[1-[5-[4-(trifluoromethoxy)phenyl]-2,4-pentadienoyl]piperidin-4-yl]thio]-2-butanol,
3-methyl-1-(1 H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-3-[[2-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[4-(trifluoromethylthio)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
3-[[2-[4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1 H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol,
1-(1 H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethylsulfinyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-cyclohexyl]thio]-2-butanol,
2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[6-[4-(trifluoromethyl)phenyl]-1,3,5-hexatrien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
2-(2,4-difluorophenyl)-3-methyl-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol or
2-(2,4-difluorophenyl)-1-(1 H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1-buten-3-yn-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
or a pharmacologically acceptable salt thereof.
26. An antifungal agent containing the triazole compound or a pharmacologically acceptable salt thereof according to
claims 1
 to
25
 as an active ingredient.
US09/794,177 1995-04-06 2001-02-27 Triazole antifungal agent Abandoned US20010031768A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/794,177 US20010031768A1 (en) 1995-04-06 2001-02-27 Triazole antifungal agent

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JPHEI7-81052 1995-04-06
JP8105295 1995-04-06
PCT/JP1996/000932 WO1996031491A1 (en) 1995-04-06 1996-04-05 Triazole antifungal agent
US08/944,304 US5977152A (en) 1995-04-06 1997-10-06 Triazole antifungal agent
US09/241,370 US6306880B1 (en) 1995-04-06 1999-02-01 Triazole antifungal agent
US09/794,177 US20010031768A1 (en) 1995-04-06 2001-02-27 Triazole antifungal agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/241,370 Division US6306880B1 (en) 1995-04-06 1999-02-01 Triazole antifungal agent

Publications (1)

Publication Number Publication Date
US20010031768A1 true US20010031768A1 (en) 2001-10-18

Family

ID=13735652

Family Applications (5)

Application Number Title Priority Date Filing Date
US08/944,304 Expired - Fee Related US5977152A (en) 1995-04-06 1997-10-06 Triazole antifungal agent
US09/241,369 Expired - Fee Related US6300357B1 (en) 1995-04-06 1999-02-01 Triazole antifungal agent
US09/241,370 Expired - Fee Related US6306880B1 (en) 1995-04-06 1999-02-01 Triazole antifungal agent
US09/794,177 Abandoned US20010031768A1 (en) 1995-04-06 2001-02-27 Triazole antifungal agent
US09/794,180 Abandoned US20010031778A1 (en) 1995-04-06 2001-02-27 Triazole antifungal agent

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/944,304 Expired - Fee Related US5977152A (en) 1995-04-06 1997-10-06 Triazole antifungal agent
US09/241,369 Expired - Fee Related US6300357B1 (en) 1995-04-06 1999-02-01 Triazole antifungal agent
US09/241,370 Expired - Fee Related US6306880B1 (en) 1995-04-06 1999-02-01 Triazole antifungal agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
US09/794,180 Abandoned US20010031778A1 (en) 1995-04-06 2001-02-27 Triazole antifungal agent

Country Status (18)

Country Link
US (5) US5977152A (en)
EP (1) EP0841327B1 (en)
KR (1) KR100367327B1 (en)
CN (1) CN1151138C (en)
AT (1) ATE206410T1 (en)
CA (1) CA2217516C (en)
CZ (1) CZ292377B6 (en)
DE (1) DE69615694T2 (en)
DK (1) DK0841327T3 (en)
ES (1) ES2164238T3 (en)
HK (1) HK1009803A1 (en)
HU (1) HU227320B1 (en)
MX (1) MX9707697A (en)
NO (1) NO319218B1 (en)
NZ (1) NZ304438A (en)
PT (1) PT841327E (en)
RU (1) RU2146250C1 (en)
WO (1) WO1996031491A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5779598A (en) * 1997-02-04 1998-08-25 Sankyo Company Limited Triazole derivatives
US6275026B1 (en) * 1999-08-10 2001-08-14 Trw Inc. Position sensing device
CZ297383B6 (en) * 1999-09-09 2006-11-15 Sankyo Company Limited Triazole derivatives exhibiting antifungal activity
US6391903B1 (en) * 1999-09-09 2002-05-21 Sankyo Company, Limited Triazole derivatives having antifungal activity
TW591024B (en) 2000-03-27 2004-06-11 Sankyo Lifetech Company Ltd An amide type triazole compound having antifungal activity
AU2002215213A1 (en) * 2000-11-16 2002-05-27 Sankyo Company Limited Carbamoyl-bearing triazole fungicides
US7687434B2 (en) 2000-12-22 2010-03-30 Monsanto Technology, Llc Method of improving yield and vigor of plants
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
BR0213586A (en) * 2001-09-27 2004-10-26 Monsanto Technology Llc Fungicidal compositions and their applications in agriculture
CA2528493C (en) * 2003-06-06 2009-01-20 Sankyo Company Limited Medicinal composition containing triazole compound
CN112137972A (en) * 2020-09-16 2020-12-29 石家庄四药有限公司 Fluconazole tablet composition, tablet and preparation method

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161382C (en) * 1982-04-01 1991-12-09 Pfizer PROCEDURE FOR PREPARING 1,2,4-TRIAZOL COMPOUNDS OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS
US4507484A (en) * 1982-07-24 1985-03-26 Pfizer Inc. Triazole antifungal agents
US4505919A (en) * 1982-10-09 1985-03-19 Pfizer Inc. Antifungal S-arylmethyl- and S-heterocyclylmethyl ethers of 2-aryl-3-mercapto-1-(1H-1,2,4-triazol-1-yl) propan-2-ols
AU572889B2 (en) * 1983-09-26 1988-05-19 Sumitomo Chemical Company, Limited 1,2,4 - triazolyl propanols
JPS6069071A (en) * 1983-09-26 1985-04-19 Sumitomo Chem Co Ltd N-substituted-1,2,4-triazole
JPS60136570A (en) * 1984-08-27 1985-07-20 Sumitomo Chem Co Ltd 1,2,4-triazolylpropanol
DE3402166A1 (en) * 1984-01-23 1985-07-25 Hoechst Ag, 6230 Frankfurt AZOLYL-ARYL-ALKANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
KR930004193B1 (en) * 1984-10-02 1993-05-21 스미또모 세이야꾸 가부시끼가이샤 Process for preparing n-substituted triazole derivatives
JPS6185369A (en) 1984-10-02 1986-04-30 Sumitomo Seiyaku Kk 1,2,4-triazole derivative
CN1008735B (en) * 1984-11-02 1990-07-11 拜尔公司 Pyrrole ylmethyl-cyclopropyl-carbinol derivatives with replacement is a composition of active components
JPH02191262A (en) * 1988-03-04 1990-07-27 Sankyo Co Ltd Triazole derivative
NO171272C (en) * 1988-03-04 1993-02-17 Sankyo Co ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,2,4-TRIAZOLO COMPOUNDS
IE903395A1 (en) * 1989-09-26 1991-04-10 Takeda Chemical Industries Ltd Triazole compounds, their production and use
TW206224B (en) * 1989-12-14 1993-05-21 Takeda Pharm Industry Co Ltd
CA2038201A1 (en) * 1990-03-15 1991-09-16 Katsumi Itoh Triazoles, their production and use
JPH04211070A (en) * 1990-03-15 1992-08-03 Takeda Chem Ind Ltd Triazole compound and its use
IE912990A1 (en) * 1990-08-26 1992-03-11 Sankyo Co Anti-fungal triazole derivatives, their preparation and¹uses
EP0510700A3 (en) * 1991-04-26 1992-12-16 Takeda Chemical Industries, Ltd. Azole compounds, their production and use
JPH06247944A (en) * 1992-12-28 1994-09-06 Sumitomo Pharmaceut Co Ltd Novel 1,2,4-triazole derivative
US5393269A (en) * 1994-01-12 1995-02-28 Atkinson, Jr.; William A. Bowling pin setting mechanism and scissor arms

Also Published As

Publication number Publication date
AU694638B2 (en) 1998-07-23
AU5162496A (en) 1996-10-23
EP0841327B1 (en) 2001-10-04
CZ310597A3 (en) 1998-02-18
EP0841327A4 (en) 1998-09-30
MX9707697A (en) 1997-12-31
CA2217516A1 (en) 1996-10-10
ATE206410T1 (en) 2001-10-15
CZ292377B6 (en) 2003-09-17
HU227320B1 (en) 2011-03-28
RU2146250C1 (en) 2000-03-10
NO974588D0 (en) 1997-10-03
US6306880B1 (en) 2001-10-23
DE69615694T2 (en) 2002-07-11
US5977152A (en) 1999-11-02
NO974588L (en) 1997-12-08
NO319218B1 (en) 2005-07-04
EP0841327A1 (en) 1998-05-13
CN1151138C (en) 2004-05-26
CN1187191A (en) 1998-07-08
HUP9801133A2 (en) 1998-08-28
PT841327E (en) 2002-02-28
KR19980703644A (en) 1998-12-05
HUP9801133A3 (en) 2000-03-28
CA2217516C (en) 2003-01-14
DE69615694D1 (en) 2001-11-08
NZ304438A (en) 1999-04-29
US6300357B1 (en) 2001-10-09
WO1996031491A1 (en) 1996-10-10
HK1009803A1 (en) 1999-10-08
ES2164238T3 (en) 2002-02-16
KR100367327B1 (en) 2003-03-03
DK0841327T3 (en) 2002-01-21
US20010031778A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
FI97382C (en) Process for the preparation of 1,2,4-triazole derivatives useful as a drug
US5039676A (en) Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5405861A (en) Triazole compounds and antifungal compositions thereof
NZ247488A (en) 2-aryl-2-hydroxy-3-azolylpropylazolone derivatives; their use as anti-fungal agents
JPH0419992B2 (en)
HU205348B (en) Process for producing triazole derivatives and pharmaceutical compositions comprising such compounds as active ingredient
KR900003302B1 (en) Process for preparing hydroxyalkyl-azolyl derivatives
US6300357B1 (en) Triazole antifungal agent
WO1989004829A1 (en) Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
JP4709148B2 (en) Antifungal azole derivative having fluorovinyl group and process for producing the same
JP3415865B2 (en) Optically active azole compound and use thereof
HU190545B (en) Process for preparing antifungal triazole-derivatives and pharmaceutical compositions comprising these compounds
JP3622882B2 (en) Medicine containing triazole derivative
US5646294A (en) Orally active azole derivatives
JP2902345B2 (en) Triazole antifungal agent
CA2217632A1 (en) Novel triazolones as apolipoprotein-b synthesis inhibitors
US5047548A (en) 3-aryl-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butyramide and derivatives as antifungal agents
JP2002535328A (en) Antifungal azole derivative having fluorinated vinyl group and method for producing the same
WO1999002524A1 (en) Antifungal triazole compounds
US4798899A (en) Combating fungi with novel azolyl-tetrahydrofuran-2-ylidene-methanes
US5095028A (en) 2-(4-chlorobenzyl)-1-(1H-imidazole-1-ylmethyl)-1-cyclohexanol and cycloheptanol
JPH10279567A (en) Triazole derivative
JPH1180135A (en) Antifungal triazol compound
JP2000044547A (en) Antifungal agent containing triazole derivative
JPH07228574A (en) Optically active azole derivative, its production and use thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION